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CHAPTER 1 
 
INTRODUCTION AND MOTIVATION 
 
Cardiac disease is implicated in one in four deaths in the United States and is the 
leading cause of death world-wide. Myocardial infarction (MI) alone afflicts close to 1.5 
million Americans annually [1]. Regardless of specific cause, cardiac disease manifests 
as significant loss of heart function following maladaptive tissue remodeling that alters 
the mechanical properties and function of the heart. Many forms of cardiac disease are 
characterized by fibrosis, a broad disease classifier marked by extracellular matrix 
(ECM) accumulation, tissue stiffening, and loss of function. Tissue remodeling, including 
fibrosis, is a cell-mediated process that dynamically changes the mechanical properties 
of the heart and has important implications to the progression of disease and patient 
outcomes.  
Many proposed pharmacological solutions have not translated well from 
experimental settings to clinical practice, failing to achieve the successful outcomes 
predicted from experimental tests [2]–[4]. Most of these treatments target chemical 
signaling pathways to regulate cell behavior. ACE inhibitors, β-blockers, and statins 
have shown some success alleviating the symptoms and slowing the progression of 
heart failure, but they can do little to restore functional heart tissue [5]. Recent 
experiments with stem cells have shown promising results, but they are limited by an 
incomplete understanding of the dynamic chemical and mechanical environment of a 
healing infarct and its effect on cellular interactions and differentiation during myocardial 
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remodeling [6–9]. Traditional biological studies often fail to consider the role of 
mechanical cues on cellular phenotype and function. To develop better therapies, we 
need to develop a better understanding of how the various cells in the heart respond to 
and alter their mechanical environment of the heart during normal function and disease.  
The heart is a complex organ comprised of several specialized cell types that 
work in concert during normal development and function, but also differentiate and 
interact in distinct ways during the progression of cardiac disease [10]. Cardiomyocytes 
(CMs) are the cellular effectors of contraction, generating the large forces which drive 
the essential pumping function of the heart. Specialized intracellular structures within 
the CMs and linkages between the CMs and a well-maintained cardiac ECM are 
required for these forces to propagate appropriately [11], [12]. The cells responsible for 
the maintenance of the ECM are cardiac fibroblasts (CFs), the next most prevalent cell 
type in healthy adult hearts [13]. During both development and fibrotic remodeling, 
these cells are activated to the myofibroblast (MyoFB) phenotype, characterized by 
increased ECM production and restructuring. Endothelial cells (ECs) line the vascular 
network oxygenating cardiac tissue, and can be an additional source of MyoFBs during 
disease [14]. Finally, inflammatory cells, including macrophages (Ms), are often 
recruited and activated to affect tissue breakdown and initiate fibrotic remodeling during 
disease [15], [16]. The cellular populations and phenotypes present in the heart change 
dramatically during the transition from healthy to diseased tissue, especially after an 
acute event such as a MI. These cells interact with one another and drastically alter the 
chemical and mechanical microenvironment, all of which is constantly contracting and 
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relaxing. Understanding cellular phenotypes in this dynamic mechanical and cellular 
environment is crucial for developing better therapies for heart disease.  
There is a growing appreciation in the field for the importance of mechanical 
context when studying cardiac cell behavior. All of these cell types are sensitive to 
changes in their mechanical environment, and their ability to sense and respond to 
mechanical forces determines both normal development and the progression of disease 
[11], [15], [17]–[19]. Mechanobiology is the study of the cellular response to altered 
mechanical inputs, which are often sensed through cellular adhesion to both the 
surrounding ECM and neighboring cells. Two key families of proteins which mediate 
cellular adhesions and transduction of mechanical signals are integrins and cadherins 
[20]. Integrins form adhesions with the ECM and trigger intracellular signaling cascades 
and cellular responses to changes in substrate stiffness and ECM composition. These 
adhesions also allow for transmission of intracellular force generated by the cellular 
cytoskeleton to the ECM [21], [22]. Cadherins mechanically link neighboring cells and 
can transmit intracellular forces between cells. They have also more recently been 
revealed to play a role in transduction of mechanical cues into intracellular signals. 
Cadherin-11 is a specialized cadherin expressed by MyoFBs, along with other cell 
types, that has been shown to contribute to the progression of fibrotic disease in several 
tissues, including the lungs and cardiac valves, but has never been studied in the 
context of myocardial remodeling [23]–[25]. 
Between the diversity of cellular populations and biological processes, as well the 
dynamic mechanical context, myocardial remodeling has a high degree of complexity. 
Biomedical engineering as a discipline is particularly well suited to tackle the question of 
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how mechanics affects cellular response during myocardial fibrosis. Engineering 
approaches including multiscale system analysis and quantitative assessment of 
mechanical forces and properties can be used to clarify specific cellular mechanisms 
within this complex problem. Traditional 2-D cell culture on tissue culture plastic or glass 
allows for rapid and reproducible study of intracellular signaling, but it is relatively poorly 
suited for studying the effect of mechanical environment and structure on cell function. 
In the highly dynamic mechanical environment of the heart, this limitation is particularly 
significant. Animal models, primarily mice, have long been used to study the organ level 
changes in function and signaling with a functional combination of these varied cell 
types; however, it can be difficult to tease out the effect of specific cell types and 
mechanisms in a whole organ context. Novel in vitro constructs have been developed 
by biomedical engineers which can be effectively used to bridge the gap between 2D 
cell culture and in vivo studies. Various 3-D scaffolds and biomimetic devices allow for 
study of cardiac cell growth, differentiation, and dysfunction in a more physiologically 
and mechanically relevant controlled systems [26]. Biomedical engineers are well 
situated to engage with this complexity and draw out biological insights. My position in 
the Merryman Mechanobiology Laboratory has allowed me to draw on a vast body of 
work in the study of fibroblast mechanobiology in the heart valve and translate it to 
studying mechanobiology in the myocardium.  
My doctoral work has aimed to gain a more complete understanding of the 
interactions between cardiac cells and their environment in the remodeling myocardium 
(Figure 1.1). The complex question of the role of mechanics and mechanosensing in 
fibrotic myocardial remodeling was addressed through three specific aims to gain a 
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better understanding of particular cellular contexts. The first portion of this work focuses 
on CFs and a subset of the intracellular signaling downstream of growth factors and 
integrins which regulates the transition from the quiescent to active MyoFB phenotype. 
Next I expanded my focus to the general population of non-CM cells and their 
interactions in the process of healing after MI. The second section focuses on cadherin-
11, a protein that sits at the intersection of mechanosensing, transmission of 
intercellular forces, MyoFB differentiation, and fibrotic cardiac remodeling. Finally, I 
address CMs, the primary source of heart contraction, and describe a set of tools and 
analyses that allow for improved characterization of cellular structure, function, and 
interactions in both healthy and diseased hearts.  
 
Figure 1.1 Graphical overview of dissertation topic and aims 
Aim 1 Aim 2 Aim 3
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The work will address three specific aims: 
 
1. Elucidate the crosstalk between growth factor signaling and integrin sensing 
of substrate stiffness in the regulation of fibroblast phenotype 
2. Determine the role of cadherin-11 in remodeling after myocardial infarction 
3. Develop tools to quantify CM mechanics in normal function and disease 
 
To begin, a detailed background on cardiac development, disease, and fibroblast 
mechanobiology is provided. Each specific aim is then considered separately with each 
section offering a focused introduction and set of research methods that were used to 
complete the study. A combination of computational, biological, and engineered tools 
were used to investigate cardiac mechanobiology with a deeper appreciation for the role 
of mechanics and mechanosensing in multiple cellular contexts.  Finally, a discussion of 
the complete dissertation is presented to highlight the potential impact of the results. 
This dissertation summarizes my findings on the role of mechanotransduction through 
integrins and cadherins, particularly cadherin-11, to regulate mechanically-induced 
differentiation and fibrosis in the context of cardiac disease. 
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Table 1.1. Vocabulary and Abbreviations 
Category Term or 
Abbreviation 
Definition 
General 
terms 
LV Left ventricle 
MI Myocardial infarction 
AV Aortic valve 
BZ Border zone 
IN Infarct region 
ECM Extracellular matrix 
EMT/EndMT Epithelial/endothelial to mesenchymal transition 
Cells 
MEF Mouse embryonic fibroblast 
CF Cardiac fibroblast 
MyoFB Myofibroblast – activated fibroblast involved in tissue remodeling 
CM Cardiomyocyte – heart muscle cells 
EC Endothelial cell – lining of vascular system 
M Macrophage – inflammatory cells  
AVIC Aortic valve interstitial cell – involved in valve ECM maintenance 
Marker of 
fibroblast 
phenotype 
α-SMA α smooth muscle actin – contractile cytoskeletal protein 
cadherin-11 Cadherin-11 – strong cell-cell adhesion molecule 
Col-1 Collagen-1 – most common ECM component of fibrotic tissue 
Markers of 
M phenotye 
F4/80 M marker 
CD14 Cell surface marker protein – indicates M1, inflammatory phenotype 
Mnr1 Mannose receptor 1 – indicates M2, reparative phenotype 
Arg1 Arginase 1 – indicates M2, reparative phenotype 
Secreted 
growth factor 
or 
inflammatory 
agent 
TGF-1 Transforming growth factor β1 – promotes MyoFB differentiation 
FGF Fibroblast growth factor – reverses MyoFB differentiation 
VEGF Vascular endothelial growth factor – promotes angiogenesis 
IL-1 Interleukin-1 – proinflammatory cytokine 
IL-6 Interleukin-6 – proinflammatory cytokine 
MMP13 Matrix metalloproteinase 13 – breaks down collagen-1 
MMP3 Matrix metalloproteinase 3 – breaks down ECM and activates MMP1 
Cellular 
signaling 
proteins and 
terms 
FA Focal adhesions – link integrins to cytoskeleton 
AJ Adheren junction – link cadherins to cytoskeleton 
FAK Focal adhesion kinase 
Src Tyrosine kinase found at FAs 
MAPK Mitogen activated protein kinase 
p38 MAPK downstream of TGF-β1 
ERK Extracellular regulated kinase – MAPK involved in many pathways 
β-catenin Component of AJ and involved in Wnt signaling 
GSK-3β Glycogen synthase kinase 3β – involved in Wnt signaling 
Assays and 
techniques 
ELISA Enzyme-linked immunosorbent assay 
Western blot Assay for quantifying protein expression 
RT qPCR Reverse Transcription quantitative polymerase chain reaction 
IHC Immuno-histochemistry 
AFM Atomic force microscopy 
Gel assay Free floating collagen gels with embedded cells to measure contractility 
ECTC Engineered cardiac tissue construct 
I-wire ECTC developed at VIIBRE 
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CHAPTER 2 
 
BACKGROUND: MYOCARDIAL DEVELOPMENT AND DISEASE 
 
Text for Chapter 2 adapted in part from: 
[7] Schroer, A.K. and W.D. Merryman, Mechanobiology of myofibroblast adhesion in 
fibrotic cardiac disease. J Cell Sci, 2015. 128: p. 1865-1875. 
 
 
Mechanobiology of myocardial development  
  A human heart will beat around two and a half billion times in the average 
lifetime. Given the high mechanical demands on the heart, it is perhaps not surprising 
that it is so prone to failure. To power the circulatory system and perfuse blood 
throughout the body, the heart uses concerted contraction of thick muscular walls called 
the myocardium that require constant perfusion of oxygenated blood. These walls form 
the four main chambers of the heart and are separated from each other and the 
outflowing vasculature by thin flexible valves. The structures of both the valves and the 
myocardium are formed early in development and rely on precise timing of cytokine 
signaling and mechanotransduction to induce proper cell alignment and vascularization 
[13], [27]. Development of the heart begins as a muscular tube lined internally with 
endocardial cells. Heart valves are formed by the differentiation of endocardial cells 
through endothelial-to-mesenchymal transformation (EndMT) into mesenchymal cells, 
which can migrate into a mixture of ECM known as the cardiac jelly. This cellular 
transformation requires the active contraction of the developing myocardium to fully 
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occur [28]–[30]. These transformed endocardial cells become the valve interstitial cells 
(VICs) in adult valves and are necessary for developing the initial structure of the valve 
and maintaining that structure through adulthood. A similar mechanism accounts for the 
origin of CFs in the myocardium. CFs are derived primarily from the proepicardial organ, 
a cluster of epithelial-like cells that migrate to cover the developing heart and form the 
mature epicardium. A significant portion of these cells undergo epithelial to 
mesenchymal transition (EMT) in response to TGF-β1 signaling to gain a more 
migratory, fibroblast-like phenotype and invade into the myocardium [31], [32]. These 
cells are believed to be the origin of vascular smooth muscle cells, vascular ECs, and 
resident CFs. During development, CFs differentiate into active MyoFBs - producing 
fibrillar collagen and organizing a 3-D network for myocardium development and 
maturation. These MyoFBs express contractile α-smooth muscle actin (α-SMA), can 
apply forces to both the developing myocytes and collagen framework, and are 
responsible for the laminar structure and fibrous alignment of the myocardium. Tissue 
remodeling by MyoFBs during development causes a significant increase in myocardial 
stiffness, in preparation for the mechanical demands of active circulation (Figure 2.1). 
From mid-development to birth, the stiffness of mouse ventricle increases from 12 to 39 
kPa, according to atomic force microscopy (AFM) measurements [33]. At the end of 
development, CFs surround and run parallel to myocytes throughout the myocardium, 
and are generally maintained in a quiescent state (Figure 2.1), producing ECM proteins 
and matrix metalloproteinases (MMPs) in a tightly regulated balance to maintain a 
stable mechanical environment [34], [35]. However, in the case of cardiac disease, 
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physiological stress can trigger the reactivation of fibroblasts into MyoFBs and begin the 
chronic process of tissue remodeling. 
 
Figure 2.1 Interplay between ECM stiffness and fibroblast phenotypes. (Figure adapted from 
Merryman et. al [36]) 
 
 Cellular players in fibrotic cardiac disease, parallels with valve disease 
While they have significant differences in composition and function, there are 
some important mechanistic similarities between the myocardium and the heart valves. 
Both are highly mechanically active tissues susceptible to fibrotic remodeling and 
progressive disease. With the Merryman Laboratory’s extensive expertise in studying 
valve disease, I was able to translate recent advances in the field of valve 
mechanobiology to the study of myocardial fibrosis. Proper function of cardiac 
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structures is dependent on their active and passive mechanical properties, and 
alteration of these properties is a hallmark of fibrotic cardiac disease. In both tissues, 
inflammation and fibrosis drive extensive tissue remodeling that significantly impairs 
cardiac function (Figure 2.2A). Inflammation triggers ECM degradation and the release 
of profibrotic factors, such as angiotensin II (AngII), transforming growth factor β1 (TGF-
β1), and fibroblast growth factor (FGF2), that promote accumulation of ECM and fibrosis 
of the valves and myocardium [37], [38]. However, drugs targeting these pathways have 
had limited success, which has been attributed to their failure to address the concurrent 
mechanical signals that play a critical role in the initiation and progression of disease 
[4]. Increased local tissue strains and stresses increase the risk of developing fibrotic 
disease by altering the phenotype of cardiac cells, which contributes to maladaptive 
tissue remodeling [15], [39], [40]. Therefore, determining how various cardiac cells 
respond to a changing chemical and mechanical environment will aid our understanding 
of heart disease development and potentially uncover novel therapeutic targets (Figure 
2.2A). 
Inflammatory cells, including neutrophils and Ms, are the first responders after 
acute injury and often act as chronic drivers of inflammation and remodeling during 
different types of cardiac disease. ECs are ubiquitous throughout the heart, forming the 
cellular coat of the valve, the heart chambers, and the dense vascular bed required for 
proper myocardial oxygenation. VICs and CFs are primarily responsible for maintaining 
the ECM, a key structural framework for the tissue. The primary cellular source of 
mechanical signals in the heart are the cardiomyocytes (CMs), which use complex 
intracellular structure and intercellular junctions to contract as a unit and effectively 
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pump blood. All of these cell types are present in both healthy and diseased tissues, 
and their interactions, both through chemical signaling and more direct mechanical 
linkages, are integral to the process of fibrotic tissue remodeling. These signals, both 
chemical and mechanical, can alter cell activation and phenotype, which are key 
components of the remodeling process. 
Mechanically-induced signaling promotes MyoFB differentiation in VICs and CFs, 
resulting in cells that exhibit increased contractility and increased secretion of growth 
factors and ECM proteins (Figure 2.2B) [41]–[43]. MyoFBs are identified by their 
expression of α-smooth muscle actin (α-SMA), a specialized cytoskeletal protein that 
allows for enhanced generation of cellular force [44]. All adherent cells interact with the 
local ECM and sense tissue forces through transmembrane ECM receptors called 
integrins. Upon adhesion to the ECM, integrins recruit intracellular proteins to form a 
focal adhesion (FA), which links integrins to the actin cytoskeleton and initiates force-
dependent signaling [45], [46]. In addition to force transduction from the ECM to the 
cells, integrins also regulate force transmission from intracellular stress fibers to the 
local microenvironment [47].  
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Figure 2.2: Relevance of adhesion mechanobiology to fibrotic heart disease. Fibrotic disease affects 
both heart valves and heart myocardium and is characterized by changes in the mechanical properties of 
the ECM and the cellular phenotypes present in the tissue. Healthy valves have primarily quiescent 
fibroblast-like cells called valvular interstitial cells (VICs) that are embedded in a stable, organized ECM 
and surrounded by a single layer of valvular endothelial cells (VECs). Similarly, healthy myocardium 
contains cardiomyocytes (CMs), cardiac fibroblasts (CFs), and endothelial cell-(EC) lined blood vessels 
embedded in stable ECM. Disease can be initiated by acute or chronic cardiac conditions. Inflammation 
initiates ECM breakdown and accumulation of inflammatory cells (ICs), fibroblast-like cells, and 
endothelial-to-mesenchymal-transformed cells (EndMTCs). Inflammation can transition into fibrosis, which 
is characterized by accumulation of stiff ECM and a large number of myofibroblasts (MyoFBs) that are 
derived from VICs, CFs, and EndMTCs. MyoFBs are particularly relevant to disease because they are 
able to initiate ECM remodeling and intercellular signaling pathways. The MyoFB phenotype is promoted 
by combined inputs of mechanical and chemical signals, which are transduced through integrins and 
cadherins, and signaling factor receptors, respectively. Increased expression of α-SMA in MyoFBs 
stabilizes and further activates integrins and cadherins; this increases intracellular force generation and 
actively remodels the ECM. MyoFBs also express ECM and growth factors, which not only affect 
themselves but also neighboring cells. (Figure adapted from Schroer et al [19]) 
 
Intercellular forces are also transmitted between neighboring cells through 
adherens junctions (AJs), which contain calcium-dependent adhesion proteins called 
cadherins. Classical cadherins form homotypic bonds to neighboring cells and 
mechanically link the cytoskeletal elements of both cells. Different cadherins are found 
in various cell types, and major shifts in cell phenotype are often accompanied by a 
corresponding shift in cadherin expression. For example, cadherin-2 is typically 
expressed in CMs and quiescent fibroblasts, whereas cadherin-11 is highly expressed 
in MyoFBs [44], [48]–[50]. Cadherin-11 forms significantly stronger bonds than 
cadherin-2 and is thus able to transmit increased levels of intercellular tension 
generated by α-SMA in MyoFBs [44], [51]. Recent studies have revealed novel signaling 
roles for cadherins in addition to their structural function [52], [53]. Signaling effectors 
downstream of cadherins, including β-catenin, undergo significant crosstalk with 
cytokine and integrin signaling in the regulation of MyoFB differentiation and function 
[54]–[56]. 
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Etiology of fibrotic cardiac disease 
 Fibrotic disease affects both the valves and the myocardium and is characterized 
by significant changes in tissue composition and biochemical signaling, which in turn 
affect cell behavior and accelerate progression of disease (Figure 2.1A). Several 
cardiac conditions with large clinical impacts are perpetuated by active remodeling of 
the ECM by VICs in valves and by CFs in the myocardium. 
Heart valve disease 
Valve diseases affect over six million Americans and are associated with 
changes in mechanical properties of the leaflets that impair normal blood flow through 
the heart.[1] The etiologies of these conditions are often linked to altered mechanical 
loading (e.g. hypertension, ventricular remodeling, bicuspid aortic valve mutation), and 
in all cases tissue remodeling is perpetuated by sustained inflammatory and fibrotic 
responses, which trigger ECM degradation and accumulation, respectively [57], [58]. 
The mitral and aortic valves on the left side of the heart are most susceptible to disease, 
which manifests most often as regurgitant flow or stenosis [1]. Regurgitant mitral valve 
disease has the highest prevalence (1.7% of adults), but aortic valve disorders are 
associated with higher mortality, especially when calcification and stenosis of the valve 
is evident [1]. The mitral valve is particularly susceptible to tissue weakening in a 
process known as myxomatous remodeling, whereas the aortic valve is susceptible to 
tissue stiffening in response to fibrosis and sclerotic remodeling [59], [60]. Myxomatous 
remodeling is characterized by increased expression of TGF-β1, matrix 
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metalloproteinases (MMPs), and a variety of ECM components and results in valve 
billowing and regurgitant blood flow [59], [61], [62]. Calcific aortic valve disease (CAVD), 
a stenotic disease often necessitating valve replacement, is characterized by increased 
TGF-β1 and collagen expression and the development of calcified nodules, resulting in 
a stiff, partially occluded, stenotic valve [63], [64]. These pathologic alterations to the 
mechanical properties of the tissue are primarily mediated by VICs, a heterogeneous 
population of fibroblast-like cells that differentiate into active MyoFBs in response to 
fibrotic signaling factors and mechanical cues (Figure 2.1) [65]. 
Cardiac fibrosis  
Cardiac fibrosis is a hallmark of heart failure, and results in an increased passive 
stiffness of the heart wall, diastolic dysfunction, and poor long-term prognosis [61–64]. 
Many chronic cardiovascular conditions, including valve disease and hypertension can 
cause pressure overload in the ventricles, which subsequently develop hypertrophy and 
fibrosis [61,65]. Another common initiator of cardiac fibrosis is scar formation after MI, 
which affects over one million Americans annually [1]. MI occurs when an occluded 
coronary artery causes ischemic cell death in a region of the myocardium. In both 
chronic conditions and MI, inflammatory cytokines induce tissue remodeling and 
degradation of ECM in the myocardium [71], [72]. The loss of ECM can result in a 
temporary decrease in the passive wall stiffness and increase in diastolic strains in the 
infarct region, which increase the chance of myocardial wall rupture [12], [73]. 
Deposition of de novo ECM is necessary to maintain structural integrity and requires the 
switch from inflammatory to profibrotic signaling factors [4]. In both chronic and acute 
myocardial remodeling, AngII inhibits the degradation of collagen-1 and promotes the 
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expression of FGF2 and TGF-β1, which in turn promote fibroblast growth and collagen 
production in the diseased myocardium [34], [70], [74], [75]. TGF-β1 inhibits 
inflammation and promotes the differentiation of fibroblasts into MyoFBs and the 
accumulation of dense ECM in the myocardial interstitium [76]. This increases stress on 
the remaining contractile myocardium, resulting in further adverse remodeling and 
fibrosis largely mediated by CFs that have differentiated into active MyoFBs (Figure 
2.1A) [77].  
Myocardial infarction 
The same signaling modalities that contribute to the gradual progression of 
cardiac decline in cardiac fibrosis are drastically dysregulated after acute MI. MI causes 
an immediate and extensive myocardial injury, requiring a dramatic cellular response 
and significant tissue remodeling. Hypoxia in the environment triggers the release of 
more cytokines and increases fibroblast sensitivity to other available cytokines [78]. 
Repair of MI entails the formation of a large collagen scar, which significantly impairs 
cardiac function and often results in cardiac fibrosis, dilated cardiomyopathy, or 
secondary MI.  
There are four partially overlapping phases to healing after MI that are regulated 
by an array of cytokines and cellular responses (Figure 2.3). The first phase is an 
inflammatory response characterized by expression of pro-inflammatory cytokines and 
recruitment of leukocytes within 24 hours after MI. The immune cells and resident 
fibroblasts produce proinflammatory cytokines like tumor necrosis factor α (TNFα) and 
interleukin 1 (IL-1) to recruit Ms, which proceed to phagocytose cellular debris and 
release more cytokines and MMPs to clear the necrotic tissue and debris from the area. 
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These inflammatory cytokines also stimulate the release of MMPs by fibroblasts in the 
wound area. IL-1 and hypoxia are known to stimulate CF release of MMP1, which is 
responsible for degrading collagen-1 [34]. The wound size expands beyond its initial 
borders as MyoFBs and Ms produce MMPs and other proteases to breakdown 
damaged ECM and allow for increased cell migration. At this point, there is an influx of 
fibroblasts from non-infarct areas of the myocardium and from differentiated bone-
marrow derived cells and endothelial derived cells [79], [80]. The resulting increase in 
cellular density is known as the granulation phase (days three to seven post MI) and is 
characterized by high levels of cytokine signaling, specifically AngII, FGF2, TGF-β1, and 
vascular endothelial growth factor (VEGF) to promote matrix remodeling and 
angiogenesis [34], [81]–[83]. AngII suppresses expression of MMP1, and TGF-β1 
suppresses inflammatory cytokines to end the controlled destruction of inflammation 
and allow for de novo accumulation of ECM in the infarct area. A combined treatment of 
angiotensin converting enzyme (ACE) inhibitors and AngII type 1 antagonist (ARB) was 
shown to reduce TGF-β1 and collagen expression and inflammatory cell infiltration in rat 
hearts, but without reduction in infarct size [84]. Finally, one to two weeks after initial 
infarct many of the invaded cells in the granulation tissue undergo apoptosis and only a 
small population of MyoFBs and blood vessels persist in a collagen-rich initial scar. 
Over the following weeks, MyoFBs produce more collagen and contract the collagen 
scar in a TGF-β1-mediated process of fibrosis. Each of these phases performs an 
essential function for surviving significant myocardial damage, but results in the 
formation of a collagen scar. Disruption of these phases can prevent adequate scar 
formation to resist dilated cardiomyopathy or rupture [4]. 
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Figure 2.3. Schematic of the stages in healing after myocardial infarction Following initial cell death, 
the infiltration of leukocytes marks the start of inflammation response, which clears debris and makes way 
for new tissue formation during the granulation phase. A large population of MyoFBs participates in 
producing pro-fibrotic signals that ultimately result in the formation of a stiff collagen scar. (Adapted from 
Boudoulos et. al, 2009 [79]) 
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The scar formed after MI is significantly stiffer than the surrounding tissue; the 
resulting reduced contractile capacity and increased mechanical resistance puts stress 
on the remaining myocardium. This stress often leads to adaptive remodeling, generally 
characterized by dilated cardiomyopathy or cardiac hypertrophy and fibrosis. The 
mechanisms controlling dilated cardiomyopathy are not fully understood, but some 
evidence points to extended inflammation and ECM break down. TGF-β1 is crucial in 
suppressing inflammation signals after initial clearance of debris, and its expression 
must be maintained at least until the end of inflammation [37]. However, excessive 
TGF-β1 signaling has been implicated in the other commonly observed example of 
maladaptive remodeling. Cardiac hypertrophy and fibrosis and scarring after MI are 
examples of fibrotic diseases with a large effect on our population. Both are 
characterized by an accumulation of ECM proteins, notably type-1 collagen, and a loss 
of tissue compliance, which can severely impair organ function [63]. In both cases, 
reduced electrical conductivity of the scar increases the risk for arrhythmia and sudden 
cardiac death [85]. Understanding the processes by which MyoFB activation occurs and 
is regulated is especially crucial to understanding the progression of infarct expansion 
and fibrotic remodeling after MI.  
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CHAPTER 3 
 
BACKGROUND: FIBROBLAST MECHANOBIOLOGY 
 
Text adapted from  
[7] Schroer, A.K. and W.D. Merryman, Mechanobiology of myofibroblast adhesion in 
fibrotic cardiac disease. J Cell Sci, 2015. 128: p. 1865-1875. 
 
MyoFB differentiation in response to mechanical stress 
In healthy tissue, quiescent fibroblasts maintain tissue homeostasis by a 
controlled and balanced release of ECM proteins and proteases [80]. However, these 
fibroblasts transition to an active MyoFB phenotype during injury or disease in response 
to the synergistic contributions of growth factor signaling (primarily TGF-1) and 
mechanical cues (Figure 3.1) [79–81]. In reality, this differentiation occurs along a 
spectrum, often with at least one intermediate state often described as a 
protomyofibroblast, which has some features of MyoFBs, but is still highly migratory, 
characterized by expression of Fibronectin EDA and lack of α-SMA [88]. Decreasing 
substrate stiffness and treatment of MyoFBs with FGF2 have been shown to reverse 
MyoFB differentiation and promote the quiescent fibroblast phenotype in vitro [82, 83, 
84]. However, the increased mechanical stimulation during fibrosis may prevent such a 
dedifferentiation and could be responsible for the long-term persistence of MyoFBs that 
are observed in disease. The three main mechano-sensitive mechanisms of cellular 
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differentiation that give rise to MyoFBs in the heart during disease initiation are 
described below (Figure 3.1). 
 
Endothelial to mesenchymal transition 
ECs directly contribute to tissue remodeling by differentiating into fibroblast-like 
cells in response to chemical and mechanical signals through EndMT (Figure 3.1A). 
These cells lose their endothelial cell-cell adhesions, including cadherin-5 (also known 
as vascular-endothelial (VE)-cadherin), and express migratory, mesenchymal cell 
markers, including cadherin-2, MMP-2 and α-SMA [32]. A similar mechanism is 
responsible for the origin of both VICs and CFs during development and is enhanced by 
active contraction of the myocardium and surrounding matrix [25, 28]. Inflammation and 
TGF-β1 signaling both promote EndMT in valve ECs during the initiation of valve 
disease [29,85]. EndMT also accounts for approximately 25% of the α-SMA-positive, 
MyoFB-like cells that are found in the myocardium after infarction; this transition is 
dependent on canonical Wnt signaling, a pathway that also promotes fibrosis in concert 
with TGF-β1 [86, 87]. These cells participate in ECM remodeling during the transition 
from inflammation to fibrosis, but future work is needed to completely characterize this 
cell population and its contribution to disease manifestation.  
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Figure 3.1. Mechano-sensitive mechanisms of MyoFB differentiation. MyoFBs play a central role in 
fibrotic disease progression in the heart because of their roles in cellular force generation and 
transmission, intercellular signaling, and ECM remodeling. One important mechanism yielding MyoFBs is 
endothelial-to-mesenchymal transformation (EndMT) (A), by which endothelial cells (ECs) lose their 
endothelial markers (including VE-cadherin) and become migratory and contractile. Valvular interstitial 
cells (VICs) and cardiac fibroblasts (CFs) can differentiate into MyoFB in response to high mechanical 
strain (B), which is often experienced during inflammation with the degradation of initial ECM and a 
corresponding decrease in tissue stiffness. Quiescent VICs and CFs can also differentiate into MyoFBs in 
response to high mechanical stress (C), caused by both increased tissue stiffness and increased tissue 
forces. MyoFBs increase the overall stress in the environment by producing excess ECM and contracting 
existing ECM through increased cellular contractility. MyoFBs also release profibrotic signaling factors, 
including TGF-β1 and Wnt, which promote further MyoFB differentiation and tissue stiffening. This forms 
a positive feedback loop leading to progressively worsening fibrosis. Tissue stiffening also often leads to 
compensatory increases in ventricular pressure, which increases the applied tissue forces and reinforces 
this positive feedback loop. (Figure replicated from Schroer et al [19]). 
 
Strain-induced MyoFB differentiation 
Another well-established mechanism for MyoFB differentiation that is relevant to 
the progression of cardiac disease is the differentiation of quiescent VICs and CFs in 
response to high strains (Figure 3.1B). Pressure overload increases strains in the 
valves and myocardium, and the initiation of inflammation causes a breakdown of ECM, 
which can further increase local strains. Ex vivo aortic valves that are exposed to 
pathologic strain (15-20% of original length) expressed more matrix metalloproteinases 
(MMP1, -2, and -9) and collagen-I than valves that are exposed to physiologic valve 
strains (10%) [93]. MMPs and other proteases are also expressed by MyoFBs in infarct 
regions to breakdown any damaged ECM and allow for increased fibroblast migration 
into the infarct region [14], [75], [94]. The resulting decrease in stiffness would lead to 
higher strain when subject to mechanical loading, which is especially relevant at the 
border between the infarct tissue and the remaining contractile myocardium. CFs 
proliferate and express increased levels of α-SMA and MMP-2 in vitro after exposure to 
approximately physiological cyclic strain between 5 and 15 % [95]. In addition, 
expression of MMPs and α-SMA increases the ability of CFs to migrate through and 
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contract 3-D substrates [96]. High local strain may also signal the transition from 
inflammation to fibrosis. In response to increased cyclic strain, aortic VICs (AVICs) 
express reduced levels of inflammatory markers and increased levels of profibrotic 
factors including TGF-β1 [97]. Furthermore, strain can activate latent TGF-β1 that is 
sequestered in the ECM [98], [99]. Strain and TGF-β1 together enhance MyoFB 
differentiation and cell contractility and increase the formation of calcified nodules by 
AVICs in dynamic culture [86], [100], [101]. This increase in calcific nodule formation is 
dependent on the establishment and intercellular transmission of cellular tension by α-
SMA and cadherin-11, respectively [51], [101].  
Stress-induced MyoFB differentiation 
A third mechanical trigger for MyoFB differentiation is increased mechanical 
stress (Figure 3.1C). In vitro, increased substrate stiffness promotes MyoFB 
differentiation in AVICs, leading to increased calcific nodule formation, α-SMA 
expression, and expression of TGF-β receptor type 1 [83, 95, 96]. On stiff 2D 
substrates, CFs exhibit an increase in the expression of α-SMA, TGF-β1, and collagen-
1 [96–98]. MyoFBs generate increased intracellular tension to balance the increase in 
extracellular tension they experience on stiffer substrates, and can then use this tension 
to remodel their local microenvironment [105]. After cells have increased their 
intracellular tension, the surrounding ECM becomes more taut, compact, and stiff, which 
can in turn promote the differentiation of nearby fibroblasts and perpetuate disease 
progression [104].  
Besides their active role in ECM modification after differentiation into MyoFBs, 
CFs can alter myocardial structure by affecting the behavior and function of CMs. Direct 
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intercellular contacts between CFs and CMs in vitro decrease the contraction velocity of 
CMs and increase the expression of inflammatory cytokines therein [12]. CF-induced 
changes in ECM stiffness and composition can also promote CM hypertrophy [106]. 
Finally, the release of profibrotic factors, such as TGF-β1, AngII, and FGF2  by CFs 
have all been shown to promote CM hypertrophy, which leads to a thickening of the 
muscular walls that are then able to generate stronger contractions and enhance 
mechanotransductive signaling throughout the heart [107]. These tissue-level forces are 
transmitted to the different cardiac cells through the cardiac ECM and through 
intercellular adhesions between them. In the following sections, we highlight recent 
research that has provided new insights into the molecular mechanisms by which 
mechanical signals are transduced from the cellular microenvironment in order to elicit 
these tissue-level changes.  
 Mechano-sensitive adhesion proteins, including integrins and cadherins, 
transduce mechanical signals between cells and their microenvironment and can 
stimulate cellular responses including cell growth and differentiation. Both integrins and 
cadherins are large families of proteins, and expression of specific isoforms within these 
families is associated with cell phenotype changes and disease progression (Table 3.1-
2). The following sections will summarize the integrin and cadherin isoforms that are 
upregulated in fibrotic disease in the heart and discuss the mechanosensitive signaling 
pathways they initiate. 
 27 
Table 3.1. Summary of integrin isoform expression in normal function and disease 
Tissue Integrin 
type 
ECM Binding 
Partner 
ECM Expression 
Normal   Diseased 
References 
Valves α2β1 Collagen-1 Arranged 
circumferentially, 
primarily in the 
fibrosa layer 
Increased, 
disorganized 
expression 
throughout valve 
[81] 
α1β1 Collagens IV 
and VI 
Basal lamina of 
endothelium and 
fibrosa 
Increased 
expression 
throughout valve 
[39] 
α3β1 Collagens IV 
and VI 
Basal lamina 
of endothelium 
and fibrosa 
Increased 
expression 
throughout valve 
[82] 
α5β1 Fibronectin Limited expression 
in basal lamina 
Increased 
expression 
throughout valve 
[83] 
αvβ3 RGD Minimal 
expression and 
exposure 
Primarily exposed 
and expressed in 
areas of MyoFB 
differentiation 
[84] 
Myocardium α2β1 Collagen-1 Organized network 
surrounding CMs 
and CF 
Major component 
of scar after MI 
and general 
cardiac fibrosis 
[85] 
α1β1 Collagen-1 Organized network 
surrounding CMs 
and CF 
Major component 
of scar after MI 
and general 
cardiac fibrosis 
[85] 
α5β1 Fibronectin Limited expression 
in basal lamina 
Increased 
throughout the 
myocardium 
[85] 
α7β1 Laminin Expressed 
throughout the 
myocardium 
Increased 
throughout the 
myocardium 
[85] 
β1 Fibronectin/ 
collagen 
Organized network 
surrounding CMs 
and CF 
Increased 
throughout the 
myocardium 
[86] 
α8β1 RGD Organized network 
surrounding CMs 
and CF 
Increased collagen 
and fibronectin 
throughout 
myocardium 
[87] 
αvβ3 RGD Organized network 
surrounding CMs 
and CF 
Increased collagen 
and fibronectin 
throughout 
myocardium 
[88, 89] 
 
 
 
 Table 3.2. Summary of cadherin isoform expression in normal function and disease 
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Tissue 
Cadherin Expression 
Normal            Diseased 
Cell Type 
Mechanotransductive 
effect 
References 
Valves 
cadherin-2 cadherin-11 AVIC 
Increased cell tension, 
calcific nodule formation 
[28] 
cadherin-5 cadherin-2 VEC 
EndMT, migratory, α-
SMA positive cell 
[90] 
Myocardium 
cadherin-2 cadherin-11 CF unknown [91] 
cadherin-2 cadherin-2 CM reduced cell contraction [91] 
cadherin-5 cadherin-2 EC 
EndMT, migratory, α-
SMA positive cell 
[1] 
 
 
Integrins sense mechanical signals from the ECM 
Integrins are a diverse class of ECM receptors comprised of heterodimers of α 
and β subunits that determine ECM binding specificity and intracellular signal 
transduction. Upon ECM engagement, integrins recruit FA proteins that mechanically 
link the cytoskeleton to the ECM, mediating a force balance between stress fibers and 
ECM fibrils and initiating downstream signaling pathways. This signaling is sensitive to 
ECM composition, stiffness, and applied strains and regulates cell phenotype, which in 
turn affects ECM synthesis and integrin expression throughout the progression of 
disease.  
The β1 subunit is part of most collagen-binding integrins in the heart and can 
induce force-dependent cellular responses, including cell growth and MyoFB 
differentiation through activation of FAK, ERK, p38 and other mitogen activated kinases 
(MAPKs) and their downstream signaling cascades. The exact functional effects depend 
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on the cell type and the local microenvironment. For example, CM-specific deletion of 
β1-mediated adhesion results in cardiac fibrosis and heart failure in response to 
pressure overload by disrupting CM membrane integrity and contractile function [108]. A 
recent study investigating cardiac fibrosis in an aortic constriction model showed a 
correlation between β1 integrin persistance and the severity of cardiac fibrosis and 
remodeling, in the context of depleted disintegrin and metalloproteinase ADAM17 
expression [109]. In addition, α7β1 integrin, a laminin receptor, has also been shown to 
have a protective effect in CMs that are exposed to ischemic stress [110]. Removal of 
the β1 integrin-associated mechanosensitive protein melusin alters signaling through 
ERK and glycogen synthase kinase 3β (GSK-3β) and leads to dilated cardiomyopathy 
and fibrosis in response to pressure overload in the heart [111]. These studies highlight 
that β1 integrin helps to protect CMs from adverse effects of the mechanical strains they 
experience. 
Another β1-containing integrin that protects cardiac cells against fibrosis is α2β1 
integrin, the primary receptor for collagen-1, which forms the largest fraction of healthy 
ECM in both valves and the myocardium [112], [113]. Fibrillar collagen-1 networks are 
maintained in a tightly regulated homeostasis that has been shown to be dependent on 
α2β1 integrin-mediated adhesion in fibroblasts [114]. Consequently, blocking α2β1 
adhesion causes a build-up of ECM in the skin and in collagen gel lattices, which is 
prevented by α2β1-induced release of the collagen-1 protease MMP-13  [114]–[117].  
However, while α2β1 integrin inhibits fibrosis in healthy tissues, other β1 integrins 
promote MyoFB differentiation and fibrosis. For instance, α1β1 has been shown to 
promote both inflammation and MyoFB differentiation in adult connective tissue [110, 
 30 
111]. In addition, α3β1 integrin promotes EndMT and MyoFB differentiation in fibrotic 
lungs and mediates crosstalk between factors involved in TGF-β1- and Wnt-associated 
signaling [120]. These integrins are expressed in the heart and bind to non-fibrillar 
collagens IV and VI, which are upregulated during valve disease and myocardial fibrosis 
[61], [121], [122]. Another β1 integrin that has been linked to cardiac fibrotic disease is 
α5β1 integrin, the classic fibronectin receptor. Expression of α5β1 is increased in fibrotic 
myocardium, and signaling downstream of α5β1 promotes the expression of additional 
fibronectin in an example of positive feedback [99], [123]. Secretion of fibronectin 
contributes to further MyoFB differentiation by initiating signaling through FAK that 
facilitates the formation of new integrin adhesions and increases matrix stiffness 
(Figure 3.1C). Fibronectin-induced signaling promotes MyoFB differentiation and MMP 
release by fibroblasts in 3-D in vitro systems, but these effects are reduced or reversed 
by the addition of collagen-1 to the matrix [124], [125]. Another fibronectin-binding 
integrin, α8β1, is specifically enhanced in MyoFBs in fibrotic hearts [126]. Overall, β1 
integrin expression is increased in fibrotic and hypertrophic hearts, and, moreover, 
fibroblast-specific deletion of β1 integrin causes insufficient wound healing and reduced 
MyoFB differentiation in a dermal model [115], [127], [128]. Taken together, these data 
suggest that, despite their protective effect on CMs, β1 integrins exert a pro-fibrotic 
effect in heart fibroblasts during disease. 
Another important integrin type that has been directly linked to 
mechanotransduction and MyoFB differentiation are the β3 integrins [129]. β3 integrins 
recognize the RGD peptide sequence that is found in fibronectin, collagen, and 
vitronectin, and they are highly expressed during development and disease [130]. In 
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accordance with this, AVICs cultured on RGD-coated substrates express increased 
levels of MyoFB markers and of αvβ3 integrins and are more prone to calcification 
[131], [132]. Furthermore, β3 integrin expression in the heart is significantly increased 
after MI, and expression of β3 integrins in CFs is necessary for the accumulation of 
collagen and fibronectin in response to pressure overload [130], [133]. This effect is 
likely mediated by the FA component talin, which links integrins to the cytoskeleton and 
is required for αvβ3 integrin-mediated mechanotransduction [129]. The talin1 isoform is 
expressed in the heart during development and disease, and its deletion prevents 
pressure-induced hypertrophy and fibrosis in the myocardium by altering signaling 
through p38, ERK, protein kinase B (Akt), and GSK-3β [134]. All of these kinases are 
involved in TGF-β1-induced MyoFB differentiation and promote the expression of α-
SMA and increased intracellular tension. Furthermore, β3 integrin engagement with 
ECM proteins enhances TGF-β1 signaling through Src and p38 to further promote the 
expression of α-SMA and of β3 integrins, thereby forming another positive feedback 
loop [135].  
The convergence on TGF-β1 signaling is but one example of the significant 
crosstalk between integrin and growth factor signaling that is involved in the regulation 
of MyoFB differentiation in the heart (Figure 3.2) [92]. Non-canonical TGF-β1 signaling 
through Src and p38 promotes the production of α-SMA in AVICs by the transcription 
factors myocardin related transcription factor (MRTF) and serum response factor (SRF) 
[136]–[138]. FGF2 signaling through FAK and ERK has been shown to prevent MyoFB 
differentiation in MEFs and to reverse TGF-β1-mediated expression of α-SMA [139], 
[89], [140], [141]. Src and FAK are directly activated by β3 and β1 integrins, 
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respectively, and the effects of the adhesions they mediate on MyoFB differentiation is 
mirrored in this crosstalk (Figure 3.2). Compounding this crosstalk, integrin signaling 
also regulates the expression and activation of growth factors. For example, β1 integrins 
regulate the expression of the angiotensinogen gene in CFs through p38 signaling in 
response to mechanical stretch. This effect is mediated by activation of Rac1 and 
inhibition of RhoA, intracellular kinases involved in cytoskeletal organization and 
contraction [142].  
 
 
Figure 3.2. Crosstalk between growth factor and adhesion protein signaling. Illustrated here are the 
intracellular signaling pathways and crosstalk between integrin, growth factor and cadherin signaling. β3 
integrin signals through the same intracelullar pathways as TGF-β1 increasing α-SMA expression and 
cellular contractility. β1 integrin shares pathways with both TGF-β1 and FGF2, which may in part explain 
its context-dependent effects on MyoFB differentiation. Cadherins regulate the availability of β-catenin to 
participate in Wnt signaling, a pathway that promotes cadherin switching and fibrosis. Both integrins and 
cadherins mechanically link the ECM and the actin cytoskeleton and are sensitive to increases in applied 
force from extracellular or intracellular sources; therefore, increased expression of α-SMA in MyoFBs 
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forms a positive feedback loop to further promote adhesion stability and associated signaling pathways. 
Figure replicated from Schroer et al [19]). 
 
 
In addition to such ‘outside-in’ signaling, integrins can also participate in ‘inside-
out’ signaling, by which FA proteins can modify the intracellular domain of integrin 
subunits to activate them, resulting in stronger adhesions to the ECM [143], [144]. 
Vinculin is a force-sensitive FA protein that is recruited to FAs in a tension-dependent 
manner, and has been shown to strengthen and stabilize the FA when held under high 
tension, allowing for greater transmission of force [145]–[147]. Active vinculin can also 
recruit FA proteins including FAK to potentiate further signaling [146], [148]. Intracellular 
force generated by actin stress fibers can be transmitted through these adhesions to the 
ECM to alter its organization. Certain growth factors, including TGF-β1, are secreted 
into the ECM in an inactive form, but αvβ3 integrins can activate such latent TGF-β1 via 
ECM tension, thereby further promoting MyoFB differentiation and fibrosis [98], [99]. 
 MyoFB differentiation results in an increase in α-SMA stress fibers, which can 
strengthen and increase the activation of integrins in FAs, forming a positive mechanical 
feedback loop. The resulting increase in cellular tension can then be transmitted to 
neighboring cells through cadherin-rich AJs as discussed below. 
 
Cadherins sense intercellular forces 
Cadherins mediate mechanically-induced signaling between cells through AJs, 
which link cadherins to the cytoskeleton, as described in a recent review [52]. 
Differential cadherin expression is a major feature of cell differentiation and function 
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during disease and this ‘cadherin switching’ is mediated in part by signaling downstream 
of cadherins (Table 3.2). β-catenin is present in AJs and is intimately involved in 
crosstalk between cadherins, canonical Wnt, and TGF-β1 signaling (Figure 3.2). 
Molecular signaling or mechanical perturbations that disrupt cadherin-cadherin 
interactions between cells have been shown to release β-catenin into the cytoplasm 
where it acts in concert with growth factor signaling to promote a mesenchymal cell 
phenotype [49]. For example, exposure to oscillatory fluid flow triggers a cadherin-2-
mediated release of β-catenin and a subsequent osteogenic differentiation in stem cells 
[149]. Typically, free cytoplasmic β-catenin is rapidly marked for degradation by GSK-
3β; however, inhibition of GSK-3β by activation of TGF-β1, ERK, or Wnt allows for an 
accumulation of β-catenin in the cytoplasm and its subsequent translocation to the 
nucleus where it activates its target genes [56], [150]. In addition to signaling though β-
catenin, several recent studies have characterized a force-dependent interaction 
between vinculin and α-catenin, another protein linking AJs to the cytoskeleton [151]–
[154]. Vinculin is recruited to AJs in a force-dependent manner by α-catenin, which 
results in strengthening of the adhesion and increased cell contractility [53], [151]. This 
result indicates that integrins and cadherins might share a common mechano-sensitive 
mechanism, in which vinculin-induced stabilization of either FAs or AJs affects 
downstream signaling pathways. p120-catenin is also involved in stabilizing AJs and 
increases activation of Rac1 when bound to either N- or Cadherin-11, leading to 
increased expression of mesenchymal cadherins [155], [156].  
Cadherin-2 (N-cadherin) is the classical cell-cell adhesion protein that is 
expressed by quiescent fibroblasts and CMs in the heart. Cadherin-2 expression and 
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localization at cell-cell contacts is associated with increased stability of β-catenin and 
decreased expression of α-SMA [54]. CFs form Cadherin-2-mediated interactions with 
CMs, which influences CM structure and contractility during development, normal 
function and disease [157]–[159]. In a recent study, cadherin-2 bonds between CFs and 
CMs were shown to dynamically deform CM membranes in response to MyoFB 
contraction and induce a measurable slowing of CM conduction velocity [50]. This study 
demonstrates a mechanical signal from MyoFBs that affects the electrophysiology of 
CMs, and may contribute to risk of arrhythmia and other cardiovascular conditions 
associated with low conduction velocity [160].  
While quiescent AVICs and CFs express cadherin-2, during injury and disease 
these cells differentiate into MyoFBs characterized by expression of cadherin-11. 
Cadherin-11 (also known as OB-cadherin) was first described in 1994 in the context of 
osteogenesis and bone development, but recent work has shown its importance in a 
range of tissues [161]. Over 100 papers have been published in the past few years that 
examine the role of cadherin-11 in cancer and fibroblast-mediated disease. In the 
context of cancer, cadherin-11 expression is associated with increased migration and 
metastasis, especially metastasis to bone [162]. As cell differentiation and migration in 
cancer and inflammatory disease show some similarities, cadherin-11 has been 
proposed as a common possible therapeutic target for both types of disease [163]. 
Cadherin-11 plays an important role in inflammation in the context of rheumatoid 
arthritis; it stimulates synovial fibroblasts to release proinflammatory cytokines upon 
cadherin engagement [19, 155]. Celecoxib, a pharmacological inhibitor of 
cyclooxygenase-2 that inhibits inflammation during rheumatoid arthritis, has been 
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shown to bind to cadherin-11 [163]. Inflammation often leads to fibrosis, which is 
mediated by activated MyoFBs. In this context, cadherin-11 has been implicated in the 
progression of dermal and pulmonary fibrosis and suggested to promote MyoFB 
differentiation through interactions with β-catenin [25], [164]. In accordance with this, 
injection of a function-blocking antibody against cadherin-11 improves bleomycin-
induced dermal and pulmonary fibrosis, but its effect has not yet been investigated in 
other organ systems [21,157]. Taken together, these studies indicate that cadherin-11 is 
a promising target in the field of fibrotic disease.  
During MyoFB differentiation, TGF-β1 signaling induces an increase in cadherin-
11 concurrently with a decrease in the expression of cadherin-2 [44]. Within cell-cell 
adhesions, cadherin-11 is able to withstand significantly higher forces than cadherin-2, 
which allows for stronger matrix contraction and the transmission of higher intercellular 
tension [44], [51], [165]. Cadherin-11 has been found to localize at focal adhesions and 
promote cell-substrate adhesion [166]. Cadherin-11 is highly expressed in diseased 
heart valves in both VECs and VICs and has been implicated in the development of 
calcified nodules in the aortic valve in CAVD through increased transmission of 
intercellular force [51], [167]–[169]. It is also expressed in CFs, but the functional 
significance of this expression in the context of cardiac fibrosis and wound healing has 
not been studied. Given the known roles of cadherin-11 in inflammation and fibrosis in 
joint connective tissue and lungs, it is likely that cadherin-11 also has an important role 
in myocardial remodeling [23], [25]. 
In addition to functional mechanical roles, cadherin-11 can also potentiate 
downstream signals to control cell behavior. Although the downstream signaling of 
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cadherin-11 is still relatively uncharacterized, recent studies show a significant crosstalk 
with MyoFB regulatory signals. For instance, it was found that cadherin-11 engagement 
promotes smooth muscle cell differentiation through TGFβRII-mediated pathways and 
increases the expression of α-SMA and cadherin-11 through SRF activation [169]. 
Similarly, blocking cadherin-11 or cadherin-2 engagement reduces the expression of 
MyoFB markers in diseased dermal fibroblasts, which express higher basal levels of 
cadherin-11 and α-SMA compared to healthy fibroblasts [170]. Cadherin-11 
overexpression in fibroblasts has also been shown to increase expression of Wnt and β-
catenin, increase activation of ERK and Akt, and promote cadherin-2 expression [171]. 
These studies indicate that cadherin-11 expression and engagement promotes MyoFB 
differentiation and increase α-SMA expression. This increase in α-SMA stress fibers, in 
turn, contributes to the strengthening and further stabilization of cadherin-11 junctions, 
allowing for enhanced force transmission [44]. However, it is not clear how increased 
tension at cadherin-11 junctions effects signaling through catenins and downstream 
MAPKs. Furthermore, α-SMA and cadherin-11 are not always co-expressed or co-
regulated. For example, increased binding on cadherin-11-coated surfaces has been 
shown to inhibit α-SMA expression in porcine AVICs and knockdown of cadherin-11 has 
been shown to increase α-SMA expression [167]. Future studies are needed to clarify 
the interplay between cadherin-11 mechanotransduction and MyoFB differentiation.  
To conclude, there are mechanistic similarities between fibrotic disease 
progression in the heart wall and valves that can inform future studies of disease. 
Namely, in both myocardium and valve tissue, there is an increase in active MyoFBs 
that remodel ECM and alter cardiac mechanics and function. These cells are sensitive 
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to mechanical signals that are transduced largely through integrins and cadherins. 
Integrins react to the composition and mechanics of the microenvironment of a cell and 
can promote cell differentiation in a context-dependent manner. MyoFB differentiation 
potentiated by integrin and cadherin signaling can contribute to further ECM remodeling 
and tissue stiffening, which in turn enhances mechanotransductive signaling in nearby 
cells (Figure 3.1). Such a system of positive feedback loops can then perpetuate the 
progression of fibrotic disease. Prolonged inflammatory responses further compound 
the problem by initiating and propagating ECM remodeling. Both integrin- and cadherin-
11-mediated signaling have been implicated in inflammation, and strategies aimed at 
blocking the functions of these adhesion molecules have shown preliminary success in 
limiting inflammation-triggered maladaptive remodeling [23]–[25], [118]. The overlapping 
and integrated networks of chemical and mechanical signals that regulate fibrotic heart 
disease progression will continue to make the development of promising therapies a 
challenge. Nevertheless, the crucial role of cadherins and integrins in both chemical and 
mechanical signaling makes them excellent potential targets for therapy and future 
study [20].  
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CHAPTER 4 
 
AIM 1: ELUCIDATING MECHANOSENSITIVE SIGNALING CROSSTALK IN 
FIBROBLASTS 
 
Text for Chapter 4 taken in part from: 
[139] Schroer, A.K., Rhyzova, L.M., Merryman, W. D., Network Modeling Approach to 
Predict Myoﬁbroblast Differentiation. Cellular and Molecular Bioengineering, 
2014. 7(3): p. 446-459. 
 
Introduction 
Fibroblast cells play a key role in producing and maintaining connective tissue 
throughout the body. The ability of these cells to differentiate into active MyoFBs is 
important during development and wound healing, but prolonged MyoFB activation can 
lead to overproduction of ECM proteins and stiffening of the surrounding tissue. This 
stiffening can cause heightened differentiation of neighboring fibroblasts through force 
transduction pathways and can lead to detrimental fibrotic pathologies in many organ 
systems [172]. One hallmark of the MyoFB phenotype is the production of α-SMA stress 
fibers, which transmit intracellular forces and increase the contractility of the cells and 
surrounding tissue [88], [173]. Clarifying the inputs and intracellular mechanisms that 
govern MyoFB differentiation will provide insights into the pathophysiology of many 
fibrotic diseases.  
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 Mechanical stress and TGF-β1 are known to promote the MyoFB phenotype [88] 
and FGF2 has been shown to oppose TGF-β1 signaling and promote the quiescent 
fibroblast phenotype [83], [100], [140], but the intracellular effectors of these 
environmental cues have significant crosstalk [174], [175]. Cells can experience 
mechanical tension and substrate rigidity through integrins: transmembrane proteins 
that transduce forces from the ECM to intracellular structures like FAs and stress fibers. 
Different isoforms of integrin subunits are activated to transmit mechanical signals by 
specific ECM proteins. Integrins with β3 subunits are activated by fibronectin and 
transmit mechanical signals through the tyrosine kinase Src [129], [176]. Together, Src 
and β3 integrin enhance TGF-β1 non-canonical signaling to p38 [177], [178]. β1 integrin 
subunits activate focal adhesion kinase (FAK) in a stiffness dependent manner [179]. 
Src and FAK are important in the formation and maintenance of FAs and are known to 
form a complex and activate each other’s kinase activity to enhance downstream 
signaling [176], [180]. 
Both integrin signaling and cadherin regulation have significant interaction with 
TGF-β1 signaling pathways. TGF-1 is a major promoter of the MyoFB phenotype that 
is known to play a role in cardiac fibrosis. TGF-β1 is a key mediator of the hypertrophic 
and dilative ventricular remodeling and is released by cardiac fibroblasts and myocytes 
with pressure overload and infarction and in response to AngII expression [181], [182]. 
TGF-β1 also plays a crucial role in ending inflammation and beginning wound 
strengthening by repressing inflammatory signals and promoting accumulation of ECM 
by inhibiting proteases [182]. Canonical TGF-β1 signaling through TGF-β receptors and 
Smads 2 and 3 is required for many of these mechanisms. A recent study investigating 
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reperfusion MI in mice lacking Smad3 demonstrated that canonical TGF-β1 signaling 
through Smad3 increases collagen expression and inhibits fibroblast proliferation [170]. 
However, inhibition of Smad function did not prevent TGF-β1 induced α-SMA 
expression, indicating an important role for non-canonical signaling [137]. Non-
canonical TGF-1 signaling through Src and p38 has been implicated in the regulation 
of contractile α-SMA production. TGF-1 binding to its type 1 receptor activates Src, 
which in turn phosphorylates tyrosine 294 on TGF receptor 2 (TR2), leading to p38 
phosphorylation [177]. This signaling is crucial for MyoFB differentiation of AVICs and 
other fibroblast cell types [136], [137]. Mouse embryonic fibroblasts that cannot express 
Src family kinases (SYF-/-) express significantly fewer MyoFB markers than their wild 
type counterparts (MEF+/+) (Figure 4.1A). MAPK p38 is also critically important for 
MyoFB differentiation [137], [183]. Inhibiting p38 effectively blocks TGF-1 induced 
MyoFB differentiation, but does not interfere with canonical Smad signaling indicated by 
PAI-1 expression (Figure 4.1B). PAI-1 reduces protease activity in the local 
microenvironment and can allow for accumulation of ECM. Within the nucleus, 
transcription factors myocardin related transcription factor (MRTF) and serum response 
factor (SRF) (downstream of Src and p38, respectively) are required for the transcription 
of α-SMA and other markers of contractile MyoFBs [138].  
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Figure 4.1. Src and p38 are necessary for TGF-β1 induced MyoFB differentiation Deletion of Src 
family kinase in SYF-/- MEFs prevents TGF-β1 induced increase of a MyoFB marker (A). TGF-β1 induced 
upregulation of MyoFB markers α-SMA and SM22α, but not PAI-1, are prevented by p38 inhibition (B). 
(Figure adapted from Hutcheson et al. 2012 [137]) 
 
FGF2 is another factor that is critical for development and can have a potent 
effect on fibroblast phenotype that is upregulated in the heart after MI [74]. In addition to 
promoting proliferation, FGF2 signaling to ERK has been shown to prevent MyoFB 
differentiation in MEFs and reverse TGF-β1 induced α-SMA expression [89], [140], 
[141]. Kawai-Kowasa et al. demonstrated that expression of the transcription factor SRF 
is crucial for α-SMA expression, but its function is blocked by phosphorylated ERK after 
FGF2 treatment [140]. Greenberg et al. found that this effect is modulated by FAK and 
does not occur in FAK-/- cells [89]. FGF2 is also known to activate p38, a crucial player 
in TGF-β1 induced α-SMA expression [184]. In the context of the heart, FGF2 is 
released in response to AngII signaling and induces CM hypertrophy while stabilizing 
gap junction coupling in CMs [181]. It has been reported to have a cardioprotective 
effect during healing after MI, allowing for scar deposition and contraction, stimulating 
CM hypertrophy, and promoting angiogenesis [10], [74], [107]. With such a striking 
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effect on cardiac outcomes, it is perhaps surprising that the mechanisms for FGF2 
action on CFs are relatively poorly understood. There have been no studies 
investigating the role of FGF2 in regulating cadherin-11 expression or signaling, despite 
the growth factor’s known roles in regulating MyoFB differentiation and cardiac 
remodeling. 
In a simplified scheme of α-SMA production (Figure 4.2), signaling through 
integrins and growth factors appears to converge at the intracellular level on two 
particular kinases, p38 and ERK. TGF-β1 signaling and β1 integrin signaling both 
activate p38, which has been shown to promote the MyoFB phenotype [42], [185]. 
Conversely, ERK is required for FGF2 induction of the quiescent fibroblast phenotype 
[141], [186], [187] . FAK serves as a docking site for Src and enhances Src activation 
and signaling to p38 [136], while transducing signals from integrins and FGF2 to 
enhance ERK activation and limit α-SMA production [89], [188]. FGF2 and TGF-β1 
stimulate both p38 and ERK; however, they are known to lead to divergent outcomes 
[140], [189]. The complex and dynamic interactions of these signaling pathways 
complicates the regulation of fibroblast differentiation.  
 Figure 4.2. Relevant signaling network. The cartoon depicts the major pathways of MyoFB regulation 
and convergence on p38 and ERK kinases (A). Degradation and interactions details are not shown for the 
Activation 
modulated by 
stiffness
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sake of clarity. The schematic shows the model protein species and reactions (B). Proximity to the yellow 
node indicates that the rate of the reaction depends on the activation of the upstream protein species. 
The dashed line represents the contribution of Src. Figure replicated from Schroer et al [139]. 
 
Computational models of cell signaling networks have been developed and used 
in many biological systems to clarify complex interactions, especially when intracellular 
activation states are difficult to quantify [190]. Some models have been developed for 
subsets of this system to clarify specific mechanisms, but do little to address network 
effects and responses [191]–[193]. Modeling biological networks is challenging because 
of the high number of interactions, the range of relevant time scales, and the difficulty of 
acquiring quantitative data of intracellular kinetics. Despite these hurdles, many model 
strategies have been developed and successfully implemented in similar network 
settings [190]. A model developed by Janes et al. integrates complex cytokine signals to 
predict apoptosis, and they countered these difficulties by focusing on data-derived 
models [194]. Further analysis of the same model indicated that the dynamic range of a 
given intracellular signaling event is more important for system function than the signal 
strength, which lessens the need to define system components with absolute protein 
numbers or concentrations [195].  
 The goals of this aim are to clarify the roles of FAK and Src in linking integrin and 
cytokine signaling, and characterize the signaling profiles of TGF-β1 and FGF2 through 
p38 and ERK in the regulation of α-SMA and cadherin-11 expression. These 
experiments were used to develop a quantitative model to evaluate and compare 
potential mechanisms for protein interactions in the regulation of α-SMA expression, 
that is described in detail in APPENDIX A. Known TGF-β1, FGF2, and integrin signaling 
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to p38 and ERK through Src and FAK from previously reported literature informed the 
development of an ODE based model of fibroblast differentiation in different chemical 
and mechanical environments. The model was refined by fitting to experimental results 
for α-SMA production and dynamic phosphorylation events. We further compared the 
expression of cadherin-11 in these same conditions to gain a better understanding of 
MyoFB heterogeneity and regulation. 
Methods 
Cell Culture 
Wild type mouse embryonic fibroblasts (MEF+/+), MEFs lacking Src, Yes and 
Fyn (SYF-/-), and MEFs lacking FAK (FAK-/-) [196] were used in this study. Cells were 
cultured in DMEM supplemented with 10% FBS, 1% antibiotic-antimicrobial and 1% 
non-essential amino acids. Unless otherwise noted, cells were plated at a density of 
8000 cells/cm2 on tissue culture plastic (TCP) and kept in serum free conditions during 
treatment with 1 ng/ml TGF-β1, 10 ng/ml FGF2 or 20mM LiCl.  
PDMS for stiffness studies 
 Polydimethylsiloxane (PDMS) (Sylgard 184 from Dow Corning) culture surfaces 
were made with 10:1:0, 10:1:5, and 20:1:2 ratios of silicone-elastomer base to 
elastomer curing reagent to silicone oil as previously described [197], [198]. Bulk 
stiffness of these formulations was measured to be 2.1, 0.9 and 0.24 MPa, respectively 
[198]. The dishes were then sterilized under UV light for 40 minutes and coated with 
human full-length fibronectin in filtered carbonate-bicarbonate buffer overnight to ensure 
proper cell adhesion.  
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Immunohistochemistry 
Coverslips were coated in human full-length fibronectin by overnight incubation in 
a 50 g/ml solution in sterile carbonate-bicarbonate buffer and rinsed in PBS before 
addition of cells. After 24 hours of treatment, cells were fixed with 4% paraformaldehyde 
and permeabilized in 0.4% triton for 10 minutes, blocked in 1% BSA for 1 hour, and 
stained with a Cy3 conjugated monoclonal α-SMA antibody (Sigma) or an antibody 
against cadherin-11 (Invitrogen). Cadherin-11 primary was diluted 1:100 in 1% BSA and 
incubated overnight at 4˚ C. An antirabbit secondary conjugated to a far red fluorophore 
and the α-SMA antibody were both diluted 1:300 in 1% BSA and incubated at room 
temperature for 1 hour. Slides were mounted in Prolong Gold with DAPI mounting 
media to stain the nuclei and imaged at 20x magnification. 
Quantification of α-SMA production by indirect ELISA 
Indirect ELISA assays with α-SMA polyclonal antibody (Abcam) were used to 
quantify α-SMA expression after 24 hours in serum free conditions as previously 
described [137]. Briefly, cells were lysed in Cell lytic M media and diluted to a common 
concentration. Samples were incubated on 96 well plates in a blocking solution of 5% 
milk overnight at room temperature, incubated with an antibody against α-SMA, an 
antirabbit secondary conjugated to HRP, then incubated the Sure blue ELISA reagent, 
with thorough PBS washes between each step. 
Quantification of MAPK activation and CDH11 expression by western blot 
Western blots were used to study dynamics of MAPK activation in MEF+/+ and 
FAK-/- cells as previously described [137]. Briefly, cells were serum starved for 3-4 
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hours before treatment, and were lysed and diluted to equal protein concentration in 
RIPA buffer supplemented with protease and phosphatase inhibitors. Relative p38 and 
ERK phosphorylation was quantified by densitometry analysis and normalized to a 
loading control (-actin, total ERK, or total p38) (Cell Signaling Technologies) and then 
to the average MEF+/+ no treatment case within each time point for each experiment.  
Statistical analysis 
 For all experiments measuring outputs across a range of cell types and 
treatments, a two-way ANOVA was run within each time point to determine significant 
effects of cell type and treatment, and interactions between the two. The Holms-Sidak 
method and individual student t-tests with an overall significance level of 0.05 were 
used for multiple comparisons within cell-type and treatment groups. One-way ANOVA 
was used for dose response experiments that were limited to one cell type. Non-
parametric tests (ANOVA on ranks or rank sum tests) were used if the samples failed 
the Shapiro-Wilks normality test or had unequal variance (p < 0.05).  
Results 
Removing focal adhesion kinase proteins and growth factor treatments altered -SMA 
Immortalized cell lines generated with genetic deletions certain proteins can be a 
powerful tool to probe intracellular signaling. In these experiments we found that MEFs 
with genetically deleted focal adhesion proteins expressed significantly different levels 
of α-SMA in serum free conditions when compared to wild type cells (Figure 4.3A). 
SYF-/- cells expressed significantly less α-SMA than MEF+/+ cells in all treatment 
groups (Figure 4.3A), expressing less than 20% of the α-SMA expressed in MEF+/+ 
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cells. Furthermore, there was no significant difference between treatment groups within 
the SYF-/-. FAK-/- cells expressed significantly more α-SMA than MEF+/+ cells 
regardless of treatment, and both growth factors caused a significant effect relative to 
untreated FAK-/- cells (Figure 4.3A).  
Our next experiment clarified the relationship between growth factor 
concentration, equilibrium p38 and ERK phosphorylation and α-SMA expression in 
MEF+/+ cells. At 24 hours, there is no significant change in pp38 with treatment with 1 
or 10 ng/mL FGF2 (despite early dynamic signaling changes), but there is a significant 
log-linear increase proportional to TGF-β1 concentration (Figure 4.3B). There is 
significant ERK phosphorylation after a 24 hour treatment with TGF-β1 that is 
independent of TGF-β1 concentration. There is also a significant increase in ERK 
activation with FGF2 treatment, which is highly dependent on FGF2 concentration 
(Figure 4.3C). Finally, these data show divergent regulation of α-SMA by FGF2 and 
TGF-β1, despite acting through common intracellular mediators (Figure 4.3D). Both 
TGF-β1 and FGF2 play important roles in remodeling after MI, so their interaction and 
crosstalk deserves significant consideration in the context of myocardial remodeling. 
The demonstrated cardioprotective effects of FGF2 signaling observed in cardiac 
disease may be due in part to the suppression of highly contractile α-SMA expression 
MyoFBs [74]. 
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Figure 4.3. α-SMA is oppositely regulated by TGF-β1 and FGF2 through FA proteins and p38 and 
ERK dependent mechanisms. (A) α-SMA measured by ELISA after 24 hours of culture in serum free 
media, 1ng/ml TGF-β1, or 10ng/ml FGF2. All FAK-/- and SYF-/- were all significantly different from the 
wild type MEFs (p < 0.01). (B-D) A set of experiments to determine concentration dependent changes to 
p38 and ERK activation and α-SMA expression in response to TGF-β1 and FGF2. p38 (B) and ERK (C) 
phosphorylation determined by densitometry of western blots and α-SMA (D) expression determined by 
indirect ELISA. * denotes a significant difference between the NT and TGF-β1 treated MEFs (p < 0.05). # 
denotes significant difference from the FAK-/- NT group. ^ denotes significant difference from the MEF+/+ 
sample under a given treatment. (Figure adapted from Schroer et al. 2014 [139]) 
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TGF-β1 and FGF2 induce MAPK phosphorylation with different dynamic profiles  
Next we measured and compare the dynamic activation profiles of both p38 and 
ERK in MEF+/+ and FAK-/- cells. Western blot data showed significant and sustained 
p38 phosphorylation in response to TGF-β1 that peaked at 1 hour in both MEF+/+ and 
FAK-/- cells and remained significantly enhanced (p = 0.017) after 24 hours treatment 
(Figure 4.4A-C). While the shape of this activation was consistent between cell types, 
the peak magnitude in the FAK-/- cells was significantly lower (p = 0.007). Steady state 
p38 phosphorylation at 24 hours was also significantly lower in FAK-/- cells relative to 
MEF+/+ cells (p = 0.046). In the same set of experiments, FGF2 induced a rapid 
increase in p38 phosphorylation that attenuated to less than 1.5 fold of the non-treated 
group within one hour. FGF2 induced a dramatic increase in ERK phosphorylation in 
both cell types in five minutes that persisted for at least three hours (Figure 4.4D-E) and 
was still significantly elevated at 24 hours (Figure 4.4F). TGF-β1 induced a slight 
significant increase at 30 minutes that faded to insignificance within one hour. However, 
both cell types showed significantly enhanced ERK phosphorylation at 24 hours after 
treatment with TGF-β1 (Figure 4.4F).  
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Figure 4.4. Different dynamic activation profiles for activation of ERK and p38. Averaged results of 
western blot densitometry analysis for pp38 (A-C) and ERK (D-F) activation over a three hour time course 
in MEF+/+ (A,D) and FAK -/- (B,E) cells treated with 1ng/ml TGF-β1 or 10 ng/ml FGF2. Average p38 and 
ERK activity after 24 hours of treatment (C,F). * indicates significant difference (p < 0.05) from average no 
treatment within cell type and time course. ^ indicates significant difference (p < 0.05) from the MEF+/+ 
sample within treatment and time point. G-L are the model output values for the same quantities at the 
same time points. (Figure adapted from Schroer et al. 2014 [139]) 
 
These experiments informed the development of an ODE based signaling model 
for α-SMA regulation via TGF-β1, FGF2 and integrin signaling through the network 
depicted in Figure 4.2 [115]. The model was able to match relative α-SMA production in 
MEF+/+ and FAK-/- cells with and without TGF-β1 and FGF2 treatment. It was also able 
to predict MEF+/+ expression of α-SMA on PDMS with and without these growth factor 
treatments. Sensitivity analysis of the model correctly predicted increased sensitivity to 
growth factors in the absence of FAK. 
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We then expanded our focus on MyoFB differentiation to include cadherin-11. 
We observed a profound reduction in cadherin-11 expression in response to FGF2 
treatment in both the immunostaining and western blot results (Figure 4.5) that 
represents a novel and potentially significant finding in the field of MyoFB regulation. 
We found that cadherin-11 was regulated in parallel to α-SMA by TGF-β1 and FGF2, 
but FAK-/- cells expressed significantly less cadherin-11 than their wild type 
counterparts (Figure 4.5A-B). SYF-/- cells expressed significantly less cadherin-11 than 
FAK-/- cells (data not shown), indicating that Src family kinase signaling is critical for 
expression of both cadherin-11 and α-SMA. The inverse response of cadherin-11 and 
α-SMA to the absence of FAK suggests that the two markers of MyoFBs are regulated 
through different, FAK-dependent mechanisms. Immunostaining of MEFs on fibronectin 
coated coverslips confirms that α-SMA and cadherin-11 are not always co-expressed 
within individual cells (Figure 4.5C, white arrows). This imbalance could affect the 
ability of MyoFBs in the heart to transmit forces to their neighbors and the 
microenvironment. We also observe what appears to be cadherin-11 staining inside the 
FAK-/- cells, which may indicate an inability to effectively traffic this protein to the 
membrane (Figure 4.5C, yellow arrows). 
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Figure 4.5. α-SMA and cadherin-11 (CDH11) are not necessarily coexpressed. α-SMA (A) and 
cadherin-11 (B) expression as measured via western blot, normalized to β-actin loading controls. TGF-1 
and FGF2 treated samples are significantly different from not treated controls and FAK-/- samples are 
significantly lower than MEF+/+ (p < 0.05). (C) Immunoflourescence of WT and FAK-/- MEFs plated on 
fibronectin coated coverslips and treated with 1ng/ml TGF-1 or 10 ng/ml FGF2 for 24 hours. α-SMA is 
shown in red, cadherin-11 is shown in green, and nuclear stain is depicted as blue. Images taken at 20X 
magnification. White arrows indicate α-SMA-negative, cadherin-11 positive cells and yellow arrows 
indicate apparent transport defects in FAK-/- cells. 
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In addition to quantifying the effect of cytokine dose and FA protein removal, we 
wanted to assess the effect of mechanical stiffness on α-SMA and cadherin-11 
expression. PDMS plates of stiffnesses ranging from 230 kPa to 2.1 MPa were made 
and coated with full length fibronectin. Cells seeded on this substrate should develop 
robust FAs containing activated β1 and β3 integrins. We hypothesized that these FAs 
would signal through Src and FAK in a stiffness dependent manner. After 24 hours of 
serum starvation, cells were lysed and prepped for indirect ELISA quantification of α-
SMA production or western blot for cadherin-11 expression (Figure 4.6). We found a 
statistically significant interaction between cell type and substrate stiffness (p = 0.009). 
α-SMA production was significantly reduced when cells were cultured on PDMS, with 
the lowest α-SMA expression corresponding to a PDMS stiffness of 900 kPa. There was 
no significant difference between α-SMA expression on fibronectin coated TCP and 
uncoated TCP in either cell type. α-SMA in FAK-/- cells is significantly higher than in 
MEF+/+ (p < 0.001) on TCP (stiffness = 3E6 kPa) but is not statistically different at 
lower stiffness, indicating that the regulation of α-SMA in FAK-/- cells is more sensitive 
to changes in stiffness than in MEF+/+ cells. Cadherin-11 expression was significantly 
lower in FAK-/- cells across all stiffnesses and is less sensitive to changes in stiffness 
than α-SMA (Figure 4.6B). We did observe a significant decrease in cadherin-11 
expression from TCP to 10:1 PDMS in MEF+/+ cells. The apparent importance of FAK 
in both α-SMA and cadherin-11 regulation points to an important regulatory role for 
ERK. Inhibition of ERK has been shown to increase α-SMA and prevent TGF-β1 
induced cadherin-11 expression in porcine AVICs, but recent work in our lab suggests a 
more complex role for ERK that overlaps with the GSK-3β pathway [51]. These data 
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confirm that mechanotransduction through integrins plays a significant role in the 
regulation of MyoFB differentiation through integrins and FAK. 
 
 
Figure 4.6. α-SMA and cadherin-11 are sensitive to stiffness and the presence of FAK. WT and 
FAK-/- MEFs were seeded on fibronectin coated PDMS of varying stiffnesses and α-SMA and cadherin-
11 expression was determined by ELISA and western blot, respectively. * indicates significant differences 
from TCP. (Figure adapted from Schroer et al. 2014 [139]) 
 
 
 
We performed preliminary experiments probing canonical Wnt signaling with the 
GSK-3β inhibitor LiCl at a concentration of 20 mM in complete media. Western blot 
analysis confirmed a significant increase in phosphorylation of GSK-3β after 24 hours of 
LiCl treatment. In MEFs we observed a substantial increase in both cadherin-11 
expression and α-SMA with LiCl alone. We further observed significant reduction of 
TGF-β1 induced cadherin-11 expression with LiCl treatment. LiCl did not seem to affect 
TGF-β1 induced increase in α-SMA expression, but did partially recover the FGF-
induced decrease in both cadherin-11 and α-SMA (Figure 4.7).  
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Figure 4.7. Expression of MyoFB markers after treatment with TGF-β1 and FGF2 with GSK-3β 
inhibition. Cadherin-11 and α-SMA expression determined by western blot. Data normalized to α-tubulin 
loading control. 
 
 
Discussion 
Using genetically modified MEFs, we have highlighted the importance of Src 
family kinases and FAK in the regulation of MyoFB differentiation. Our results 
demonstrate a profound inhibitory effect of removing Src, Yes, and Fyn on α-SMA 
production and stress fiber assembly. Densitometry of western blots revealed 
comparable levels of p38 and ERK phosphorylation in SYF-/- cells relative to MEF+/+ 
cells (data not shown), so the effect is likely operating through a different mechanism. It 
is likely that signaling downstream of Cas and other Src substrates is necessary for 
proper α-SMA synthesis. TGF-β1 signals to TGF-β activated kinase 1 and subsequent 
α-SMA production is significantly reduced with Src inhibition and the removal of FAK 
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[199]. This result is consistent with recent reports of Src’s prominent role in non-
canonical TGF-β1 signaling in the context of MyoFB differentiation [137].  
Interestingly, the absence of FAK, a protein that is known to enhance Src 
activation and signal to p38, caused a significant increase in α-SMA. Given its complex 
role in multiple signaling cascades, it is not surprising that reports of the effect of FAK 
on MyoFB differentiation vary. Blocking FAK expression in cardiac fibroblasts with 
siRNA has been shown to decrease force induced α-SMA promoter activity [188]. 
Furthermore, it has been reported that α-SMA production in serum free conditions and 
after TGF-β1 treatment are higher in FAK expressing MEFs compared with FAK-/- 
counterparts [200]. Alternatively, others have reported that FAK is involved in FGF2 
signaling to ERK in response to FGF2 cells, and FAK-/- cells contain enhanced α-SMA 
accumulation and persistence after treatment with FGF2 [89], [140]. Reduced basal 
ERK phosphorylation in FAK-/- cells has also been reported, and a model proposed for 
FGF2 signaling to ERK requiring FAK [89]. This informed the development of our model 
and is consistent with the decreased initial ERK phosphorylation and increased α-SMA 
that our model predicted. Additionally, we found that FGF2 was able to induce 
significant ERK phosphorylation and lower α-SMA in the absence of FAK, which 
indicates that FAK is not required for FGF2 and ERK based inhibition of α-SMA.  
Surprisingly, our time course results show that ERK phosphorylation in non-
treated FAK-/- cells is not significantly different from MEF+/+ at 24 hours and is 
significantly higher at 30 minutes. Sensitivity analysis of the model predicted that FAK-/- 
cells would be more sensitive to changes in TGF-β1 and FGF2. Our experimental 
results seem to confirm that FAK-/- cells have a higher sensitivity to environmental 
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perturbations when the media is changed at the start of the time course. ERK’s specific 
role in α-SMA regulation has also presented in multiple perspectives. Some have 
argued that ERK is necessary for TGF-β1 induced activation [200], [201], while others 
proposed a largely inhibitory role [85], [89], [140], [202] . Several groups have shown 
that MEK1/2 inhibition significantly increases α-SMA expression in fibroblast-like cells 
[51], [203] [46, 109]. One of the goals achieved in this project was to investigate the 
possibility of matching the observed upregulation of ERK by TGF-β1 and FGF2 in a 
model with a relatively straightforward α-SMA regulatory scheme inversely proportional 
to pERK. 
Another main goal of this project was to clarify the interactions between growth 
factor and integrin signaling in the regulation of MyoFB differentiation. We first showed 
that decreasing substrate stiffness can significantly lower the expression of α-SMA in 
MEFs through a fibronectin-integrin interaction that is significantly altered in FAK-/- cells 
(Figure 4.6). Sensitivity analysis of our network model predicted that FAK-/- cells would 
be more sensitive to changes in stiffness, which we observed in the experimental data 
(Figure 4.6A). The relationship between α-SMA and stiffness has been shown 
previously and is correlated with changes in p38 activation [42]. Both β1 and β3 
integrins have been shown to have mechanosensitive capabilities and are involved in 
outside-in signaling to intracellular kinases like FAK and Src [129], [179]. β3 integrins 
are known to interact with TGF-β1 signaling to Src and p38 [204] and are a likely target 
for further insights.  
All of the work reported in Schroer et al. 2014 ([139]) used relative α-SMA 
expression as a metric of MyoFB differentiation. While it is a key and widely recognized 
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marker of the MyoFB phenotype, it is not the only indicator of an active fibroblast. 
Expression of ECM protiens, including collagen-1 and fibronectin EDA, and the cell-cell 
adhesion protein cadherin-11 are also important markers of an activated fibroblast [44], 
[88]. Understanding the heterogeneity within fibroblast/MyoFB population can be 
especially important to understand the function of CFs after MI [13].  
We also observed that while cadherin-11 expression in MEFs changes similarly 
to α-SMA in response to both TGF-β1 and FGF2, its expression is inversely affected by 
the absence of FAK. This further confirms a critical regulatory role for FAK in controlling 
the MyoFB phenotype. We also observed a decrease in cadherin-11 expression with on 
900 kPa PDMS relative to plastic, though there was no significant change in FAK-/- 
cells. Interestingly, in both MEF+/+ and FAK-/- cells, cadherin-11 expression appears to 
be trending upwards on softer PDMS samples. It is possible that fibroblast populations 
on softer, more physiologically relevant, substrates have more innate heterogeneity of 
phenotype and protein expression. While an increase in cadherin-11 after TGF-β1 
treatment has been well established, a corresponding reduction after treatment with 
FGF has not been reported. The fact that cadherin-11 expression was drastically 
decreased by FGF2 is consistent with a key function to promote quiescence in 
fibroblasts, but the mechanism of this effect is still largely undefined.  
Our first step to determining a potential mechanism, we observed a reversal of 
both TGF-β1 and FGF2 effects’ on cadherin-11 expression with the inhibition of GSK-
3β. These results suggest that GSK-3β also has a significant role in regulating MyoFB 
differentiation and influences TGF-β1 and FGF2 signaling. GSK-3β has been reported 
to regulate cadherin-11 expression [205] and is known to play important roles in healing 
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after MI [206]. The Wnt pathway has significant crosstalk with TGF-β1 in the 
progression of fibrosis and plays important roles in the origin of MyoFBs after MI [14]. 
By signaling through β-catenin, it also has some natural cross-talk with signaling 
downstream of cadherins, including cadherin-11 [48]. Signaling downstream of 
cadherin-11 has also been reported to act through p38 and ERK specifically [207]. 
Future studies are needed to elucidate signaling downstream of cadherin-11. 
There are several important limitations to the conclusions of this work that must 
be acknowledged. While they can be a powerful tool, cell-lines with a permanent 
deletion of signaling proteins often compensate by altering expression of other related 
proteins, which can have confounding effects on signaling studies. Repetition of these 
studies using an inducible knock-down cell line, siRNA, or a small molecule inhibitor 
would help to support the postulated mechanisms and confirm acute effects on 
signaling and myofibroblast regulation. Future studies could also probe the 
phosphorylation of both Src and FAK over the time course of activation and in response 
to the various conditions mentioned. Direct integrin blocking with a blocking antibody or 
knock-down with siRNA, would give more fine detail into the roles of specific integrin 
subtypes on intracellular signaling. The range of stiffnesses used in this study was 
intended to span from measured fibrotic tissue stiffness to traditional cell culture plastic 
[198]. The stiffness of 900 kPa approximately matches the stiffness of the Flexcell 
plates used in the Merryman lab to probe the effect of active strain on cellular 
phenotype. Healthy cardiac tissue is generally much softer, between 10 and 50 kPa 
depending on the measurement modality, so while the PDMS substrates are certainly 
softer than tissue culture plastic, they are not in a physiologic range. Furthermore, all of 
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these experiments were performed on 2D culture, which promotes adhesion formation 
very different from the adhesions formed in 3D environments [45]. 
Our results indicate that Src family kinases are crucial for α-SMA synthesis in 
fibroblasts and demonstrate that FAK plays an important role in integrating signals for 
the regulation of α-SMA and cadherin-11 production during MyoFB differentiation. They 
also confirm significant interaction between growth factor and integrin signaling through 
the MAPKs p38 and ERK. Finally, they suggest that cadherin-11 may have a critical role 
in both MyoFB function and regulation. Cadherin-11 expression is increased by TGF-1 
signaling and sensitive to changes in substrate stiffness, both of which are relevant in 
healing after MI.   
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CHAPTER 5 
 
AIM 2: CADHERIN-11 EXACERBATES TISSUE REMODELING AFTER MYOCARDIAL 
INFARCTION  
 
Text for Chapter 5 adapted in part from: 
[208] Schroer, A.K., Clark, C., Zhang, Q., Sanders, L.H., Hatzopoulos, A.K., Lal, H., 
Force, T., Merryman, W.D., Cadherin-11 exacerbates inflammation and 
maladaptive remodeling after myocardial infarction. Circulation Research, 2016. 
(submitted). 
 
Introduction 
Over one million Americans experience a myocardial infarction (MI) every year, 
and the resultant cardiac remodeling significantly reduces function and increases risk of 
subsequent infarctions and heart failure. The process of infarct healing requires 
complex interactions between resident and recruited cells that must coordinate the 
clearance of damaged tissue and replacement with a stable and robust collagen scar to 
prevent cardiac rupture. However, excess repair activity can ultimately lead to 
expansion of the infarct area and worsened cardiac function.  
Developing treatment strategies for MI is made particularly challenging by the 
precise and necessary timing of both chemical signals and cellular activity. Many 
treatments targeting specific growth factor cascades have failed to maintain the delicate 
balance between necessary and excessive inflammation and fibrosis. Furthermore, 
broad target treatments can often have adverse side effects on the surviving 
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cardiomyocytes (CMs), causing additional loss of contractile potential [209]. An ideal 
therapy for MI would reduce without completely blocking both the initial inflammatory 
response and later progression of fibrosis.  
One protein whose role in other inflammatory and fibrotic cell processes has 
recently been described is cadherin-11 (CDH11), a cell-cell adhesion protein expressed 
by activated fibroblast-like cells in multiple inflammatory and fibrotic disease models. 
Cadherin-11 has recently been shown to play key roles in the progression of both 
arthritis and pulmonary fibrosis, but its function in infarct healing has not been studied 
[25], [210]. 
Cadherin-11 engagement promotes the expression of the inflammatory cytokine 
IL-6 as well as profibrotic signaling factors and MyoFB markers in joints, lungs, and 
heart valves [23], [51], [163], [210]. Established inflammation-induced fibrosis in the 
lungs has been reversed by treatment with functional blocking antibody against 
cadherin-11 [25]. Mechanosensitive signaling through cadherin-11 affects both 
inflammation and fibrosis, two key phases of remodeling after MI, but the details of this 
signaling are still poorly understood. The objective of this work is to clarify the role and 
function of cadherin-11 in the dynamic chemical and mechanical context of myocardial 
remodeling. We hypothesize that preventing cadherin-11 adhesion in CFs will reduce 
inflammation-driven infarct expansion and fibrotic scar formation after MI and improve 
cardiac outcomes. 
 
Methods 
Mice 
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Vanderbilt University biomedical research programs are supported by a 
comprehensive Animal Care and Use Program (ACUP) that has been fully accredited 
by AAALAC since 12/1967 (PHS Animal Welfare Assurance No. A3722-01). All animal 
procedures were performed in accordance with the Vanderbilt IACUC approved protocol 
M/15/126. Cadherin-11 transgenic mice [209] were given to us by collaborators. These 
mice were maintained on a C57BL/6J background, and both CDH11-/- and WT 
littermates were used for experiments. C57BL/6J male mice (Jackson Labs) were 
purchased between 12 and 16 weeks of age for MI surgeries. All mice were given pre 
and post-op analgesic of 5mg/kg ketoprofen every 24 hours for 72 hours. For the 
antibody treatment study, mice were administered an intraperitoneal (IP) injection every 
four days beginning one day after surgery, consisting of 10mg/kg of a functional 
blocking antibody against cadherin-11 (SYN0012) or an isotype control antibody 
(IgG2a) dissolved in sterile saline. The last treatment was given on day 17 after infarct.   
Quantification of heart function and size by echocardiography 
Ejection fraction and LV volume were measured from m-mode images of the 
short axis of hearts captured on the Vevo 2100 system. At least 6 independent 
measures of LV diameter and wall thickness were used for each mouse for each time 
point. Ejection fraction and LV Volume were calculated from the measured LV inner 
diameter at diastole and systole. 
Measurements were made before surgery, and at seven, twenty-one, and fifty-six 
days after surgery. Mice whose ejection fraction was reduced by less than 5% or 
greater than 60% were excluded from subsequent analysis to ensure that all mice 
included had reasonably consistent, intermediate to large infarcts that had not 
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progressed to complete heart failure. Mice were euthanized in a CO2 chamber in 
accordance with university guidelines at three, seven, twenty-one and fifty-six days after 
infarct. 
Identification of non-CM cell types by flow cytometry 
Relative contributions of different cell types were measured by flow cytometry 
[13]. Hearts were isolated from animals at three or seven days after sham or MI 
surgeries and immediately placed in a solution of ice cold 5% FBS in PBS. The atria 
were removed and the ventricle tissue was minced and stored on ice. Two mLs of 
digest solution comprised of 10 mg/ml of type II collagenase in dispase was added to 
each sample, and then incubated at 37 degrees for seven minutes. The digested 
sample was filtered through a 100 m cell strainer and resultant cells were washed in 
50 mLs of ice cold PBS, and refiltered through a 70 m cell strainer. Red blood cells 
were lysed with Gey’s solution and cells were washed again in PBS and counted to 
measure the total number of viable, non-CM cells. 500 thousand cells were then taken 
from each sample, suspended in DAPI to identify dead cells, blocked with Fc antibody, 
and then stained for Ter119 (eBioscience), CD45 (BD Bioscience), CD31 (Biolegend), 
and CD11b (Tonbo biosciences). 
Windowing based on size, shape and negative staining for DAPI and Ter119 was 
used to identify viable single cells. Further windowing based on full panel minus one 
stained controls, was used to identify distinct cell populations relevant to our study. We 
identified leukocytes (CD45high), inflammatory monocytes (CD45/CD11bhigh), endothelial 
cells (CD31high,CD45/CD11blow), fibrocytes (CD31/CD45low,CD11bhigh), and fibroblasts 
(CD31/CD45/CD11blow).  
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Cryosectioning and trichrome stain/histological assessment 
Hearts were dissected into PBS, weighed, and then submerged briefly in a KCl 
solution to relax the CMs. They were then sliced in half in the transverse plane 
(orthogonal to the long axis of the heart) and mounted in OCT media and frozen. They 
were subsequently cryosectioned into 10 m thin sections and stored at -20C. A 
selection of the slides were stained with Masson’s trichrome (sigma) according to the 
manufacturers instruction to identify regions of healthy myocardium (red/pink), ECM 
(blue), and cell nuclei (black). Before staining, sections were thawed, the OCT media 
was dissolved in PBS, and the sections were fixed in Bouin’s fluid. To quantify scar 
length and thickness, we measured the fractional length and average radial thickness of 
4 sections each at least 300 m distant from each other.  
Immunohistochemistry 
Non-conjugated antibodies (CDH11, CD45, IL-6) were incubated on the sample 
overnight at 4 degrees at a 1:100 dilution in 1% BSA, then rinsed with PBS and 
incubated with fluorescently tagged secondary antibodies for 1 hour at a 1:300 dilution 
in 1% BSA. The rest of the antibodies were directly conjugated and were incubated on 
the sample at a 1:100 dilution in 1% BSA for 1 hour at room temperature. Slides were 
mounted in prolong gold with DAPI mounting media to stain the nuclei and imaged on 
an Olympus scope. 
AFM 
 After thawing frozen sections and dissolving the OCT in PBS, tissue sections 
were blocked in 10% FBS for 20 minutes, and stained for α-SMA (sigma) or a Hoest 
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nuclear stain (invitrogen) for 20 minutes. This staining allows for visualization of the 
infarct while scanning, which is performed in PBS (Online Figure II). We used a 
Biocatalyst AFM developed by Bruker to measure topography and stiffness of 10x10 m 
areas within the infarct (at least 5 per mouse from at least 2 sections). We used a 
blunted pyramidal tip specifically developed for soft biological samples (MLCT-Bio) and 
the peak force quantitative nanomechanical mapping scanning mode that provides 
robust measurement of topography and elastic modulus. Each day before scanning 
samples, the spring constant and deflection sensitivity of the probe was calculated, and 
the system was calibrated on a 40 kPa polyacrylamide gel.  
Quantification of α-SMA protein by western blot 
Protein was isolated from the organic phase of the TRIZOL samples according to 
manufacturers’ instructions and equal amounts of protein for each sample were run on 
an 8% polyacrylamide gel to separate by size. After transferring and blocking, α-SMA 
and the loading control α-tubulin was identified with fluorescently tagged antibodies and 
scanned on a LICOR scanner. Densitometry analysis was performed in the image 
studio software, and α-SMA signal was normalized to alpha tubulin.  
Cell isolation and culture 
To complement and inform our in vivo studies, we isolated cardiac fibroblasts 
[211] and intraperitoneal Ms  from mice. CFs were isolated from WT and CDH11-/- 
mice that had been bred with the immorto mouse line, so that cells from littermate 
controls could be cultured for longer. Hearts were isolated from 8 week old mice, 
minced, and digested in 2% collagenase solution supplemented with trypsin for the last 
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10 minutes of a 40 minute digest. CFs were then rinsed and plated on gelatin coated 
plates, and cultured in DMEM supplemented with 10% FBS, 1% penicillin/strep, and 
gamma interferon at 33 degrees to maintain the immortalized phenotype. Cells were 
replated in DMEM supplemented with 10% FBS and 1% penicillin/strep and grown at 37 
degrees for 48 hours to deactivate the immortalized gene.  
M exfiltration was stimulated by IP injection of 1mL of 4% thioglycollate media 
three days before isolation. Mice were sacrificed and the interperitoneal cavity flushed 
with 10 mLs of cold RPMI media to collect the cells. After washing in cold PBS, cells 
were plated in RPMI media supplemented with 10% FBS on tissue culture plastic and 
allowed to adhere for 1 hour. Non-adherent cells were then rinsed away, and the 
remaining cells should all be Ms [212]. 
Gel contraction assay 
CFs were diluted to a final concentration of 250k cells/mL in a 1.28 mg/ml 
collagen solution derived from PureCol (Advanced Biomatrix) to a final concentration of 
250 thousand cells/ml and were poured into a Teflon ring in a suspension well. After 
polymerizing for 1 hour, media was added to flood the well and release the gels from 
both the bottom of the well and the Teflon ring. The gels were imaged immediately after 
release and at different times over the next 48 hours, and the area of the gels measured 
and normalized to the original area of the gel. For comparison of IgG2a and SYN0012, 
antibody was added to the cell/gel mixture before pouring for a final concentration of 20 
g/ml, and media added to the well also contained 10 g/ml of antibody.  
I-wire contraction assay and measurement 
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 CFs were diluted in an identical collagen solution as the one used in the floating 
gel assay and added to a PDMS channel about 10 mm in length with wires crossing 
through the channel near the ends (more information about I-wire platform can be found 
in Chapter 6). After polymerizing for 1 hour, media was added. Over the course of a 
week, the fibroblasts contract the matrix to form a linearized construct supported by 
wires on each end, but suspended in media along the length of the channel. After 7 
days (changing media every 2 days), a calibrated probe was used to measure the 
passive tension in the construct in response to increasing extension. Stage 
displacement drives the probe into the construct, applying a transverse force and 
resulting in simultaneous probe deflection and construct stretch. Deflection of the probe 
was measured and used to calculate the stretch and tension in the construct, and a 
quadratic fit was used to calculate the predicted intrinsic stress present in the construct 
as formed.   
qPCR 
For assessment of in vivo transcription, hearts were isolated under RNAse-free 
conditions and immediately flash frozen until the time of analysis. Samples were 
subsequently thawed and lysed in TRIZOL, with chloroform induced phase separation 
to isolate mRNA according to manufacturers’ instruction. cDNA was synthesized using 
the Superscript IV kit (Invitrogen) from 500 ng of mRNA. Real time qPCR was 
performed to amplify specific targets from the cDNA by mixing it with SYBR green 
master mix (BIO-RAD) and primer sets (Table 5.1). The BIO-RAD CFX96 C1000 
system was used to quantify relative transcription. For all of the in vivo results we 
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averaged the three- and seven-day sham values these and normalized all post-MI 
samples to this value.  
Table 5.1 qPCR primers 
Target Forward Reverse 
GapDH ATGACAATGAATACGGCTACAG TCTCTTGCTCAGTGTCCTTG 
cTnT AGGAGCTGATTTCCCTCAAAG TTTCCTTCTCCCGCTCATTG 
Cdh11 
exon12 
TCACTATCAAAGTCTGTGGCTG CAAACAGCACAACGATGACC 
IL-6 CAAAGCCAGAGTCCTTCAGAG GTCCTTAGCCACTCCTTCTG 
F4/80 ACC ACA ATA CCT ACA TGC ACC  AAG CAG GCG AGG AAA AGA TAG 
IL-1 TCCTGTGTAATGAAAGACGGC ACTCCACTTTGCTCTTGACTTC 
TNFα AGACCCTCACACTCAGATCA TGTCTTTGAGATCCATGCCG 
MMP13  GATTATCCCCGCCTCATAGAAG TCTCACAATGCGATTACTCCAG 
MMP3 CAGGAAGATAGCTGAGGACTTTC  GGTCAAATTCCAACTGCGAAG 
TGF-1 CCTGGGTTGGAAGTGGATC TTGGTTGTAGAGGGCAAGG 
α-SMA GAGAAGCCCAGCCAGTCG CTCTTGCTCTGGGCTTCA 
collagen 1 CACCCTCAAGAGCCTGAGTC GTTCGGGCTGATGTACCAGT 
FGF2  GGAGTTGTGTCTATCAAGGGAG TGCCCAGTTCGTTTCAGTG 
VEGFa-1 AAAGCCAGCACATAGGAGAG CGAGTCTGTGTTTTTGCAGG  
Flk1 TGCGGGCTCCTGACTACACTAC TTCCCAAATGCTCCACCAACTCTG 
Mrc1 ATGGATGTTGATGGCTACTGG TTCTGACTCTGGACACTTGC 
Cd14 CCTTTCTCGGAGCCTATCTG  CAACTTTCCTCGTCTAGCTCG 
Arg1 AAGAATGGAAGAGTCAGTGTGG  GGGAGTGTTGATGTCAGTGTG 
 
Quantification of IL-6 production by indirect ELISA 
Fifty thousand CFs were plated in a 12 well plate, allowed to adhere for 20 min, 
and then supplemented with media containing between 0 and fifty thousand Ms, for a 
final volume of 1.3 mLs per well. We tested the interaction of cells (including Ms 
alone) without antibody treatment, and then specifically compared CFs and a range of 
co-culture with IgG2a or SYN0012. These samples were incubated with antibody for 15 
minutes before plating. After 48 hours in culture, conditioned media was removed from 
wells and IL-6 expression over this period was measured with a Duoset mouse IL-6 
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ELISA (R&D Systems). After boiling, 100 l of each samples were added to the 
prepared ELISA plate, and the IL-6 expression was measured in duplicate and 
compared against a provided standard.  
Statistical analysis 
 For all experiments measuring outputs across a range of time points and 
treatments, a two-way ANOVA was run to determine significant effects of time and 
treatment, and interactions between the two. The Holms-Sidak method and individual 
student t-tests with an overall significance level of 0.05 were used for multiple 
comparisons within cell-type and treatment groups. Non-parametric tests (ANOVA on 
ranks or rank sum tests) were used if the samples failed the Shapiro-Wilks normality 
test or had unequal variance (p < 0.05). F-tests were run on median stiffness values to 
compare variances of tissue stiffness. 
 
Results 
Establishing relevance of cadherin-11 after MI 
 The first step in our investigative process was to determine if, when, and where 
cadherin-11 is expressed after MI. We first confirmed that CM have significantly less 
transcription of cadherin-11 relative to non-CMs (Figure 5.1A). This confirms what had 
been reported in the literature, that CMs do not express cadherin-11 [50], and led us to 
focus subsequent experiments on the non-CM cellular population. We next established 
relevance of cadherin-11 to healing after MI by assessing transcription of cadherin-11 
after MI, which rose to the highest fold change we observed in the course of these 
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experiments with a significant, 10-fold increase above sham control hearts at day seven 
after infarct (Figure 5.1B). While we did not measure cadherin-11 in untreated mice at 
21 days, mice treated with either IgG2a or SYN0012 had similar fold-increase in 
cadherin-11 transcription relative to sham at day 7, and both groups’ transcription 
dropped notably between day 7 and day 21 (Figure 5.9B), from roughly 7-fold to 3-fold. 
Having determined when cadherin-11 transcription is upregulated, we wanted to confirm 
literature reports of the rough make-up of non-CM cell populations in the heart after MI, 
especially at days 3 and 7 after MI. As expected, the total non-cardiomyocyte cell 
population increased significantly after MI (Figure 5.1C), consisting of a large 
population of inflammatory monocytes (CD45/CD11b)high at day three, which had 
significantly shrunk by day seven after MI. There was also a significant increase in 
fibroblasts (CD45/CD31/CD11b)low cells at three days, which had not significantly 
decreased by day 7. Co-staining of a 7-day post-MI heart revealed significant cadherin-
11 staining in Ms (CD45+ and F4/80+), endothelial cells (CD31+ and CD45-), smooth 
muscle cells and MyoFBs (α-SMA+) (Figure 5.1D), indicating that all three of these cell 
types may be playing a role in the dynamic process of healing after infarct. With a peak 
in cadherin-11 transcription at day 7, when inflammation has largely subsided, it seems 
likely that MyoFBs are important cadherin-11 expressers.  
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Figure 5.1 Cadherin-11 is expressed after myocardial infarction. Cadherin-11 (CDH11) transcription 
was significantly higher in the non-cardiomyocyte (non-CM) cell population relative to cardiomyocytes 
(CM) (* indicates p < 0.05) (A). Transcription of cadherin-11 was significantly increased (# indicates p < 
0.05 relative to sham) at both three and seven days following MI (B), and was significantly higher at 
seven days than three days (^ indicates p < 0.05 difference between days). The noncardiomyocyte (non-
CM) cell population changed after MI (C) as measured by flow cytometry. There was a significant 
increase in the number of inflammatory monocytes (CD45+/CD11b+), and fibroblasts (CD45-/CD31-
/CD11b-) at both time points, no change in the number of endothelial cells (CD45-/CD31+), and a 
significant decrease in resident Ms from day three to day seven after MI. n = 3 mice per group. 
Immunostaining confirmed the presence of cadherin-11 expressing Ms, endothelial cells, and MyoFBs 
in the infarct region seven days after MI (D). Arrows indicate the location of the cells in magnified callouts. 
 
Comparison of WT and CDH11-/- animals 
 We next measured the effect of MI in WT vs. cadherin-11 null (CDH11-/-) 
animals and observed significant improvement of both ejection fraction and systolic LV 
volume in CDH11-/- animals relative to WT at seven days, but these differences did not 
persist to day twenty-one (Figure 5.2A-B). Immunostaining confirmed the presence of 
cadherin-11 in the infarct of the WT mice at twenty-one days after infarct (Figure 5.2C), 
and trichrome images suggest that the collagen in the infarct at twenty-one days is less 
compacted in the CDH11-/- animals (Figure 5.2D). Finally, a collagen gel contraction 
assay revealed a significant reduction in contractility of CDH11-/- CFs (Figure 5.2E), 
which has been reported [167]. This results confirm a functional role for cadherin-11 in 
the process of myocardial remodeling after MI. However, a global knockout can have 
subtle, negative effects on heart structure that may explain the transience of the 
beneficial effect. In any case, since there is no known clinical link between cadherin-11 
mutations and human disease, we transitioned to studying a more clinically relevant 
strategy targeting cadherin-11 adhesion after MI.  
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Figure 5.2 Cadherin-11 null (CDH11-/-) hearts respond differently to MI. Comparison between wild 
type (WT) and CDH11-/- mice ejection fraction (A) and LV volume (B) as measured by echocardiogram 
following infarct. n > 3 mice per group. Immunostaining of MyoFB markers in the infarct at twenty-one 
days (C) and trichrome images of the infarct (yellow dashed area indicates approximate area of images in 
C) to visualize scar thickness (D). Results of gel contraction assay using WT or CDH11-/- cardiac 
fibroblasts embedded in a floating collagen gel (E). n = 3 gels. * indicates p < 0.05 relative to WT. 
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Comparison of function with IgG2a or cadherin-11 blocking antibody (SYN0012) 
 Treatment with a blocking antibody against cadherin-11 has been shown to have 
beneficial effects in the case of both rheumatoid arthritis and pulmonary fibrosis, which 
supported the hypothesis that a similar strategy would prove efficacious after MI. Having 
identified injury-induced cadherin-11 expression in multiple non-CM cell types after MI, 
we moved on to test a cadherin-11 blocking antibody (SYN0012) treatment. We 
observed a small increase in survival (p = 0.16) (Figure 5.3A) and an increasingly 
improved ejection fraction (Figure 5.3B) in the SYN0012 treated group relative to 
controls over the entire time of the experiment (eight weeks). Furthermore, significantly 
increasing dilation of the left ventricle observed in the IgG2a treated mice was curtailed 
in the animals receiving the blocking antibody, resulting in improved, reduced ventricle 
volume at twenty-one and fifty-six days post-MI, in both diastole (Figure 5.3C) and 
systole (Figure 5.3D). These results were very exciting, supporting the hypothesized 
role of cadherin-11 as a regulator of both inflammation and fibrosis and further its 
suitability as a therapeutic target.  
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Figure 5.3 Cadherin-11 blocking antibody treatment improves outcomes after MI. Mice were treated 
with cadherin-11 blocking antibody (SYN0012) or isotype control (IgG2a) for twenty-one days beginning 1 
day after infarct. Fewer animals receiving SYN0012 treatment compared with IgG2a (p = 0.16) died in 
response to the large infarct (A). n > 33 mice per group initially. While ejection fraction (B) and left 
ventricular volume (C,D) was significantly changed from baseline in all groups, treated animals had 
significantly improved ejection fraction and reduced LV expansion compared to controls (* indicates p < 
0.05 difference between treatments). n > 8 mice. Furthermore, the significant change over time observed 
in control animals (^ indicates p < 0.05 difference between timepoints) was prevented by treatment.  
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Comparison of remodeling with IgG2a or cadherin-11 blocking antibody (SYN0012) 
We further assessed tissue properties with AFM and measured a significant 
decrease relative to sham animals in infarct tissue stiffness at seven days in both 
groups (Figure 5.4A). The mean and median stiffness measurements were lower in the 
IgG2a treated animals compared to the SYN0012 stiffness at day seven, and the 
variability was significantly less than both sham and SYN0012 animals. However, by 
day twenty-one, both groups stiffened significantly, their mean and median stiffness 
rising above the sham myocardial stiffness. The range of measured stiffnesses in the 
IgG2a treated hearts exceeded the time-matched SYN0012 group, especially at 56 
days-post MI. These results suggest that during the first week after infarct, more tissue 
breakdown (and subsequent softening) occurs in the IgG2a treated hearts compared to 
SYN0012. Between week one and three, both groups appear to experience similar 
stiffening with the creation of a collagen scar, but there is more heterogeneity in the 
properties of the scar in the control group.  Histologic assessment revealed that scars in 
SYN0012-treated animals spanned a lesser fraction of the circumference of the left 
ventricle at both twenty-one and fifty-six days after MI and were thicker in the radial 
direction (Figure 5.4B-D). Western blots also revealed a decrease in α-SMA expression 
at twenty-one days after infarct (Figure 5.4E). These findings indicate that infarct 
expansion due to inflammation and myofibroblast-driven scar compaction and 
remodeling were both reduced by SYN0012 treatment.  
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Figure 5.4 SYN0012 reduces infarct remodeling and MyoFB differentiation. Atomic force microscopy 
was used to measure median stiffness of 10x10 m regions throughout the infarct over time. Colormaps 
of representative scans are depicted above the corresponding plot of average median stiffness (A). 
Representative trichrome sections (B) used to quantify the relative length of the infarct (C) and the scar 
thickness (D). Western blot revealed that α-SMA was significantly reduced at twenty-one days after infarct 
in the treated animals (E). # indicates p < 0.05 relative to sham, ($ indicates p < 0.05 relative to variance 
of IgG2a, * indicates p < 0.05 between treatment, ^ indicates p < 0.05 relative to previous timepoint. n > 3 
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CF contractility with IgG2a or cadherin-11 blocking antibody (SYN0012) 
We next wanted to determine whether CF contractility was similarly affected by 
blocking cadherin-11 engagement as by removal of cadherin-11. A gel contraction 
assay (n=3) showed no difference in bulk gel contraction between IgG2a treated and 
SYN0012 treated CFs (Figure 5.5A). There was also no change in lateral compaction in 
the I-wire construct mold, but assessment of the intrinsic stress developed in the 
construct after seven days using a parabolic fit to the passive elasticity/stress curve 
(Figure 5.5B) revealed a significant decrease in intrinsic stress developed under 
linearized tension in the SYN0012 treated samples (Figure 5.5C).  These findings 
highlight a functional difference between a genetic knock-down and blocking antibody 
treatment.  
 
Figure 5.5 SYN0012 effect on CF contractility. Results of collagen gel contraction assay (A) with 
representative images of gels at 0 and 48 hours. Schematic of I-wire construct system inset above 
stress/displacement curves in I-wire construct from representative constructs (B) with intrinsic stress 
(arbitrarty units) marked by open circles. Yellow scale bar represents about 1 mm in image callouts below 
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graphs. Average relative intrinsic stress from I-wire constructs (n = 3) (C). * indicates significant difference 
(p > 0.05) between IgG2a and SYN0012 samples. 
 
IL-6 expression with IgG2a or cadherin-11 blocking antibody (SYN0012) 
While cadherin-11 transcription peaked at day 7 after infarct, the fact that there 
were significant differences in function at day 7 indicates that the treatment is having 
some sort of effect on the cells of the heart within the first week, during the inflammatory 
and granulation phases. To determine the cellular changes that mediated these 
changes in dynamic tissue remodeling, we evaluated transcriptional changes of a 
variety of inflammatory and fibrotic markers over the time course of experiment. We 
observed a decrease in transcription of IL-6, a pro-inflammatory cytokine, in the 
antibody treated group three days post-MI (Figure 5.6A). This reduction seems to occur 
primarily in the non-CM cells of the infarct, a mixed population of inflammatory cells, 
endothelial cells and myofibroblasts (Figure 5.6B). Pronounced IL-6 expression can still 
be seen in the CMs of the BZ in both groups, as compared to low IL-6 expression in the 
distant myocardium. 
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Figure 5.6 Reduction of IL-6 observed three days post-MI in vivo with SYN0012 treatment. 
Transcription of IL-6 after MI relative to sham. # indicates significant (p > 0.05) difference from sham, and 
* indicates significant difference (p > 0.05) between IgG2a and SYN0012 samples. Immunostaining for IL-
6 three days after infarct at the border zone (BZ) and transition to the infarct (IN). 
Macrophage alterations with IgG2a or cadherin-11 blocking antibody (SYN0012) 
Expression of IL-6 has been shown to be enhanced in a mixed population of 
fibroblasts and Ms [213], which motivated us to look at M markers and localization in 
the infarct after MI. Transcription of F4/80 was significantly reduced at day seven in 
vivo, suggesting a decreased number of Ms present at this time, though there was no 
significant difference in transcription at day three or 21 (Figure 5.7A). Immunostaining 
of hearts at day three after infarct show an apparent reduction in the colocalization of 
(and hence the likely interactions between) activated MyoFBs (α-SMA) and Ms 
(F4/80) in the infarct and border zone (Figure 5.7B).  
 
Figure 5.7 Reduction of F4/80 observed three days post-MI in vivo with SYN0012 treatment. 
Transcription of F4/80 over time, with the relative fold change at seven days called out for clarity (A). # 
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indicates significant (p > 0.05) difference from sham, and * indicates significant difference (p > 0.05) 
between IgG2a and SYN0012 samples.  
 
Transcriptional changes of inflammatory and fibrotic signaling factors 
Expression of other inflammatory markers was not changed significantly over this 
time course by SYN0012 treatment (Figure 5.8), but the average transcription of 
MMP13 in control animals at day seven was significantly enhanced relative to sham, 
whereas the expression of MMP13 had dropped back to baseline levels by day seven in 
the SYN0012 treated case (Figure 5.8D). Profibrotic/myofibroblastic markers, including 
TGF-1, cadherin-11, α-SMA, and collagen-1 were also not dramatically changed by 
treatment (Figure 5.9). Of the profibrotic markers, note that TGF-1 transcription is no 
longer significantly enhanced in the SYN0012 treated group, at seven days after MI, in 
contrast to the control group (Figure 5.9A). Furthermore, it may be noted that cadherin-
11 transcription is more slowly upregulated with SYN0012 treatment, which may 
indicate a positive feedback effect of signaling downstream of cadherin-11 engagement 
(Figure 5.9B). Also, this confirms that cadherin-11 transcription is significantly 
increased above sham over the three weeks of myocardial remodeling, but does appear 
to peak at seven days. Finally, while there is no significant difference in transcription of 
either collagen-1 (Figure 5.9C) or α-SMA (Figure 5.9D), transcription of both was 
moderately reduced by SYN0012 treatment over the time course of the experiment.  
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Figure 5.8 Transcriptional changes of inflammatory proteins after MI. IL-1 (A), TNF-a (B), MMP3 
(C), and MMP13 (D). # indicates significant difference (p < 0.05) from sham. n > 3 animals. 
 
Days post-MI
0 5 10 15 20 25
M
M
P
3
 t
ra
n
s
c
ri
p
ti
o
n
0
2
4
6
8
10
12
Days post-MI
0 5 10 15 20 25
T
N
F
 t
ra
n
s
c
ri
p
ti
o
n
0
1
2
3
4
5
6
7
8
Days post-MI
0 5 10 15 20 25
IL
-1
 t
ra
n
s
c
ri
p
ti
o
n
0
5
10
15
20
25
30
#
#
#
#
#
#
#
#
A B
C
IgG2a 
SYN0012 
sham
Days post-MI
0 5 10 15 20 25
M
M
P
1
3
 t
ra
n
s
c
ri
p
ti
o
n
0
1
2
3
4
5
6
7
8 #
#
#
D
M
M
P
1
3
 t
ra
n
s
c
ri
p
ti
o
n
 85 
 
Figure 5.9 Transcriptional changes of pro-fibrotic proteins after MI. TGF-1 (A), cadherin-11 (B), 
Collagen-1(C), and α-SMA (D). # indicates significant difference (p < 0.05) from sham. n > 3 animals. 
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Transcriptional changes of pro-angiogenic signaling factors 
We also measured transcription of known pro-angiogenic signaling factors FGF2, 
VEGF-a and the VEGF receptor Flk-1 (Figure 5.10A-C) and were surprised to observe 
decreased expression of all three across all timepoints, which were significant at twenty-
one days in the case of VEGF-a. FGF2 was significantly enhanced relative to sham at 
all time points in control, but only at day three in the SYN0012 treated group. Despite a 
marked reduction in angiogenic signaling, we did not observe a reduction in vascular 
density in vivo, and in fact observed increased numbers of muscularized vessels and 
fewer MyoFBs in the SYN0012 treated infarct at twenty-one days (Figure 5.10D). This 
observed reduction in MyoFBs in the infarct corresponds well with the reduction in α-
SMA and reduced scar compaction (Figure 5.4B-E). 
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Figure 5.10 Transcriptional changes of pro-angiogenic proteins after MI. Relative fold change from 
sham for FGF2 (A), VEGF-a (B), and Flk-1 (C) reduced by SYN0012 treatment in vivo. n > 3 animals. # 
indicates significant (p > 0.05) difference from sham, and * indicates significant difference (p > 0.05) 
between IgG2a and SYN0012 samples. Immunostained hearts isolated twenty-one days after infarct, 
stained for endothelial cells (CD31) and smooth muscle cells or MyoFBs (α-SMA). IN indicates the infarct 
area, BZ indicates border zone, and IT indicates inflammation tissue. White arrows indicate the location of 
muscularized arterioles and arteries, while red arrows indicate locations of MyoFBs (α-SMA without 
CD31).  
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Co-culture of CFs and Ms increase expression of inflammatory signals 
Given the changes we observed in IL-6 and F4/80 we observed in vivo, we 
hypothesized that SYN0012 treatment might be preventing M/CF interactions reported 
to promote IL-6 transcription, either by blocking direct cadherin-11 bonds between cell 
types or by preventing their interactions in vivo. To test this hypothesis, we used a co-
culture system of CFs and intraperitoneal Ms. Co-culture of fifty thousand CFs with 
zero to fifty thousand Ms showed significant increases in IL-6 expression with addition 
of Ms, with all CF containing samples producing significantly more IL-6 than Ms 
alone (Figure 5.11A). qPCR of these samples confirmed that transcription of F4/80 
closely corresponds to the number of Ms present (Figure 5.11B), and furthermore that 
transcription of MMP13 was significantly increased over CFs alone by co-culture with 
Ms (Figure 5.11C). Transcription of MMP13 was roughly two-fold higher in Ms alone 
than in a 1:1 coculture in a previous experiment, so this increase is likely due mostly to 
the increased number of Ms. The addition of IgG2a to this in vitro co-culture 
environment did not significantly alter the secretion of IL-6 from the non-treated controls, 
but SYN0012 treatment did significantly lower IL-6 production in the 1:1 co-culture 
condition (Figure 5.11D). Comparison of F4/80 transcription indicated that the blocking 
antibody had no significant effect on the relative proportion of Ms in the co-culture 
system (Figure 5.11E) or on the co-cultured production of MMP13 (Figure 5.11F).  
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Figure 5.11 Co-culture of Ms and fibroblasts increase expression of IL-6 and MMP13. # indicates 
significant (p > 0.05) difference from sham, and * indicates significant difference (p > 0.05) between 
IgG2a and SYN0012 samples.  n = 3. 
 
Further analysis of the transcription in the co-culture setting indicates that TGF-
1 transcription was significantly enhanced by co-culture and, somewhat surprisingly, 
was also significantly enhanced by SYN0012 in the co-culture setting (Figure 5.12A). 
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or by co-culture (Figure 5.12B,C,F), indicating that different cellular mechanisms must 
be regulating their expression in vivo. Transcription of both α-SMA and Collagen-1 were 
significantly reduced in the co-culture system, likely because these proteins are not 
expressed by Ms, so the relative transcription was reduced by the same proportion of 
relative CF decrease (50%) (Figure 5.12D,E).  
 
Figure 5.12 Co-culture effects on other aspects of inflammatory/remodeling cascade. 
Transcriptional levels of TGF-1 (A), MMP3 (B), VEGF-a (C), Collagen-I (D), SMA (E), and FGF (D) in 
CF/ Mco-culture. # indicates significant (p > 0.05) difference from sham, and * indicates significant 
difference (p > 0.05) between IgG2a and SYN0012 samples. n = 3. 
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Comparison of Mpolarization in vivo and in vitro 
Given the recent rise in interest in the role of Ms and Mpolarization in 
remodeling after infarcts, we measured the transcription of three markers of 
Mphenotype in both our in vivo time course and in vitro co-culture system to see 
whether it would be effected by SYN0012 treatment. CD14 is associated with the 
proinflammatory M1 Mphenotype, while mannose receptor 1 (Mnr1) and arginase-1 
(Arg1) are associated with the reparative M2 phenotype. The M2 phenotype is 
associated with scarring and remodeling, as well as the resolution of inflammation. We 
observed no significant differences between the treatments in vitro, though all three 
proteins had a larger relative reduction in the SYN0012 treated group between day 
three and day seven (Figure 5.13A-C). In the co-culture setting, there was no change 
with SYN0012 for either CD14 or Mnr1, but we did observe a significant increase in 
transcription of Arg1 with SYN0012 treatment (Figure 5.13D-F).  
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Figure 5.13 Transcriptional changes of markers of M polarization. Transcription of M polarization 
markers in vivo (A-C) n > 3 animals, an in vitro (D-F) n=3. # indicates significant (p > 0.05) difference from 
sham, and * indicates significant difference (p > 0.05) between IgG2a and SYN0012 samples. 
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Discussion 
Our findings confirm that cadherin-11 is highly expressed in primarily non-CM 
cells after MI and furthermore plays a functional role promoting tissue breakdown and 
myocardial remodeling. A peak of cadherin-11 expression at seven days suggests a 
prominent role for MyoFBs, which are particularly active between weeks two and three 
following MI when the bulk of scar formation occurs [79]. However, the fact that 
cadherin-11 is already significantly enhanced at day three, suggests that other cell 
types, especially cells derived from inflammatory monocytes, including Ms, are also 
relevant. Immunostaining revealed that a subset of Ms, endothelial cells, smooth 
muscle cells and MyoFBs in the infarct region seven days after MI all express cadherin-
11. This is the first reported evidence that cadherin-11 plays a functional role after MI.   
To better understand how this protein may be functioning in the heart, we 
compared the response of littermate control WT and global CDH11-/- animals. Results 
indicated that cadherin-11 may be playing a functional role increasing LV remodeling 
after MI in the first seven days. The null mice had significantly improved EF and LV 
systolic volume relative to WT, but these changes do not persist to day 21. 
Immunostaining confirmed that much of the increase in cadherin-11 expression 
observed in overall transcription is localized to the infarct. Trichrome staining shows 
less collagen compaction in the null animals, which is likely due to contractile 
deficiencies in cadherin-11 null cells, as reported elsewhere [169]. We confirmed 
intrinsic differences in contractile ability of WT and CDH11-/- CFs that are likely relevant 
to infarct healing. Insufficient scar compaction can lead to increased wall strain and 
remodeling. Additionally, there may be compensatory mechanisms in the null mice, 
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whereby a permanent deletion of cadherin-11 leads to overexpression of related 
adhesion and signaling proteins. In any case, a genetic deletion is less relevant to 
clinical applications, since there are no known connections between cadherin-11 
mutations and cardiac disease.  
We next moved onto a therapeutic model using a blocking antibody against 
cadherin-11 that has proven to be effective in the contexts of pulmonary fibrosis and 
rheumatoid arthritis, two conditions characterized by excessive, inflammation-driven 
fibrotic remodeling. Our treatment strategy did not require pretreatment or acute 
application to achieve significant benefits in vivo. While we did not observe a significant 
increase in survival (Figure 5.3A), twice as many mice died in the control group relative 
to the treated cohort during the highest risk period for cardiac rupture (days 3-7). This is 
likely a consequence of the tissue breakdown and subsequent softening of the 
myocardial wall mediated by the inflammatory response. The control animals had more 
consistently softer infarcts at seven days (Figure 5.4A). SYN0012 treatment caused 
significant improvement of ejection fraction relative to IgG2a treated controls by seven 
days after infarct, which was maintained up to 5 weeks past the end of treatment 
(Figure 5.3B). This result indicates that cadherin-11 is in some way contributing to the 
loss of functional contractile cardiomyocytes during the inflammatory and proliferative 
phases in the first week of remodeling. Treatment with a blocking antibody more 
effectively preserves cardiac function within the first week, and prevents the continued 
worsening of function from day seven to day fifty-six that occurs in the IgG2a treated 
animals. Furthermore, while the left ventricular volume was not significantly altered by 
treatment at seven days, the dramatic increases in both diastolic and systolic volumes 
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between days seven and twenty-one, and again between days twenty-one and fifty-six, 
observed in controls were completely prevented in mice who received SYN0012 
treatment (Figure 5.3C,D). This combined with the peak of cadherin-11 expression 
occurring near day seven seems to suggest that cadherin-11 expressing cells play an 
active role in LV remodeling and expansion during the fibrotic phase of infarct healing. 
LV expansion is a common, generally irreversible feature in the eventual progression to 
heart failure, which is a factor in 1 in 9 deaths in the United States [1]. A treatment that 
effectively limits this remodeling could have profound impacts on patient outcomes after 
MI.  
Using AFM, we observed changes in the mechanical environment of the infarct 
over the time course of infarct healing. The initial drop in tissue stiffness in response to 
the inflammatory response observed at seven days is necessary to clear dead cells but 
contributes to risk of cardiac rupture (Figure 5.4A). While it has often been assumed, 
there are very few direct measurements of decreased stiffness after infarct. Our system 
allows for a quantitative assessment of regional tissue stiffness changes through the 
time course of healing. The stiffening of the developing scar we measured between 
days seven and twenty-one preserves the mechanical integrity of the LV, but also 
increases substrate stiffness in the infarct itself, as well as potentially increasing local 
strains in the microenvironment of the infarct and border zone. This increases 
mechanical activation of fibroblasts (see chapters 3-4) and can lead to progressive 
fibrotic remodeling especially at the vulnerable border zone. Indeed, our technique of 
AFM of fresh frozen tissue gives a more accurate representation of the 
microenvironment experienced by the cells, which may be much more variable than 
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bulk tissue measurements would indicate. By day 56, we observed that while the control 
infarcts were still highly variable, across a large range of medium and high stiffness, the 
treated hearts have much more consistent measured stiffnesses that correspond well to 
the original myocardial stiffness (Figure 5.4A). Trichrome analysis of the infarct size 
confirms that the fractional length of the infarct continues to increase from day twenty-
one to day 56 and is significantly larger than the corresponding scar size in SYN0012 
treated animals (Figure 5.4B). Significant scar thinning in the radial direction observed 
in controls is also not seen in the treated animals. This compaction is likely mediated by 
α-SMA expressing MyoFBs, which are not enhanced in SYN0012 treated hearts at 
twenty-one days (Figure 5.4D). A recent analysis of the mechanics of infarct expansion 
an remodeling based on a review of a number of published in vivo studies concluded 
that limiting radial scar thinning was an attractive target for improving functional 
outcomes [214]. Maintaining relatively high scar thickness was found to reduce LV 
expansion during diastole and, by consequence, increase the ejection fraction and 
function of the hearts in a finite element model. Our functional data corresponds well to 
this report, showing that limiting scar thinning (potentially through targeting cadherin-11 
expressing MyoFBs) better preserves cardiac function. 
We next measured the contractility of CFs embedded in a 3D-collagen matrix 
after incubation with either IgG2a or SYN0012 (Figure 5.5). Given the profound 
reduction in gel contraction in CDH11-/- CFs (Figure 5.2 E), the absence of a 
SYN0012-mediated effect in the collagen gel assay was initially surprising. The genetic 
deletion of cadherin, and subsequent cellular adaptation, must be mediating a dramatic 
change in CF contractile machinery that is not triggered by blocking cadherin-11 
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adhesion. The blocking antibody does not prevent transcription of cadherin-11 or 
localization at the cell membrane, so it is likely that cadherin-11 is still acting to 
assemble adherens junction proteins and link the cell membrane to the cytoskeleton. 
The blocking antibody prevents a large portion of the cadherin bonds between cells, 
which can interfere with transmission of both force and mechanotransductive signals. 
Using the novel I-wire system, an ECTC that allows for CF contraction of 3D collagen 
under tension, we were able to detect a difference in intrinsic longitudinal stress created 
in the construct after 7 days of SYN0012 treatment. This finding supports the hypothesis 
that blocking cadherin-11 bonds between cells may effectively prevent mechanosensing 
and cellular reinforcement of environmental mechanical stress.  
Having determined a clear functional effect of cadherin-11 blockade in limiting 
myocardial remodeling and infarct expansion after MI, we set out to determine the 
cellular mechanisms mediating this effect. We used real time qPCR, which allowed for 
an examination of transcriptional changes of many signaling factors and cellular 
markers over the range of infarct healing. Our first measurable change was a significant 
reduction in IL-6 expression at three days following infarct (Figure 5.6). This reduction 
was most evident in the non-CM cells. IL-6 has been shown to have a multifaceted role 
in cardiovascular disease, and there is evidence that blocking IL-6 leads to CM loss and 
worsened outcomes [215], [216]. However, IL-6 has also been shown to promote the 
infiltration, migration, and polarization of Ms, as well as MyoFB activation [217]–[220]. 
It seems likely that by specific targeting of the non-CM cell population of the heart, our 
treatment effectively limits the negative cell activating effects of IL-6, without interfering 
with its function in CMs. The decrease in IL-6 was evident at three days, which is a time 
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point associated with a high number of Ms and the beginning of the transition from 
inflammatory to proliferative phase of healing.  
 In addition to a direct decrease of IL-6 expression early in the healing process, 
our data also suggest that blocking cadherin-11 limits the persistence or proliferation of 
Ms in the heart between day three and day seven (Figure 5.7), perhaps contributing 
to the increasing infarct size and remodeling observed in controls between day seven 
and day fifty-six (Figure 5.3-4). There has been an increased interest in the role of Ms 
in the process of healing and remodeling after MI [4], [15], [16]. It has been reported that 
interactions between fibroblasts and Ms promote increased expression of IL-6, though 
the mechanisms of this interaction had not been completely described. We 
hypothesized that cadherin-11 might regulate the interactions between fibroblasts and 
Ms, and observed that three days after MI, there appears to be more interactions 
between Ms and MyoFBs in the IgG2a treated hearts than the SYN0012 treated. This 
indicates that while there may not have been a significant difference in the number of 
Ms (indicated by F4/80 transcription), blocking cadherin-11 adhesion may prevent the 
migration of Ms throughout the infarct and border zone, minimizing their subsequent 
interaction with resident MyoFBs. By day seven after infarct, we measured a significant 
reduction in F4/80, indicating that there are significantly fewer Ms present in the heart 
by this time. Regardless of their particular phenotype, Ms are significant drivers of 
tissue remodeling, especially when interacting with MyoFBs. 
We also measured a number of other inflammatory, fibrotic, and angiogenic 
signals and proteins over the time course of healing (Figure 5.8-9). While none of these 
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were significantly altered by SYN0012 in the first week after infarct, we did observe a 
faster return to baseline values by day seven for MMP13 and TGF-β1, which are 
associated with tissue breakdown and fibrosis, respectively. We also observed a 
reduction in transcription of both FGF2, VEGF-a, and Flk-1 that are often associated 
with improved revascularization and improved outcomes [74], [94] (Figure 5.10). 
However, we observed increases numbers of arterioles in the treated groups at twenty-
one days, corresponding to a time of reduced angiogenic markers. VEGF-a transcription 
has been shown to peak in the border zone within 12 hours of MI, but be reduced 
overall in the infarct area, especially in later stages of remodeling [221]. It is possible 
that SYN0012 allows for more preservation of the native vasculature or faster 
restoration/maturation of new vasculature, so that the hypoxic conditions that typically 
drive angiogenic signaling are reduced. Blocking cadherin-11 adhesion in endothelial 
cells may also be limiting the number of endothelial cells driven to undergo EndMT, 
which may help preserve vascularization and limit numbers of MyoFBs in the infarct. 
Future studies will more fully explore the role of cadherin-11 in vasculogenesis and 
endothelial cell behavior after MI.  
We decided to investigate the M/CF interaction and how it contributes to the 
inflammatory and remodeling signaling observed in vivo. Specifically, interactions 
between Ms and fibroblasts have been reported to regulate IL-6 expression, response 
to TGF-β1 signaling and fibrosis [213]. To this end, we performed co-culture 
experiments to determine whether cadherin-11 may mediate interactions between Ms 
and MyoFBs in the regulation of inflammatory and fibrotic signaling. Our in vitro findings 
confirm that co-culture of these cells promotes significant expression of inflammatory 
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compounds like IL-6 and MMP13, and suggest that cadherin-11 is partially responsible 
mediating the fibroblast/M interaction that promotes IL-6 expression by fibroblasts 
(Figure 5.11D). Preliminary immunostaining of Ms and MyoFBs in vitro shows 
potential evidence for direct cadherin-11 bonds between these cells, but more work is 
needed to characterize the specific effect of SYN0012 on the formation of such 
adhesions (Figure 5.14). 
We were initially surprised to see a significant increase in TGF-β1 transcription 
with SYN0012 (Figure 5.12A) in vitro, given the generally pro-fibrotic role of this growth 
factor. However, upon reflection, TGF-β1 is a necessary cue for the resolution of 
inflammation [76], [81], [222]. SYN0012 treatment may be promoting enhanced TGF-β1 
expression between days three and six that speeds the resolution of inflammation, 
contributing to the reduction of F4/80, TGF-β1 and MMP13 expression observed in vivo 
at days seven and twenty-one. Future experiments are necessary to further investigate 
this finding. Because TGF-β1 is released in an inactive form, mere transcriptional 
changes are not sufficient to determine the actual role of TGF-β1 signaling in the heart.  
This study led us to develop the following potential cellular mechanism for the 
role of cadherin-11 in the remodeling infarct (Figure 5.14). Interactions between Ms 
and CFs, in part mediated by cadherin-11, promote the expression of IL-6, as well as 
MMP13 and TGF-1. The intracellular signaling that mediates these transcriptional 
changes is not well understood, but given reports in the literature (Chapter 3), it is likely 
that p120 catenin is involved in the transmission of signals through Rac1, and -catenin 
is involved in signaling with significant crosstalk with MAPKs and Smads. Expression of 
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these proteins promotes inflammation, tissue breakdown, and myofibroblast 
differentiation. Cadherin-11 may also be involved in mechanosensing of increased 
strain in this low stiffness environment, and in sensing increased substrate stress in 
fibrotic environments. Future studies will clarify the specifics of mechanotransductive 
signaling downstream of cadherin-11 adhesion in both CFs and the other cell types of 
the heart.  
 
Figure 5.14 Proposed cellular roles of cadherin-11 on Ms and CFs.  
M polarization has been much discussed as a critical regulator of inflammation 
and remodeling, but we did not observe any differences in M markers in vivo (Figure 
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5.13A-C). More recent work has highlighted the incompleteness of an M1/M2 paradigm, 
so more work would be needed to understand the alterations to M phenotype induced 
by this treatment [223], [224]. One telling result is the significant increase in Arg1 
expression induced by SYN0012 treatment in vitro. Arg1 is typically associated with M2 
Ms, the reparative phenotype. Arg1 inhibits nitric oxide synthesis, and promotes cell 
proliferation and tissue repair [219], [225], [226]. It is possible that SYN0012 is also 
promoting a relative increase in Arg1 expression in vivo, but the concurrent reduction in 
overall Ms is masking the effect.  
Overall, we believe that cadherin-11 is expressed by and mediates activation of 
multiple non-CM cell types to promote the persistence of active remodeling in the infarct 
and border zone after MI. Treatment with SYN0012 does not prevent the necessary 
inflammatory and reparative response, but does facilitate a faster and more complete 
resolution of inflammation and active remodeling, resulting in a stable, smaller scar and 
less myocardial remodeling. We believe that this effect is mediated in large part by 
reducing the interactions between Ms and fibroblasts in the healing infarct area, both 
directly by preventing cadherin-11 bonds, and indirectly by limiting the migration, 
proliferation and persistence of Ms in the tissue (Figure 5.15).  
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Figure 5.15 Summary of proposed mechanism. SYN0012 mediates improvement after MI by reducing 
the intensity and duration of active remodeling in the infarct and border zone throughout the time course 
of healing. We propose that SYN0012 limits the in vivo interactions between MyoFBs and Ms that 
promote pro-remodeling protein expression, and further, that SYN0012 directly effects some of these 
expression effects. 
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represent the range of M subtypes found in vivo after MI, or how those populations 
change in response to treatment. Future studies using flow cytometry and a broader 
range of in vivo and in vitro techniques will strengthen and help clarify the cellular 
mechanisms we have described in this work.  
This aim characterizes phenotypic changes and tissue remodeling throughout the 
course of infarct healing and highlights a potential new treatment strategy for improving 
outcomes after myocardial infarction: an antibody blockade of cadherin-11. Importantly, 
the administration of this functional blocking antibody did not need to be acute (within 12 
hours of injury) to have demonstrative and multifaceted, positive effects on healing and 
cardiac function. These data suggest that targeting cadherin-11-expressing Ms and 
MyoFBs limits inflammation-driven remodeling while preserving cardiac function.  
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CHAPTER 6 
 
AIM 3: QUANTIFYING CARDIOMYOCYTE MECHANICS  
 
Text for Chapter 6 adapted in part from: 
[227] Manalo, A., Schroer, A.K., Fenix, A., Coogan, J., Brolsma, T., Burnette, D., 
Bader, D., The loss of protein CENP-F disrupts cardiomyocyte architecture and 
function. Circulation Research, 2016. (in preparation). 
 
[228] Schroer, A.K., Shotwell, M., Sidorov, V.Y., Wikswo, J.P., Merryman, W.D., I-
Wire Heart-on-a-Chip II: Biomechanical analysis of contractile, three-dimensional 
cardiomyocyte tissue constructs. Acta Biomaterialia, 2016. (in press). 
 
Introduction to CM biology and relevance to disease 
 CMs are the cellular source of the mechanical forces that determine both heart 
function and the mechanical environment experienced by all the non-CM cells described 
in the previous chapters. CMs have complex internal and junctional machinery, which 
allows for the coordinated contraction of the myocardial wall and effective pumping of 
blood throughout the body. However, a host of clinically relevant mutations and 
pharmacological compounds can negatively affect this function and lead to detrimental 
cardiomyopathies. Altered demands on the heart, in response to either pressure 
overload or ischemic disease, can also trigger CM remodeling and pathologic 
cardiomyopathy.  
Despite a large range of etiologies, many of these CM-originating pathologies are 
also associated with interstitial fibrosis and increased risk of heart failure. This is likely in 
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response to disruption of the mechanical and chemical signaling occurring in the heart 
between native CMs and non-CM cells, especially CFs. Recently developed biological 
and biomedical tools can be used to investigate the function and structure of CMs in 
vitro to identify structural and functional changes associated with disease and 
dysfunction in vivo.  
CENP-F mutation alters cardiac cell structure and mechanics 
There are many mutations that are known to cause CM dysfunction, and 
subsequent cardiomyopathies, cardiac fibrosis, and heart failure. While many of the 
most commonly studied directly affect the sarcomeric structure, which is responsible for 
contraction, other proteins associated with the sarcolemma and cell adhesion have also 
been linked to cardiomyopathies [229]–[231]. Deficiency for both integrin linked kinase 
and N-cadherin lead to the development of dilated cardiomyopathies in mice [232], 
[233]. Another cytoskeletal accessory protein that causes dilated cardiomyopathy is 
centromere protein F (CENP-F), which participates in the regulation of microtubules. 
Mutations of this protein have been linked to human cardiomyopathies, and the 
development of the dilated cardiomyopathy phenotype with substantial interstitial 
cardiac fibrosis has been reported in mice with a CM specific knock out [234], but the 
particular effect of the mutation on both fibroblast and CM structure and function was 
largely unknown.  
As part of a collaboration with the Bader lab, specifically with Annabelle Manalo, I 
was able to use both image processing in MATLAB and AFM to clarify the effect of this 
mutation in isolated MEFs, CFs, and CMs. First, CMs were isolated from WT and KO 
mice and were subsequently fixed and stained for alpha actinin, or β-catenin and actin. 
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Cells were imaged on a high magnification confocal microscope, whereupon I assessed 
their sarcomeric structure using Fast Fourier analysis of the spatial frequency of the 
cells. After rotating to a consistent, horizontal axis, a trace of pixel intensity was taken 
along the length of the cell at regular intervals, and a FFT was performed on that trace 
allowing for the calculation of the average sarcomere length per slice (calculated from 
the first peak spatial frequency from a plot of FFT magnitude) (Figure 6.1). While there 
was no significant difference in sarcomere length between WT and KO cells (Figure 
6.1D), the 2D power spectrum show significantly fewer defined peaks in the KO cell 
images, corresponding to a loss of sharp edges in the z-disks with the mutation (Figure 
6.1E).  
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Figure 6.1 Quantification of sarcomere length. Confocal images of individual CMs stained for alpha-
actinin were rotated to align the cell horizontally (A) and a horizontal traces (representative trace shown 
by yellow line) at 10 pixel vertical spacing gave a vector of intensity (B), and a smoothed amplitude 
spectrum of the FFT transform of this intensity signal (C) was used to find the primary peak frequency. 
The inverse of this frequency gives a measure of sarcomere length per slice and these were averaged 
together (D) to reveal consistent sarcomere lengths between groups (N=3 cells per group). 2D FFT in 
MATLAB allows for visualization of the overall frequency power spectrum (E). 
 
 
I further characterized the amount of β-catenin present at adherens junctions in 
several slices of a WT and KO CM. By thresholding the intensity of the β-catenin image 
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and eliminating isolated pixels, I could identify the adherens junctions and quantify their 
overall area and average intensity (Figure 6.2).  
 
Figure 6.2 Quantification of adheren junction β-catenin. Confocal images of individual CMs stained 
for actin and β-catenin were rotated to align the cell horizontally (A) and a horizontal traces 
(representative trace shown by yellow line) at 10 pixel vertical spacing gave a vector of intensity (B), and 
a smoothed amplitude spectrum of the FFT transform of this intensity signal (C) was used to find the 
primary peak frequency. The inverse of this frequency gives a measure of sarcomere length per slice and 
these were averaged together (D) to reveal consistent sarcomere lengths between groups (N=1 cell).  
 
Finally, I used a Bruker biocatalyst atomic force microscope (AFM) system to 
measure the stiffness of live isolated cardiomyocytes, MEFs, and CFs. The quantitative 
nano-mechanical mapping mode was used to assess both the topography and elastic 
modulus of WT and KO cells. We used a blunted pyramidal tip to indent and gather 
mechanical information from about a micron below the cell surface. The system was 
calibrated on a 40kPa polyacrylamide gel. Between four and ten cells were scanned per 
group and the median elastic modulus calculated from approximately 10x10 micron 
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scans for each cell (>10,000 measurements per scan). The average median cell 
stiffness was calculated and compared between WT and KO cells with a student t-test. 
AFM assessment revealed that the elastic modulus of the KO CM was significantly less 
than the WT cells. Conversely, KO MEFs were significantly stiffer (Figure 6.3). 
Additionally, scanning CFs isolated from adult WT and KO hearts revealed that many of 
the KO cells had loss of detectable intracellular fibers, and instead had stiff, round 
protrusions, predominantly near the cell nucleus (Figure 6.4). These features may 
correspond to the whorls of over-stabilized microtubules observed in immunostaining of 
these cells [227].  
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Figure 6.3 Quantification of cardiac cell stiffness. AFM of WT and CENP-F KO CMs and MEFs. Bright 
field images of representative cells with approximate scan area highlighted in red. Next a colormap of the 
elastic modulus of an approximately 10x10 m scan, overlayed on a 3D rendering of the topography of 
the cell surface. Finally the average median elastic modulus of each cell type is presented. * indicated p < 
0.05 relative to WT. N < 11 for CM, N < 5 for MEFs. 
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Figure 6.4 Quantification of CF stiffness. Atomic force microscopy of WT and KO cardiac fibroblasts. 
Bright field images of representative cells with approximate scan area highlighted in red. Next a colormap 
of the elastic modulus of an approximately 10x10 m scan, overlayed on a 3D rendering of the 
topography of the cell surface. Finally the average median elastic modulus of each cell type is presented. 
 
 
These findings suggest that the CENP-F mutation is disrupting the internal 
mechanical structure of both CMs and fibroblasts by altering microtubule structure and 
stability. It also highlights a distinct role and function for microtubules in CMs, which is 
relatively undefined. Specifically, while the loss of CENP-F on average increases 
stiffness of fibroblasts, it functionally decreases the stiffness of CMs in the region just 
proximal to the membrane. This area contains both costamere structures and the 
sarcolemma, both of which are involved in mechanotransductive signaling in the CM, as 
well as transmitting forces generated in the myofibrils to neighboring cells and the ECM. 
When this structure is disrupted (as occurs with CENP-F mutation), the effects extend 
internally to overall sarcomere alignment (measured by both TEM and quantification of 
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immunostaining (Figure 6.2)), and externally to reduced heart function and the 
development of dilated cardiomyopathy [234].  
The organ level effects of this mutation, especially the observable interstitial 
fibrosis, are likely due to alteration of CF behavior. In the original study of this CENP-F 
mutation in mice, a CM specific deletion caused significant interstitial fibrosis, mediated 
by the genetically normal CFs. Given the natural sensitivity of fibroblasts to 
dysregulated mechanical environments and their in vivo localization interspersed among 
CMs, it is not then surprising that evidence of profibrotic MyoFB activity is evident in 
vivo. With an observable decrease in stiffness near the cell membrane and 
dysregulated junctions and sarcomeres, the CENP-F knock-out CMs likely exert 
irregular force profile on interstitial CFs in vivo, leading to the observed cardiomyopathy. 
While this study has been limited to investigation of the internal structure of individual 
cardiac cells, it is expected that the complex, 3D interactions of CMs and CFs direct the 
progression of this disease, along with many cardiac diseases. Future study is needed 
to observe and characterize these cellular interactions and their relative effects on 
contractile function and ECM remodeling. 
 
Introduction of engineered cardiac tissue constructs  
One class of tools that has been developed to better characterize cardiac cell 
function in vitro is engineered cardiac tissue constructs (ECTCs), which allow for 
recreation of some of the cellular components of cardiac tissue, but also for more 
precise measurement of physiological properties, including mechanical function. 
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Cardiac thin films have been used in many applications, and are attractive for their ease 
of production and adaptability for use in different contexts [18], [235], [236]. However, 
they are limited by a two-dimensional frame. There are some three-dimensional 
constructs, but many of these, like most traditional muscle measurement techniques, 
rely on either isometric or isotonic setups, whereas in the heart, the muscle is 
contracting against an applied transverse load in an auxotonic manner.  
To address some of the limitations of existing ECTCs, a team at Vanderbilt 
developed the I-wire construct, which consists of a linear cellular construct suspended 
in media in a PDMS channel and mounted on conductive wires at each end. The 
construct is formed from a suspension of cells in an ECM solution (either collagen or 
fibrin) which is poured into the channel and allowed to compact over the course of a 
week. A calibrated probe can then be brought into contact with the side of the construct, 
and displacement of the stage used to stretch the construct. The system is mounted on 
an inverted microscope, so the deflection of the probe can be measured optically, both 
at static equilibrium at different stage positions and, in the case of CM containing 
constructs, with the addition of electrical stimulation. An initial study was conducted to 
describe the creation of these constructs using neonatal rat CMs and the ability of the 
system to replicate relevant parameters in CM biology. In tandem with this work, I 
worked with the original creators of the I-wire platform, as well as Matthew Shotwell, to 
develop a mathematical modeling strategy to describe the construct mechanics using a 
Hill-type model.  
The following study presents the biomechanical analysis of the “I-Wire” platform 
using a modified Hill model of muscle mechanics that allows for further characterization 
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of construct function and response to perturbation. The I-Wire engineered cardiac tissue 
construct (ECTC) is a novel experimental platform to investigate cardiac cell mechanics 
during auxotonic contraction. Whereas passive biomaterials often exhibit nonlinear and 
dissipative behavior, active tissue equivalents, such as ECTCs, also expend metabolic 
energy to perform mechanical work that presents additional challenges in quantifying 
their properties. The I-Wire model uses the passive mechanical response to increasing 
applied tension to measure the inherent stress and resistance to stretch of the construct 
before, during, and after treatments. Both blebbistatin and isoproterenol reduced 
prestress and construct stiffness; however, blebbistatin treatment abolished subsequent 
force-generating potential while isoproterenol enhanced this property. We demonstrate 
that the described model can replicate the response of these constructs to intrinsic 
changes in force-generating potential in response to both increasing frequency of 
stimulation and decreasing starting length. This analysis provides a useful mathematical 
model of the I-Wire platform, increases the number of parameters that can be derived 
from the device, and serves as a demonstration of quantitative characterization of 
nonlinear, active biomaterials. We anticipate that this quantitative analysis of I-Wire 
constructs will prove useful for qualifying patient-specific cardiomyocytes and fibroblasts 
prior to their utilization for cardiac regenerative medicine. 
Three-dimensional engineered cardiac tissue constructs (ECTCs) fill an 
important gap in understanding cardiomyocyte (CM) function, fibroblasts, and the 
extracellular matrix (ECM) they produce in a physiologically relevant, in vitro context. 
ECTCs exemplify the challenges associated with characterizing a nonlinear, dissipative, 
active biomaterial with a mathematical model. We developed the “I-Wire” ECTC 
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platform to probe the function of CMs while both the applied force and length are 
changing during auxotonic contraction [237]. This ECTC design better approximates the 
environment in vivo, since CMs contract against the changing load of ventricular 
pressure in their native environment. While the I-Wire offers useful insights into CM 
mechanics and function, the dynamically changing length and force can make analysis 
more complex than a simple isometric or isotonic contraction. Here we have developed 
an analysis strategy that permits extraction of different CM and ECTC properties and 
physiologic responses.  
The force-generating capacity of cardiac muscle is inherently dependent on 
length, passive stiffness, and velocity of contraction [238]–[240]. A simple model for 
muscle mechanics that includes damped parallel and series elastic springs was 
originally proposed by Hill, and it has been used to describe striated muscle mechanics 
in many contexts [238], [241]–[245]. Although the Hill model has limitations, it has been 
used and modified in numerous applications, such as predictions of the relevant 
mechanics involved in heart failure and interventional treatment strategies [246]–[250]. 
The objective of this work is to use a modified Hill model to predict changes in CM 
mechanics in the I-Wire construct to gain insight into clinically relevant mechanical 
effects, and to demonstrate the detailed characterization of an active tissue equivalent 
of significant clinical interest.  
 
Methods of I-wire development and analysis 
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ECTC creation and measurement 
 ECTCs were formed and their mechanical response to increasing, 
perpendicularly applied tension was measured as described [237]. Neonatal rat 
ventricular cells were obtained from 2-day-old neonatal Sprague-Dawley [91] rats using 
a trypsin digestion protocol with agitation overnight at 4˚C [251]. The population of 
isolated cells used to form the construct was heterogeneous, including CMs, CFs, ECs, 
and vascular smooth muscle cells [19]. The isolated cells were mixed with fibrinogen (5 
mg/mL, Sigma-Aldrich, St. Louis, MO, USA) / Matrigel (100 L/mL, BD Biosciences, 
San Jose, CA, USA) plus thrombin (30L/mL, Sigma-Aldrich, St. Louis, MO, USA) [54], 
and pipetted in a casting mold (Figure 6.5A). The construct polymerized for one hour at 
37˚C, then 2 mL of cell culture media was added per well. Over time, the preparation 
contracted to form an elongated construct roughly 350-400 m in diameter and 7 mm 
long. After 13-15 days of culturing, the contractility and stiffness of the engineered 
cardiac tissue construct (ECTC) (Fig. 1B, C) could be measured using a microscope-
based optical setup. 
 To create longitudinal tension in the construct, a translatable stage applies 
transverse force to the construct with a flexible probe, and the deformation of the probe 
allows for precise measurement of both the tensile properties and the developed force 
in the construct over the course of a contraction (Figure 6.6B). Contraction was 
stimulated by a 5 ms pulse (six times threshold) delivered through the anchoring wires, 
and probe position was recorded at 200 frames per second. For each contraction 
condition, seven successive contractions were averaged.  
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Figure 6.5. Platform description and model schematic. (A) Representation of the I-Wire construct from 
above, with the unloaded position of the probe indicated by the dotted green circle. (B) Image of I-wire 
construct. (C) Schematic simplified to highlight relevant measurements. See text for variable names. (D) 
Diagram of the relevant mechanical model (a modified, Hill type model), consisting of the muscle 
mechanics components (left side of dashed line) linked to a nonlinear (with respect to L) spring 
representing the probe (right side of dashed line).  
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The passive and peak developed force, as presented in the companion paper, were 
calculated as the transverse force exerted on the probe by the construct (  ) and were 
proportional to the deflection of the probe from center (𝛥𝑠 ) multiplied by the stiffness of 
the probe (KP); (Figure 1F of [237]) and Equation 6.1. The following equations describe 
how to transform a transverse force applied by the probe by stage displacement to a 
longitudinal force along the length of the construct (  ). We start with Hooke’s law  
      𝐾 𝛥𝑠  . Equation 6.1 
The lateral deflection of the probe tip (𝛥𝑠 ) and the lateral displacement of the construct 
midpoint (𝛥𝑠 ) sum to the total deflection of the stage (𝛥𝑠 ): 
 𝛥𝑠   𝛥𝑠 − 𝛥𝑠  . Equation 6.2 
𝛥𝑠  can be calculated from the extension of the construct (𝛥𝐿) according to the 
Pythagorean Theorem 
 𝛥𝑠   √(𝐿 + 𝛥𝐿) − 𝐿  √Δ𝐿(2𝐿 + Δ𝐿) , Equation 6.3 
which in turn can be substituted into Equation 6.2, and further into Equation 6.1 to yield 
 𝛥𝑠   𝛥𝑠 − √Δ𝐿(2𝐿 + Δ𝐿) ,  Equation 6.4 
      𝐾 (𝛥𝑠 − √Δ𝐿(2𝐿 + Δ𝐿)) , Equation 6.5 
which describes the transverse force in terms of construct stretch along its length and 
initial stage displacement. Finally,    is balanced by the lateral component of force 
developed along the construct direction in both halves of the construct. Simple 
trigonometry shows that  
    
  (    )
    
   
  (    )
 √  (     )
 , Equation 6.6 
as derived in Appendix B. 
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Table 6.1. Model variables 
 
Action potentials in ECTC were recorded by using floating micropipettes filled 
with 3-M KCl [252]. The micropipettes were pulled from borosilicate glass capillaries 
(WPI, Sarasota, FL) by a micropipette puller (P80/PC, Sutter Instruments, Novato, CA, 
USA). The tips of the micropipettes were mounted on a platinum wire of 50 µm 
diameter. The reference Ag/AgCl electrode (EP8, WPI, Sarasota, FL, USA) was placed 
in the well next to the PDMS insert. The electrodes were connected with a dual 
differential electrometer (Duo 773, WPI, Sarasota, FL, USA) and signals were digitized, 
visualized, and recorded by a digital oscilloscope (TDS5034B, Tektronix, Beaverton, 
OR, USA). The sampling rate was 25 kHz. The recorded data were processed with a 
Variable Description (units) 
𝛥𝑠 Distance I-Wire frame is moved  laterally to apply force with the probe (m) 
𝛥𝑠  Distance the end of the cantilever probe is deflected (m) 
𝛥𝑠  𝛥𝑠 − 𝛥𝑠   (m) 
FP Transverse force delivered by the cantilever probe (N) 
FC Longitudinal force within the ECTC in response to FP (N) 
L Half-length of unstretched I-Wire construct, in practice 3.5 mm (m) 
𝐿    Intrinsic half-length of the ECTC were its end wires released (m) 
𝛥𝐿 Change in ECTC half-length as the probe stretches the ECTC (m) 
𝛥𝐿       
Estimated difference between L and 𝐿    
int. (m) 
prestress Estimated tension in unstretched construct at length L (N) 
KM Steady-state stiffness of muscle construct (Nm
-1) 
KP Cantilever probe spring constant (Nm
-1) 
KPEam Spring constant of actin/myosin parallel element (Nm
-1) 
KSE Spring constant of series element (Nm
-1) 
KPEn Spring constant of non-actin/myosin parallel element (Nm
-1) 
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Savitzky-Golay digital filter (OriginLab, Northampton, MA, USA). To inhibit contractility, 
the excitation-contraction uncoupler blebbistatin (Sigma-Aldrich, St. Louis, MO, USA) 
was applied at a concentration of 6 µM. 
Model development  
In recognition of the complexity of cardiac tissue as a biomaterial, we divided the 
parallel elastic resistance term in the traditional Hill model to differentiate the passive 
contributions of actin myosin interactions and other passive mechanical linkages, 
including microtubules, z-discs, and extracellular matrix. The second passive element 
(KPn) (Figure 6.5D) was not responsive to treatment with blebbistatin or isoproterenol. 
Blebbistatin is a reversible specific inhibitor of the actin-myosin interaction [253]. 
Particularly, it binds to the myosin-ADP-Pi complex, impedes phosphate release, and 
thereby stabilizes the metastable state of myosin [254]. Whereas isoproterenol is a 
known -adrenergic stimulator, which affects both contractility and heart rate [255].  
When transformed from passive transverse force exerted on the probe to passive 
tension along the construct length (Equation 5.6), the resultant forces have a linear 
relationship with respect to the steady-state relative passive length change with a non-
zero prestress y-intercept (Figure 6.6A,B) as follows: 
    𝐾 ∗ (𝛥𝐿 +  𝛥𝐿      )  𝐾 ∗ 𝛥𝐿 + 𝑝𝑟𝑒𝑠𝑡𝑟𝑒𝑠𝑠 , Equation 6.7 
with KM serving as a lumped parameter of the three elastic elements, 
   𝐾  
               ∗
     
   
  
     
   
 . Equation 6.8 
This muscle mechanics model is linked to a nonlinear (with respect to 𝛥𝐿) spring 
(Figure 6.5C; right side) that represents the force applied by the probe to the construct 
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(Equation 6.9), which should be equivalent to the value of the force in the construct 
(Equation 6.7),  
     
 
 
𝐾 (
  
√  (     )
−  ) (𝐿 + 𝛥𝐿)  . Equation 6.9 
The passive resistance of the muscle was used to estimate model parameters KM, 
prestress, and 𝛥𝐿    (Figure 6.5) for each construct, before and after different 
perturbations (blebbistatin treatment: 6 M; isoproterenol treatment: 1 M; the 
incubation time for blebbistatin and isoproterenol was 10 min; shortening the construct: 
~20 percent of original length).  
 The final step in the analysis, described in detail in Appendix B, is to derive the 
differential equation that relates 𝛥𝐿 to its rate of change of  Δ?̇? 
Δ?̇?  
(  
      
   
)  (  )   (           )    
 (  
  (  )      
   
 )
 ,   Equation 6.10 
which can be used to predict the contraction traces by solving it in MATLAB using 
ode15s. 
 
 Study design statistical analysis  
Five independent constructs were treated with blebbistatin and changes in KM 
were quantified from the mean of the constructs’ passive tension before and after 
treatment over a range of stage displacements (0-1300 µm).  Experimental 
measurements are presented as means ± SEM, and force measurements were 
compared at each stage position using an unpaired t-test. Seven constructs were 
treated with isoproterenol, and their passive mechanics and dynamic contraction were 
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fit independently over a range of stage displacements (0-2000 µm), which correspond to 
increasing applied transverse loads.  
The passive model parameters were estimated for each construct using linear 
least squares analysis of the passive force measurements. Active contraction was then 
simulated in the model by an activation force function originating in the contractile 
element with a magnitude of around 1.4 mN (within a physiological range for a construct 
with 0.1 mm2  area [256]) and a duration of 250 ms (the measured length of an action 
potential in these constructs [237]). Three active parameters (KSE, KPEam, and b) were 
estimated using a nonlinear least squares optimization technique in MATLAB. More 
information about the model formulation and optimization techniques can be found in 
the supplemental materials. The confidence intervals of parameter estimates were 
approximated using the observed information method [257]. The effects of 
pharmacologic treatment on the model parameters conserved across constructs were 
assessed using paired t-tests. One construct was shortened to assess the model’s 
accuracy at different lengths.  
 
Results of I-wire analysis 
Chemically induced changes in passive mechanics and developed force 
We transformed the measured data from the transverse-force and transverse-
deflection I-Wire coordinate system into longitudinal force and length changes along the 
construct. This allowed us to demonstrate a significant reduction in passive tension after 
treatment with blebbistatin over all applied transverse loads (Figure 6.6A). Our model 
framework assumed that blebbistatin treatment would abolish the actin-myosin 
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contribution to passive stiffness (represented by KPEam), causing the overall passive 
parameter KM to be equal to KPEn (Equation 6.8). A linear fit to the passive force 
measurements both before and after introduction of blebbistatin revealed that the non-
actin myosin passive stiffness element contributes approximately 67% percent of the 
total passive force in the muscle and about 73% of the prestress (Figure 6.6A). We also 
measured the effect of isoproterenol treatment, a β-adrenergic agonist known to 
increase the rate of calcium cycling and muscle contractility while reducing muscle 
tension [258]. There was a significant reduction in passive force at every applied load 
after isoproterenol treatment (Figure 6.6B). When analyzing these data using our 
passive mechanics model, we observed a slight, insignificant decrease in the overall KM 
as well as a significant reduction of both prestress and 𝛥𝐿       values (Table 6.2). We 
also observed a significant increase in the developed force generated by the constructs 
(Figure 6.6C).  
 
Table 6.2. Passive mechanic metrics for control and isoproterenol-treated ECTCs 
 
  
 
Control Isoproterenol p-value 
KM 0.7 ± 0.05 Nm
-1 0.6 ± 0.05 Nm-1 0.054 
prestress 0.22 ± 0.02 mN 0.12 ± 0.01 mN <0.001 
 𝛥𝐿       311 ± 14 m 210 ± 25 m  0.003 
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Figure 6.6. Passive and developed forces in constructs are affected by pharmacological 
perturbations. (A) Passive force in constructs treated with blebbistatin was significantly reduced (p < 
0.01) for all samples. (B) Passive force was significantly reduced (p < 0.01) between all isoproterenol 
treated samples, and the predicted and calculated force in the ECTC had relatively close agreement with 
experimental data. (C) Peak developed force was significantly increased (p < 0.05) in the isoproterenol-
treated constructs at most applied tensions (* indicates p < 0.5). Experimental data presented as mean ± 
SEM. 
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Simulation of active contraction 
Once we estimated the passive muscle stiffness, prestress, and offset for each 
construct, active contraction was simulated at a variety of starting tensions 
corresponding experimental range of stage displacement. An idealized biexponential 
curve was used to simulate the activation force generated by the CMs in response to 
electrical stimulation (Figure 6.7A) [244]. We simulated muscle inactivation by setting 
KSE to zero, and the model predicted no muscle shortening, as was observed with 
blebbistatin treatment of the constructs. Three active parameters (KSE, KPEam, and b) 
were estimated using a nonlinear least squares optimization technique in MATLAB. 
Regardless of starting conditions or relative elastic element contributions, this procedure 
consistently found that the isoproterenol-treated constructs had a significant reduction 
(50%; p < 0.05) in the estimated viscosity parameter of the contractile element (b). 
Independent optimization of KSE and KPEam also found a significant reduction (p < 0.05) 
of KSE in the isoproterenol groups relative to control. In general, this optimization 
reduced the overall mean squared error of the model fit by between two- and five-fold 
across the seven constructs. Using these techniques, the model successfully predicted 
the experimentally measured developed force (Figure 6.7B-C) and length changes of 
individual constructs (Figure 6.7D-E). Furthermore, averaging the estimated 
parameters across constructs gave a robust fit of the average developed force (Figure 
6.7F).  
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Figure 6.7. Predicted active force in ECTCs. (A) Biexponential activation force input used. (B,C) 
Predicted developed force and (D,E) relative predicted length compared to measured data for 
representative construct. (F) Predicted model fit to average data using average of best fit parameters. 
Experimental data presented as mean ± SEM. 
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Simulating active contraction with microelectrode trace 
After characterizing the fidelity of our model fit using an idealized biexponential 
function, we repeated these analyses using data from a microelectrode trace of the 
action potential as the activation force (Figure 6.8A). The estimated model parameters 
using this alternative activation force function confirmed a reduction of the viscosity 
parameter (b) with isoproterenol treatment, and the experimental data were well fitted 
by visual inspection. However, the mean squared error was approximately two- to four-
fold higher, relative to that associated with the biexponential activation force function 
(Figure 6.8B-E). Next, we modified the width of the activation force trace to attempt to 
recreate the mechanical restitution curve described in the original paper describing the 
I-wire device [237]. By varying the action potential duration from 150 ms to 250 ms 
(Figure 6.8F), the model predicted increasing force traces (Figure 6.8G) and peak 
forces (Figure 6.8H) that greatly resembled the experimental data presented in Figures. 
2 and 4 of the companion paper [237]. 
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Figure 6.8. Simulation of active contraction using construct action potential. (A) Activation force 
shape taken from a measurement of the action potential voltage (1) scaled similarly to idealized 
biexponential function. (B) Developed force traces, (C) peak forces, and (D,E) relative length fit in a 
representative construct. (F) Horizontal scaling of activation force traces to match measured values at 
different pacing frequencies. (G) Predicted model response to these inputs for the construct at a tension 
0.54 mN, and (H) the peak developed force plotted over the estimated pacing frequency. 
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Shortening construct to predict length-related effects 
We tested the model’s response to reducing the length of a preformed construct 
by ~20% by moving one of the anchoring wires to a new groove in the PDMS mold 
(Figure 6.9A). The experimental results revealed an overall decrease in the peak 
developed force, as well as a flattening of the downward trend of force generation 
(Figure 6.9B). This experiment was simulated in the model first by assuming that the 
measured mechanical stiffness of the construct would remain unchanged by the release 
of tension, merely shifting over to have an offset and prestress of 0 (Figure 6.9C, black 
line). This manipulation resulted in a large mismatch with the experimental passive force 
data and a poor fit to the peak developed force data (Figure 6.9D black line). Next, the 
KM was estimated using the passive force measurements in the shortened constructs 
(45% reduction from original), but prestress was still defined as 0 (Figure 6.9C, dark 
grey line). This correction improved the fit of the passive and developed force (Figure 
6.9D, dark grey line) but the data were still mismatched. Next, both the KM and 
prestress were fit to the experimental data, giving a much better fit of the passive force 
(Figure 6.9C, light grey line), but significantly under-predicting the peak force (Figure 
6.9D, light grey line). Finally, the ratio of KSE to KPEam was changed to restore the value 
of the series element stiffness to that of the KSE original construct length, and the results 
showed significant improvement of developed force fit (Figure 6.9D, dashed light grey 
line), as well as overall fit. 
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Figure 6.9. Shortening construct to predict length-related effects. (A) Schematic of construct 
shortening. (B) Traces of developed force in the original and shortened configurations. The thicker lines 
represent the shortened configuration. (C,D) Experimental and model fits of passive force and peak 
developed force in construct before and after shortening.  
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fibroblasts highlights the uniqueness of the CM intracellular structure, and the impact 
that internal structure can have on organ level disease. The rest of the chapter focuses 
on the development of a ECTC and a strategy for analysis that can be used to study 
cardiac cell mechanics in response to a host of perturbations, including clinically 
relevant mutations. 
We have presented a model-based method to quantify the passive elasticity and 
active contractility of an ECTC that is extremely useful to the biomedical, bioengineering 
and physiology communities. This analysis allows an in-depth characterization of the 
mechanics of a 3D cardiac muscle construct that is able to dynamically contract while 
subjected to a range of applied transverse forces, and it complements the presentation 
of the data in the original paper [237]. The analysis strategy presented here allows for 
translation from force generated in the construct applied as a perpendicular load (FP) to 
the longitudinal tension internal to and along the length of the construct (FC). The peak 
force developed along the construct following contraction consistently decreased with 
increasing applied tension and applied stretch (Figure 6.6C). This was likely a result of 
the intrinsic force-length relationship of striated muscle cells, including CMs, in which 
the force-generating potential rapidly declines past the optimal length [238], [239]. This 
construct-focused analysis also makes it possible to estimate the prestress generated 
by CMs as well as fibroblasts during the process of construct formation and compaction. 
We demonstrated that this stress is significantly reduced by both blebbistatin and 
isoproterenol treatments. Blebbistatin is known to disrupt actin/myosin interactions 
within CM sarcomeres and has been shown to disrupt traction forces generated by 
fibroblasts [259], [260]. 
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This model also enables simulation of active muscle contraction. The 
comparisons in Figures 6.7 and 6.8 demonstrate that either a biexponential curve or 
that resembling an action potential can be used as activation force inputs to drive the 
model, although the biexponential activation force trace delivers consistently better fits 
to the experimental measurements. In the future, microelectrode trace measurements 
could be used to predict altered mechanics in response to genetic mutations or drug 
effects. Parameter estimation using either activation force function revealed a significant 
decrease in effective contractile element viscosity (b), and suggests a potential 
decrease in KSE after treatment with isoproterenol. Both effects are likely related to the 
increase in calcium availability and turnover mediated by isoproterenol, which 
decreases the short-term stiffening effect of actin-myosin interactions [247], [258], [261]. 
Future experiments to image intracellular calcium transients during contraction should 
make it possible to quantify these changes. 
The collection of experimental data examined here was not sufficient to 
definitively differentiate the relative contributions of the model parameters and the active 
force function using the nonlinear least squares estimation method. The dynamic nature 
of the modified Hill model, however, allows prediction of mechanical responses to 
differing mechanical and electrical stimuli. Thus, it is possible to consider hypothetical 
experiments in silico, and to design experiments that are more highly informative about 
the underlying model components. For example, in order to distinguish the model 
parameters from the active force function, a natural next step experimentally would be 
to vary the rate and shape of mechanical loading in the absence of electrical stimuli 
(i.e., no active force). Supplemental Figure B4 illustrates the mechanical stimuli and 
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resulting passive changes in construct length for two such hypothetical experiments. 
These findings would permit independent assessment of the contributions of KPEam, KSE 
and b, which in turn would enable an inverse analysis of the data to estimate the 
activation force traces. Further development of the model should benefit from additional 
measurements that record the calcium transients associated with CM contraction and 
that image the differences in both transmembrane calcium potential between 
simultaneous field stimulation of the entire construct and the response that propagates 
from a bipolar stimulating electrode at one end of the fiber. It is likely that these calcium 
traces will correspond with the predicted activation force traces, improving the model fit 
and providing insight into electromechanical coupling. 
This model is also able to recreate changes in muscle mechanics in response to 
changing electrical and physical inputs. Recreating the pacing frequency restitution 
curve confirms that using action potential traces is a viable input for predicting 
contractile response. Furthermore, the shortening experiments provided an interesting 
opportunity to test and refine the model. The peak force developed by the shortened 
ECTC was significantly lower than that for the original length, which suggests that the 
construct length has been reduced below some optimal length, thus reducing force-
generating capacity. Our initial assumption that construct stiffness would be preserved 
with a large reduction in length proved to be a poor fit to the data. Subsequent trials 
revealed that at the reduced length, the construct has a much lower linear passive 
stiffness and retains some prestress even at low initial stretch. These results indicate 
that the stiffness that appeared linear at the original length is actually part of an 
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exponential or partially nonlinear stiffness function common in biological tissues [247], 
[262].  
The I-Wire platform and these measurements and estimates of intrinsic muscle 
properties (KM, prestress, and viscosity b) provide a powerful new tool for quantifying 
the effects of pharmacological strategies on CM function in vitro. Of particular 
importance, the constructs have a uniform cross-sectional area over most of their 
length, in contrast to animal papillary and trabecular muscles. In addition, it is feasible to 
study 3D ECTCs formed with CMs that are derived from human induced pluripotent 
stem cells. The I-Wire platform and our model-based analysis will also inform more 
complex models of heart function for interventional planning purposes [248]–[250] [246], 
[263]–[266].  
With the advancement of induced pluripotent stem cell (iPSC) technologies 
specific to the heart [267], there is the possibility of being able to use cell-based 
technologies to support cardiac regeneration [26], [268]. This would then present the 
challenge of qualifying the cells that will be used to repair an ailing heart – one must be 
able to assess the mechanical, electrical, and metabolic potential of the cells prior to 
their use in a patient, particularly if those cells were derived from the patient’s own 
iPSCs. The I-Wire platform in the accompanying paper [237] in combination with the 
modeling described in this one may provide this capability: prior to the utilization of the 
cardiomyocytes, fibroblasts, and other cells for regenerative therapy, these same cells 
could be used to create an in vitro I-Wire construct whose performance could be 
evaluated using a standardized protocol. Given such a protocol, one then might be able 
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to further refine the process by which these cells are derived to better optimize their 
performance in vivo. 
Overall, we believe that this new technique will improve our understanding of the 
complex interplay between CM mechanics and function, and will also serve as a 
demonstration of model-based quantification of mechanically active tissue equivalents. 
Furthermore, we have in this paper outlined a computational procedure that should be 
applicable to many other active, contractile biomaterials and their mimics [269]–[271]. 
This platform, in addition to the single cell analysis techniques used to characterized the 
CENP-F KO cells, will provide valuable insight into the CM contributions to disease and 
cardiac mechanobiology.  
 
 
 
  
 137 
CHAPTER 7 
 
Impact and Future Directions 
 
Summary and impact of results 
 This work approaches the pressing clinical issue of cardiac fibrosis from several 
perspectives, with the aim of developing better understanding of the cellular players and 
their respective roles in the complex biomechanical environment of the heart (Figure 
7.1). Mechanobiology is particularly relevant in the heart because of the unique 
mechanical demands of cardiac function, and the dynamic process of tissue remodeling 
(and subsequent alteration of mechanical cues) that occurs during disease. Cadherin-
11 is a mechanosensitive protein that mediates cell-cell interactions and transmission of 
force, so it was a natural focus of interest. We confirmed an important role for cadherin-
11 in regulating both inflammation and fibrotic remodeling after myocardial infarction.  
The first part of this dissertation focuses on a portion of the complex crosstalk 
between growth factor signaling and mechanosensing in fibroblasts. I primarily 
investigated the crosstalk between TGF-1, FGF2, and integrin signaling in the 
regulation of MyoFB phenotype. TGF-β1 and FGF2 oppose one another in the 
regulation of both α-SMA and cadherin-11 expression, but both are active during the 
proliferative and fibrotic phases of myocardial remodeling. While these two cytokines 
lead to opposite end-points of fibroblast differentiation, they signal through similar 
intracellular mechanisms. Specifically, both cytokines cause phosphorylation of both 
MAPK p38 and ERK. Substrate stiffness is also a key modulator of MyoFB phenotype 
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and is transduced through integrins via p38 and ERK as well. In this case, we found that 
different dynamic signaling through Src, FAK, p38 and ERK could explain the inverse 
effects of TGF-1 and FGF2 on α-SMA expression [139]. We also observed a decrease 
in expression of MyoFB markers α-SMA and cadherin-11 when plating on a softer, 
fibronectin-coated PDMS substrate. While α-SMA and cadherin-11 were similarly 
regulated by TGF-1, FGF2, and stiffness, the absence of FAK had inverse effects on 
the expression of these two MyoFB proteins. Indeed, recent investigation of cadherin-11 
has revealed that there is complex and in some ways inverse relationship between the 
expression of cadherin-11, α-SMA, and other MyoFB markers. In addition to MAPK 
signaling, GSK-3β and β-catenin signaling also play roles in signaling through growth 
factors in the regulation of MyoFB markers. In addition, β-catenin associates with 
cadherins and participates in mechanotransduction downstream of cadherins, including 
cadherin-11. This work can inform future studies into the regulation of the MyoFB 
phenotype, which has important implications for wound healing and fibrosis in both the 
heart and other organ systems. There is still much to be learned about heterogeneity 
within MyoFB populations, and how this heterogeneity can affect the relative 
accumulation and remodeling of ECM during development and disease. This study 
identified some of the common and distinct mechanism that regulate expression of two 
important MyoFB markers, cadherin-11 and α-SMA. Understanding the different signals 
that control generation vs. transmission of intracellular forces may clarify how fibroblasts 
coordinate large ECM remodeling efforts.  
 The next portion of my doctoral work expanded the focus to examine the 
population of non-CM cells that are relevant to cardiac fibrosis after MI, with a particular 
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focus on the cell-cell adhesion protein cadherin-11. We identified and described a 
critical role for cadherin-11 in the process of inflammation and fibrotic remodeling after 
MI. We discovered that cadherin-11 is expressed in non-CM cells in the heart and is 
highly expressed after MI in inflammatory cells, endothelial cells, smooth muscle cells, 
and MyoFBs. In vivo comparisions of wild type and cadherin-11-/- mice indicated that 
cadherin-11 functions to promote and increase initial inflammatory remodeling after MI. 
Next we tested a potential therapeutic blocking antibody against cadherin-11 
(SYN0012) and found dramatic improvement in function, corresponding to a reduction in 
remodeling, measured by echocardiography, histological assessment, and atomic force 
microscopy. Mechanical and histological assessment of the hearts would suggest that 
the control hearts would experience higher amounts of strain due to tissue breakdown 
and remodeling, which would likely increase strain induced MyoFB differentiation. While 
CDH11-/- CFs have significantly impaired contractility, we observed no difference in CF 
contractility after treatment with SYN0012 in a free-floating gel environment in vitro. 
However, using the I-wire platform we were able to detect a significant reduction in 
intrinsic stress generated in a linearized, tensioned construct.  This suggests that the 
dynamic mechanical environment of an infarct is important for SYN0012-mediated 
effects on MyoFB differentiation. It also highlights the functional difference between a 
mutation and a blocking antibody treatment. The former removes cadherin-11 from all of 
its potential roles interacting with other proteins in the cell membrane or adherens 
junction, while the latter specifically prevents cell-cell cadherin bonds.  
After extensive screening of transcriptional changes due to SYN0012 treatment 
over time, we concluded that the beneficial effect is mediated by an overall reduction in 
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the inflammatory/remodeling program. This effect begins with a reduction in IL-6 
expression in the non-CM cell population at day three post-MI, followed by a significant 
decrease in Ms present at seven days post-MI. According to the results of an in vitro 
co-culture study, reduced interaction between fibroblasts and Ms in vivo would 
decrease IL-6 expression and MMP13 expression. IL-6 expression was also directly 
reduced by SYN0012 treatment in the co-culture system, indicating that the mechanism 
for Minduced stimulation of IL-6 expression by CFs is partially dependent on 
cadherin-11. TGF-β1 was increased by SYN0012 treatment in the in vitro co-culture 
system, but the overall TGF-β1 in vivo was reduced at seven days. This is likely due to 
a faster and more effective resolution of inflammation with treatment, mediated by 
decreased IL-6 and increased TGF-β1 in the first week. We also observed a decrease 
in FGF2 and VEGF-a, that surprisingly did not seem to correlate with decreased 
vascularization. To conclude, we discovered that cadherin-11 promotes an overall 
increase in cellular activity and inflammation-driven remodeling and presents an 
attractive therapeutic target for improving outcomes after MI. Targeting cadherin-11 has 
several advantages: targeting the extracellular portion of a protein expressed by 
activated cell types simplifies effective drug delivery, blocking cadherin-11 modulates 
but does not eliminate the necessary components of inflammation and fibrotic 
remodeling, and studies using a similar strategy in other organs have not revealed any 
significant side-effects. This study also highlights the significance of proteins like 
cadherin-11 that mediate cellular interactions and force transmission.  
 Finally, I developed tools to investigate CM mechanics, which can provide 
additional information to understand cardiac function during disease and the mechanical 
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microenvironment experienced by cardiac cells. I first quantitatively analyzed the effects 
of a cytoskeletal structuring protein (CENP-F) on the internal structure of CM, as well as 
the mechanical properties of both CMs and fibroblasts. We observed that the loss of 
CENP-F reduces sarcomeric regularity and integrity. It also decreases the amount of β-
catenin in the junctions between CMs, which potentially indicates insufficient transfer of 
force between CMs. Disrupted structural and specifically junctional integrity of CMs has 
been shown to drive the development of dilated cardiomyopathy in several papers, and 
this is also the main tissue phenotype that occurs as a result of the CENP-F mutation. 
Furthermore, microtubule disruption similar to the effects of the CENP-F mutation is a 
key method of action for several chemotherapeutics with known cardiotoxic effects. 
Cardiomyopathies in general are often associated with an increase in interstitial fibrosis 
that can be attributed to a disrupted mechanical environment between CMs, the natural 
location of interstitial fibroblasts and Ms. Understanding how such intracellular 
changes affect cellular interactions and function could have a large impact on cardiac 
health. 
Another important experimental tool that can bridge the gap between single cell 
studies of structural and mechanical changes and organ level changes is engineered 
cardiac tissue constructs. The final piece of my doctoral work focused on improving the 
mechanical analysis of one such construct, the I-wire construct. I developed a Hill-
based modeling strategy that allowed for the quantification and comparison of 
mechanical properties including passive construct elasticity and initial prestress with 
pharmacological treatments including blebbistatin and isoproterenol. Both of these 
treatments decreased prestress in the constructs, and blebbistatin significantly 
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decreased the overall passive construct stiffness by disrupting the contributions of the 
actin-myosin interactions. We further used the model to estimate best-fit values for the 
dynamic mechanical parameters by comparing measured and simulated force traces in 
response to idealized and measured microelectrode activation traces. We observed a 
significant decrease in the functional viscosity of the constructs in response to 
isoproterenol treatment. We were also able to replicate the measured pacing restitution 
curves using measured activation traces, reinforcing that microelectrode traces could be 
a reasonable input for predicting mechanical tissue outputs. Finally, by shortening the 
construct, we were able to determine that our assumptions of linear mechanic 
components, not surprisingly, are not able to fully capture the mechanics of muscle 
tissue constructs at significantly reduced lengths. This may very well translate to the 
dramatically reduced function observed in vivo after dramatic LV expansion and 
remodeling. This construct platform can also be used for investigation of non-CM cell 
remodeling. Our initial test with CFs treated with or without SYN0012 revealed a 
difference in intrinsic stress generated by CFs that was not quantifiable with a traditional 
contractility assay. This finding highlights the need for platforms like I-wire to advance 
our ability to quantify cellular mechanics.  
Overall, this doctoral project approaches the mechanobiology of cardiac fibrosis 
from the perspective of multiple cell types, covering a range of molecular sources of 
signaling and disruption. Given its critical role in fibroblast force transmission and 
regulation of signaling, I focused on cadherin-11 in the context of MyoFB differentiation, 
heterotypic cellular interactions, and remodeling after MI. My findings relating to 
regulation of the MyoFB phenotype will inform future studies into integrin signaling and 
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MyoFB population heterogeneity. Furthermore, I have determined and described a 
significant role for cadherin-11 in promoting inflammation and remodeling in the heart 
after MI and present it as a viable therapeutic target for improving outcomes. Finally, the 
techniques for quantifying CM structure and mechanics presented in this work will allow 
for better understanding of the cardiac mechanobiology throughout development and 
disease. 
 
Figure 7.1 Graphical summary of dissertation topic and aims. The work described in this dissertation 
contributed to several publications, which will, along with this dissertation, distribute these insights and 
findings to a broader audience. Ch. 1-3 [19], Ch. 4 [139], Ch. 5 [208], Ch. 6 [227], [228] 
 
 
Aim 1 Aim 2 Aim 3
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Future directions 
 This work makes some important steps forward to understand the cellular 
components of cardiac fibrosis and mechanobiology, and can be used to inform new 
hypotheses and experimental directions. More study into the intracellular signaling both 
upstream and downstream of cadherin-11 expression and engagement will be very 
helpful for clarifying its specific place in the cellular regulatory network. Two of the most 
likely candidates for signaling downstream of cadherin-11 are β-catenin and p120 
catenin. Both of these proteins associate with the intracellular domain of the cadherin-
11 protein to form components of the adherens junction complex which mechanically 
link cadherins to the cytoskeleton. They have also both been shown to participate in or 
overlap with signaling downstream of TGF-β1 and Wnt signaling. Both participate in 
some degree of signaling downstream of cadherin-11 expression and engagement, but 
their particular roles in cadherin-11 mechanotransduction of applied strain, substrate 
stiffness, and intercellular tension has not been fully explored. β-catenin has been 
shown to participate in strain induced signaling downstream of cadherin-1 and -2, but 
the distinctions between these different cadherins as it affects mechanotransduction has 
yet to be explored [188, 189]. In vitro techniques including the application of exogenous 
strain with a Flexcell system, AFM, or 3D tissue construct system could all be utilized in 
pursuit of this knowledge. Each of these experimental systems has distinct advantages 
and disadvantages, but used together they can provide a clearer picture of cadherin-11 
mechanobiology. 
 These studies can be performed in multiple cell-types to better understand the 
multifaceted role of cadherin-11 in complex cardiac remodeling. The work presented in 
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this dissertation primarily focused on CFs, as they are the main cell type responsible for 
ECM synthesis during fibrosis. However, our results revealed potentially important 
functions for cadherin-11 in both Ms and ECs in the context of healing after MI. In the 
case of Ms, future studies are needed to clarify the specific roles cadherin-11 play in 
M recruitment, migration, proliferation, and polarization. Flow cytometry and MRI 
studies could be used to great effect to observe alterations in M subpopulations and 
their recruitment in hearts after infarction, or in different cardiovascular disease models. 
More work is also needed to clarify the role of cadherin-11 in EC function in disease, 
specifically as it relates to EndMT, angiogenesis, and arteriogenesis. Cadherin-11 has 
been reported in ECs, and has been shown to promote EndMT, but whether there is a 
specific mechanobiological cue for that transformation has not been determined. 
Angiogenesis and arteriogenesis are both important and complex cellular processes 
that are correlated with improved outcomes after MI. Investigation of these in vivo 
processes and related cellular assays in vitro with and without cadherin-11 
perturbations will clarify what role cadherin-11 might play in promoting cell differentiation 
and migration. All of these studies will clarify the mechanisms of SYN0012 effects.  
 High resolution imaging modalities like MRI could also allow for more complete 
characterization of the dynamic mechanical strain environment of both the infarct and 
the border zone during the time course of remodeling.  Finite element inverse modeling 
from high resolution images could be used to estimate mechanical properties 
throughout the myocardium from measured strain profiles, and our AFM measurement 
technique could be used to validate and gain a more complete understanding of the 
spatial heterogeneity of tissue stiffness. Combining this technique with immunostaining 
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of tissue sections could allow for direct assessment of how microenvironmental 
mechanics effect cell phenotype and migration.  
Future studies altering the specific timing and volume of SYN0012 treatments, 
targeting only the first week or later weeks of remodeling, will also clarify both the role of 
cadherin-11 in disease and the suitability of a blocking antibody therapeutic strategy. It 
would also be a natural next step to investigate whether cadherin-11 plays a role in 
cardiac fibrosis downstream of other sources of cardiac disease, including pressure 
overload, dilated or hypertrophic cardiomyopathies.  
 Finally, the tools developed in Aim 3 can be used to better understand CM 
structure and mechanics in multiple applications and disease models. Both single cell 
assessment and larger tissue construct systems allow for more complete functional 
characterization of CMs derived from human induced pluripotent stem cells. These cells 
have been developed as a useful model system to understand the etiology of human 
disease and consequences of specific mutations and drugs [11]. The ability to quantify 
intracellular organization and stiffness along with multicellular functionality will prove 
very helpful to these ends. Future work with the I-wire system will be used to more 
conclusively distinguish between the different dynamic parameters (Figure B6). This 
model will also be used to design optimal experiments to most efficiency optimize the 
information gleaned from the I-wire construct system. The I-wire system can also be 
used to investigate the relative contributions of different ECM components, integrin 
signaling, cadherin blockade, and the effect of co-culture in 3D in a more physiologically 
relevant, tunable system.  
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 To conclude, my doctoral work has advanced the field of mechanobiology and 
cardiac fibrosis, identifying a critical role for the mechano-sensitive junctional protein 
cadherin-11 in cardiac remodeling after myocardial infarction. These studies have 
centered on the focal role of mechanosensing in cardiac cell activation and progressive 
tissue remodeling. I have also identified a viable therapeutic target for limiting adverse 
remodeling and improving outcomes after MI: cadherin-11. Future development and 
testing of the blocking antibody treatment described herein will hopefully have a large 
beneficial impact on the millions who suffer from myocardial infarction and cardiac 
fibrosis each year.  
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APPENDIX A 
 
Model of Myofibroblast Differentiation 
Model Development  
The model is a system of ODEs describing the dynamics of relative protein 
activation and α-SMA production in fibroblasts. To simplify the model, a normalized 
closed system was assumed, wherein the total amount of each protein species in the 
signaling pathway is conserved at a value of 1. While many of these proteins have 
multiple phosphorylation states and conformations which affect their enzyme activity, 
most protein species were simplified to 2 activation states, “on” or “off”. Src, FAK, and 
TR2 were given 3 activation states to capture more system interactions. In total, the 
model contains nine active variables (Table A1), 27 kinetic rate coefficients (Table A2), 
and 12 inputs and boundary conditions which can be varied experimentally and in silico. 
Figure 1B shows a general descriptive schematic of the interactions and protein species 
represented in the model. First order activation rates proportional to the relative 
activation of the upstream species were used to model signaling cascades, unless more 
specific interactions were known. Michaelis-Menten kinetics was used in cases of direct 
phosphorylation, as with Src activation of FAK tyrosines in the 400-900 range and Src 
phosphorylation of TGF receptor 2 (TR2).  
Table A1 List of Active Variables.  
Variable name Description 
B1on amount of activated 1 integrin as a fraction of total 
B3on amount of activated 3 integrin as a fraction of total 
TBRT TGF-β1 receptor (TR2) with TGF-β1 ligand attached 
pTBR2 phosphorylated and ligand bound TGF-β1 receptor (TR2) 
pS activated Src kinase 
pFAK FAK phosphorylated on tyrosine 397 
3pF FAK phosphorylated on tyrosines in 400-900 range with active kinase activity 
pP active p38 
pE active ERK 
The total amount of each protein is conserved and given a value of 1, so the inactive 
species fraction is calculated at each time point as 1 -  (active protein species). 
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Regulation of α-SMA production 
In the simplification of this system, we focused on p38 and ERK as the sole 
regulators of α-SMA production. Phosphorylated p38 (pp38) promotes the production of 
α-SMA while pERK inhibits α-SMA accumulation by slowing the rate of production. 
According the model proposed by Kawai-Kowase et. al, ERK activated by FGF2 
signaling prevents smooth muscle gene expression by interfering with serum response 
factor (SRF) function via an unknown mechanism [140]. We represented this in the 
model with the following equation: 
  Equation 4.1 
 
This equation was chosen assuming that the rate of production of α-SMA at any given 
moment would be roughly proportional to the amount of active p38, but also decreased 
by increasing activation of ERK. Because cells always express a baseline level of α-
SMA, the reduction by ERK was limited by the addition of a +1 term, so that the initially 
low amount of active ERK would not cause an unstable increase in α-SMA. 
After initial experimental results showed a dramatically lower amount of α-SMA in 
SYF-/- cells despite comparable levels of p38 phosphorylation, a modified equation for 
α-SMA production was devised.  
  Equation 4.2 
This equation somewhat artificially delivers a dramatic reduction in α-SMA expression 
when Src is absent, without requiring a subsequent decrease in p38 activation. We 
assume that p38 in this case is roughly proportional to SRF activity, and this additional 
Src term may represent downstream activation of MRTF, which works in concert with 
SRF to regulate α-SMA production. The addition of the 0.01 term within the Src 
activated expression similarly allows for some, diminished quantity of α-SMA expression 
even in the absence of Src. 
Parameter Estimation 
Parameters were estimated by comparison with previously published models and 
by calculating the maximum relative activation changes in relevant experimental 
contexts. Both p38 and ERK are activated via cascades of signaling events downstream 
of growth factor receptors, Src, and FAK [96, 190], but these cascades are 
approximated as a single step with a lump parameter for the sake of model simplicity. 
To estimate values for these lump parameters, we measured α-SMA expression and 
relative ERK and p38 phosphorylation in MEFs after 24 hours of treatment with 1 or 10 
ng/ml TGF-β1 and FGF2. We also tuned our model’s sensitivity to changes in 
mechanical stiffness by measuring α-SMA in cells plated on PDMS of stiffnesses 
ranging from 230 kPa to 2.14 MPa and on TCP (stiffness ~ 3 GPa [275]). The MATLAB 
optimization function lsqnonlin was used to vary up to three parameters at once to find 
the set of parameters which minimized the mean squared error (MSE) of the model fit to 
the growth factor sensitivity curves or the stiffness curve. While comparing candidate 
𝑆𝑀𝐴 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 =
𝑑 𝑆𝑀𝐴 
𝑑𝑡
=
𝑘𝑎𝑆𝑀𝐴𝑓 ∗  𝑝𝑝38 
(𝑘𝑎𝑆𝑀𝐴𝑖 ∗  𝑝𝐸𝑅𝐾 + 1)
 
𝑆𝑀𝐴 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 =
𝑑 𝑆𝑀𝐴 
𝑑𝑡
=
𝑘𝑎𝑆𝑀𝐴𝑓 ∗  𝑝𝑝38 ∗ (0.01 + 𝑝𝑆)
(𝑘𝑎𝑆𝑀𝐴𝑖 ∗  𝑝𝐸𝑅𝐾 + 1)
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models, two parameters (kTpP and kα-SMAf) were optimized to fit the growth factor 
calibration data set for each model. 
Table A2: List of parameter values 
Parameter Description 
Value 
[hr-1] 
Source 
k1f rate of 1 integrin adhesion and activation 23 Estimated from [273] 
k1r rate of 1 integrin deactivation 0.567 Estimated from [273] 
k2f rate of 3 integrin adhesion and activation 23 Estimated from [273] 
k2f rate of 3 integrin deactivation 0.567 Estimated from [273] 
k3f 
rate of TGF-β1 ligand attachment to 
TBR2 receptor 
60 [193] 
k3r rate of TGF-β1 disassociation 15 Estimated from [193] 
kIpF rate of 1 integrin activation of FAK 0.454 
estimated from [179], 
[273] 
kIpS rate of 3 integrin activation of Src 20.15 
estimated from [273], 
[276] 
kTpS rate of TGF receptor activation of Src 120 
estimated from [137], 
[177], [178] 
kSpF 
rate of Src association with FAK and 
activation of secondary phosphorylation 
sites 
29 
estimated from [180], 
[192], [273] 
KmSF 
Michaelis Menten constant for Src 
activation of FAK 
0.1 estimated from [192] 
kFAKpE rate of FAK activation of ERK 240 
estimated from [273], 
[277] 
kFGFpERK* rate of FGF activation of ERK 40 
estimated from [89], 
[140] 
kSpT rate of Src phosphorylation of TBR2 40 
estimated from [177], 
[178] 
KmST 
Michaelis Menten constant for Src 
activation of TBR2 
0.1 
estimated from [177], 
[178] 
kTpP* rate of TGF-β1 activation of pp38 
130.4-
1076 
estimated from [177], 
[178] 
kIpP* rate of 1 integrin activation of p38 50 
estimated from [42], 
[185] 
kPr rate of p38 dephosphorylation 579.6 [278] 
kEr rate of ERK dephosphorylation 210 estimated from [273] 
kSr rate of Src dephosphorylation 432 estimated from [273] 
kFr rate of FAK dephosphorylation 48.35 estimated from [273] 
kTr rate of ligand induced TBR2 deactivation 15 [193] 
kE intrinsic rate of ERK activation 10 estimated and optimized 
kP intrinsic rate of p38 activation 10 estimated and optimized 
kαSMAf* rate of p38 promotion of αSMA 1.1-11 
estimated and optimized 
for each model 
kαSMAi* rate of ERK inhibition of αSMA production 20 estimated and optimized 
kαSMAr rate of αSMA degredation 1.03 estimated from [279] 
Initial estimates of values were calculated from literature and varied to find the optimal 
parameter set. Parameters that were optimized to calibration data set indicated by * 
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Model derivation: 
This ODE model was developed and analyzed in MATLAB. The initial conditions of all 
active protein species were set at 0.001, the environmental conditions were matched to 
experimental levels, and the model was allowed to equilibrate by simulation of 24 hours 
of culture, resulting in a steady state values for each parameter. Using these steady 
state variable values as a starting point, the dynamic response of the system to 
treatments like addition of TGF-1 or FGF2 was simulated. For the sake of model 
stability and parsimony the total quantity for each of the protein species was set to 1 
and the quantity of the inactive species was calculated within the ODE expression per 
the following conservation equations. In other words, the variables for active protein 
species were calculated and processes as a fraction of the total protein pool. 
An ODE function was assembled containing the conservation equations (Table A3) and 
all the rate equations outlined below (Table A4-A10). This function was called within an 
ode solver in MATLAB, and the following conservation equations and current value for 
the active variables (Table A1) – another input into the solver - were used to calculate 
the amount of inactive or unphosphorylated species for each protein. These variables 
were used to calculate the rate of change of each active species from each biological 
source. The rate equations are listed in Tables A4-A10, divided by the region of the 
signaling network. 
 
Table A3: Table of active protein species conservation equations. The prefix ‘p’ 
indicates a phosphorylated species and the suffix ‘tot’ indicates the total value of the 
protein species.  
 Protein Conservation equation 
1 β1 integrin B1tot = B1off + 2*(B1on)  
2 β3 integrin B3tot = B3off + 2*(B3on) 
3 FAK Ftot = F + pF + 3pF 
4 Src Stot = S + pS + 3pF 
5 p38 Ptot = P + pP 
6 ERK ERKtot = ERK + pERK 
7 TGF-β1 receptor TBR2 = TBR2off + TBR2T + pTBR2 
 
More details on the specific activation steps can be found below. Net rate of change 
equations for each species are bolded. 
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Integrin activation and clustering 
Both intracellular and extracellular cues can lead to and strengthen integrin activation, 
but this model focuses on “outside-in” signaling linked to adhesion to ECM proteins 
collagen and fibronectin. Integrins with a 1 subunit can adhere to both fibronectin and 
collagen and are known to stimulate the activation of the autophosphorylation site on 
FAK (y397) [123], [179], [273]. Integrins containing the 3 subunit are activated by 
adhesion to the RGD subunit of fibronectin and can directly activate Src [276], [280]. In 
both cases, integrin clustering reinforces integrin activation and allows greater signaling 
to downstream targets like Src and FAK. In the model, dynamic clustering is 
approximated by a simple dimerization step whereby ECM adhesion leads to a pair of 
activated 1 or 3 integrins which in turn stimulate FAK or Src activation at a 
proportional rate. Hammer et al. made a similar assumption in their model of integrin 
signaling through integrin to FAK and ERK, and the rate constants k1f, k2f, k1r and k2r 
were calculated from the referenced model parameters. The active dimerized pair is 
accounted as B1on or B3on variables and is regulated by a second order equation (see 
table A4). Since the formation of this pair requires 2 inactive integrins, the conservation 
equation for both integrin species includes a scaling factor of 2 (See table A3) so that 
the total amount of integrin remains constant. The rate of integrin activation was made 
proportional to the availability of fibronectin (Fn) or collagen (Cl). Again, these are 
assumed to have a maximal value of 1, equivalent to a coated surface. Since MEFs are 
known to excrete fibrullar collagen and fibronectin in culture [40], [123], especially on 
stiff substrates, we assumed that cells plated on plastic had the equivalent of 20 percent 
of fibronectin present on a fibronectin coated surface (assumed to be a maximum value 
of 1) and 10 percent collagen of maximum collagen.  
Taking the rate of change of activated 1 integrin dimers as an example, the first step is 
to calculate the amount of unengaged integrin subunits B1off, using equation A3.1. 
B1tot = B1off + 2*(B1on) =1 equation A3.1 
  
B1off = 1 – 2*(B1on) 
This value is then used to calculate the rate of new activated dimerization resulting from 
interaction with fibronectin according at a rate proportional to Fn, the fraction of 
available unengaged 1 integrin subunits (squared since two subunits are needed for 
each reaction), and the rate constant k1f: 
 B1on_rate_Fn = k1f * Fn * B1off *B1off   . 
A similar expression gives the rate of dimerization due to collagen (Cl), which was 
assumed to have the same rate constant k1f 
 B1on_rate_Fn = k1f * Cl * B1off *B1off   . 
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Finally, these dimers (B1on) disassociate at a rate proportional to k1r: 
 B1on_rate_diss = B1on*k1r    . 
Combining these expressions gives the net rate of active 1 integrin dimer (B1on) 
formation, as follows: 
 B1on_rate = k1f *Fn*B1off*B1off + k1f *Cl*B1off*B1off – k1r *B1on.Equation A4.1 
This equation, and a similar expression for 3 integrin is presented below.  
Table A4: Equations describing integrin activation and clustering.  
 Description Equation 
1 β1 integrin activation and 
clustering 
B1on_rate = k1f * Fn * B1off *B1off + k1f 
*Cl*B1off*B1off – k1r *B1on 
2 β3 integrin activation and 
clustering 
B3on_rate = k2f * Fn * B3off *B3off – k2r *B3on 
 
This activation is also modulated by the log of the substrate stiffness, since β1 integrin 
subunits are known to activate the autophosphorylation site tyrosine 397 of FAK 
proportionally to the log of substrate stiffness [179]. p38 phosphorylation is sensitive to 
stiffness, and since β1 integrin is known to activate p38, all candidate models besides 
model 5 contain a stiffness dependent activation of p38 [42], [281]. These reactions are 
proportional to both the (normalized) number of active integrin dimers, and the amount 
of the unphosphorylated species of FAK, Src, and p38 (F, S, and P, respectively) as 
calculated from the conservation equations in Table A3. These equations are also 
contain a rate contant (kIpF, kIpS, kIpP) estimated from literature as described above. 
These equations will be included in the net rate of phosphorylation for FAK, Src, and 
p38, as described with more detail below. 
Table A5: Equations describing integrin based activation intracellular kinases via force 
sensitive mechanisms 
 Description Equation 
1 β1 integrin activation of FAK IpFrate = kIpF * log10(10*stiffness)*B1on*F 
2 β3 integrin activation of Src IpSrate = kIpS * log10(10*stiffness)*B3on*S 
3 β1 integrin activation of p38 IpPrate = kIpP * log10(10*stiffness)*B1on*P 
4 β1 integrin activation of p38  
(model 5) 
IpPrate = kIpP * B1on*P 
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TGF-1 signaling and Src based regulation 
 Src has an important role in non-canonical TGF-β1 signaling to p38 in the 
regulation of MyoFB differentiation. After TGF-β1 ligand binding, the 284 tyrosine 
residue on TGF-β1 receptor 2 (TβR2) must be phosphorylated by Src for TGF-β1 
induced activation of p38 to occur [177]. This two-step activation is accounted for by the 
inclusion of an intermediate activation state for the TβR2 receptor (TBR2T) which is 
associated with a TGF-β1 ligand and able to activate Src kinase activity, but unable to 
activate p38. The net rate of change for this species is given in equation A6.1, with a 
forward rate proportional to the amount of available TGF-β1 (Tgfb), the amount of 
unbound TβR2 (TBR2off) and a forward rate constant k3f and a reverse rate 
proportional to the amount of bound receptors (TBR2T) and a reverse rate constant.  
Both bound (TBR2T) and bound, phosphorylated TβR2 (pTBR2) can lead to Src 
phosphorylation, so the rate of TGF-β1 receptor activation of Src is proportional to the 
sum of these two species and inactive Src (Equation A6.2).  Since Src is known to 
directly phosphorylate bound TβR2, the equation for this activation step follows classic 
Michaelis Menten kinetics, with a forward rate equation and a Michaelis Menten 
constant (Equation A6.3). 
The phosphorylated form of the receptor (pTBR2) is able to induce p38 
phosphorylation and Src activation [177] (Equation A6.4).  
Half of the TBR2 becomes recycled to a ligand free state after 
dephosphorylation, which can be seen in the last component of the net rate of change 
TBR2T. 
Table A6: Equations describing TGF-β1 signaling and receptor activation 
 Description Equation 
1 TGF-β1 binding to receptor TBRTrate = k3f * Tfgb * TBR2off – k3r * TBR2T 
2 TGF-β1 based activation of 
Src 
TpSrate = kTpS * S * (pTBR2 + TBR2T)  
3 Src phosphorylation of TβR2 SpTrate = kSpT * TBR2T * pS/(KmST + TBR2T) 
4 TGF-β1 based activation of 
p38 
TpSrate = kTpP * P * pTBR2 
5 Dephosphorylation of TβR2 dpT= - kTr * pTBR2 
6 Net rate of change of TBR2T dTBR2 = TBRTrate – SpTrate – 0.5*dpT 
7 Net rate of change of pTBR2 dpTBR2 = SpTrate - dpT 
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FGF2 signaling 
  Since there are no known activation or regulatory steps for the FGF receptor by 
the proteins in this network, we used a more simplified set of equations to reflect FGF 
activation of both FAK and ERK, with a direct forward reaction proportional to the 
relative amount of FGF present, and the amount of inactive FAK and ERK (F, and ERK, 
respectively). 
Table A7: Equations describing FGF2 signaling  
 Description Equation 
1 FGF2 activation of FAK FGFpFrate = FGF2 * kFGFpF *F 
2 FGF2 induced activation of ERK 
pERKrate = FGF2 * kFGFpERK*ERK 
 
Src-FAK interactions 
 Src and FAK have a complex series of interactions and cross-phosphorylation 
which require special attention in the model. FAK is a large scaffolding protein with 
several phosphorylation sites and interactions with a large number of other proteins. 1 
integrin activation leads to phosphorylation of the autophosphorylation site of FAK, 
tyrosine 397 [123]. An association of the SH2 domain of the Src protein with the 
phosphorylated tyrosine 397 promotes the open conformation of Src that prevents 
deactivation by phosphorylation of tyrosine 527 and allows for more phosphorylation of 
tyrosine 416, increasing in Src kinase activity [282], [283]. When Src is associating with 
FAK in this manner, it can also cause the phosphorylation of FAK at tyrosines 576, 577, 
861, 925, and others. This secondary phosphorylation activates the kinase activity of 
FAK and allows for signaling to downstream targets like ERK and p38. It also promotes 
FAK autophosphorlyation of y397 of surrounding FAK proteins [180]. This complex 
relationship is represented in the model by a 3 step activation scheme for FAK: inactive 
(FAK), phosphorylated on 397 (pFAK), and in a complex with Src with the additional 
tyrosine residues of FAK phosphorylated (3pF). Src also has 3 active states: inactive 
(Src), active (pSrc), and in the Src/FAK complex. Src phosphorylation of FAK creates 
this complex (Equation A8.1) and primarily follows Michaelis Menten kinetics, but a 
subset follows a standard rate equation format. Autophosphorylation of inactive FAK by 
the activated kinase form also follows Michaelis Menten kinetics. Dephosphorylation of 
both proteins follows a fairly straightforward first ord A similar Src/FAK activation model 
was used in a model developed by Caron-Lormier et. al in 2004 [192]. Whether or not 
Src in complex with FAK is able to phosphorylate pp38 or perform other roles is one of 
the questions investigated by model comparisons. 
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Table A8: Equations describing Src and FAK activation  
  Description Equation 
1 Src phosphorylation of FAK SpFrate = kSpF * S * pF + 10 * kSpF * pS * 
pF/(KmSF+pF) 
2 FAK autophosphorylation FpFrate = kFpF * F * p3F /(KmFF + F) 
3 Dephosphorylation of Src  dppS = kSr * pS  
4 Dephosphorylation of pFAK dppF = kFr * pF 
5 Net changes in Src 
activation 
dpS = IpSrate + TpSrate - dppS –SpFrate +kFr * 
p3F/10 
6 Net changes in FAK y397 
phosphorylation 
dpF = IpFrate + FpFrate - dppF – SpFrate 
+FGFpFrate + kFr*p3F 
7 Net changes in FAK-Src 
complex with 
phosphorylated kinase 
domain 
dp3F = SpFrate – kFr * p3F  
 
Ten percent of the complex returns to pS phase after dissolution of the 3pF state, and 
all of it returns to the pF state.  
Remaining activations and dephosphorylation of p38 and ERK 
These equations follow standard forward and reverse kinetics. 
Table A9: Regulation of p38 and ERK 
 Description Equation 
1 Src phosphorylation of p38 SpPrate = kSpP * (pS) * P  
2 FAK phosphorylation of ERK FpErate = kFakpE * p3F *ERK 
3 
Dephosphorylation of p38 
dppP = - kPr * pP 
4 Dephosphorylation of ERK dppERK = - kEr * pERK 
5 Net changes in p38 
activation 
dpP = IpPrate + TpPrate + SpPrate + dppS  
6 Net changes in ERK 
phosphorylation 
dpERK = FpErate + pERKrate + dppERK + kE*ERK 
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Dynamic feedback loops 
A major goal of this study was to understand the crosstalk between direct TGF-β1 and 
FGF2 signaling to p38 and ERK. To account for the transient nature of signaling to both 
p38 and ERK, some of the candidate models included negative feedback to Src and 
ERK. The Src feedback loop approximates the role of Csk to limit Src kinase activity as 
focal adhesions mature over time. Src and FAK activation signal through Cas and cause 
an accumulation of paxillin in focal adhesions roughly proportional to the accumulation 
of α-SMA [284]. Paxillin recruits Csk, which lowers Src activity [197, 202]. Another 
potentially relevant feedback mechanism is calpain, which is activated by ERK and 
degrades FAK and β3 integrin [286]. Finally, we simulated a positive feedback loop by 
which p38 stimulates β3 integrin expression [135]. These mechanisms add complexity 
to the model but also make the model more relevant to the biological system and 
provide closer matching with the dynamic phosphorylation events.  
Table A10: Equations describing potential feedback loops 
 Description Equation 
1 
Time dependent negative  
feedback to Src 
dppS = - kSr * pS –kSr *100*α-SMA * pS 
2 Time dependent feedback to 
ERK 
dppE = - kEr * pERK -10 *pERK/α-SMA  
3 β3 integrin activation and 
clustering 
(model 6) 
B3on_rate = k2f * Fn * B3off *B3off – k2r *B1on  
+ kPB3 * B3off * B3off 
4 Accumulation of active calpain 
(model 7) 
calrate = kEaC*pERK – cal *kcaldeg 
5 β3 integrin activation and 
clustering  
(model 7) 
B3on_rate = k2f * Fn * B3off *B3off – k2r *B1on  
–kcaldeg*cal*B3on 
6 Dephosphorylation of pFAK 
(model 7) 
dppF = - kFr * pF – kcaldeg *cal*B3on 
 
The final step of the ODE function assembled all of the expressions for net change of 
phosphorylation events, combining the net equations given above as the output of the 
ODE function.  
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Sensitivity Analysis 
 Both the initial conditions and rate constants were varied over two decades around the 
primary estimation, and the relative change in output (α-SMA concentration) and 
sensitivity coefficients S (relative change in output per relative change in parameter (P)) 
were calculated and ordered. This analysis provides insight into the bottlenecks and 
critical junctions where the system is more or less sensitive to perturbations. 
 
     Equation 3   
 Candidate Model Development and Statistical Comparison  
We developed a set of candidate models which contain modified signaling 
mechanisms, reflecting different hypotheses. A data set independent from the 
calibration curves used to refine the model was used to evaluate model fit and 
quantitatively assess the likelihood of certain interaction mechanisms. After simulating 
the set of 8 experiments with each candidate model, we calculated the 𝜒2 statistic for 
the set of experimental results. The 𝜒2 statistic is a metric for measuring model fit while 
accounting for variability in experimental measurements.  
       Equation 4  
When 𝜒2 is minimized, the agreement between the model prediction and the data is 
optimized.  
 
Model evaluation using the Using the Akaike Information Criterion (AIC) 
The Akaike information criterion (AIC) is a metric for comparing models with different 
numbers of independent parameters (K), to attempt to optimize both the accuracy and 
the model simplicity, or parsimony, of different models variants [205, 206].  
      Equation 5 
N reflects the number of experimental data points and MSE is the mean squared error. 
This criterion can be used to great effect in determining the relative likelihood of multiple 
models. 
 
 
 
𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟 𝑆 =  
∆ 𝛼𝑆𝑀𝐴/𝛼𝑆𝑀𝐴
0
∆ 𝑃/𝑃
0
 
χ2 =  
(𝑦_𝑒𝑥𝑝𝑖 − 𝑦_𝑚𝑜𝑑𝑒𝑙𝑖)
𝜎𝑖
N
i=1
 
𝐴𝐼𝐶 = 2𝐾 + 2((𝑁 2) ∗ log(2𝜋 ∗ 𝑀𝑆𝐸 + 1)) 
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A.2 - Results 
TGF-β1, FGF2, and stiffness modulate α-SMA in a predictable manner 
We conducted calibration experiments to correlate growth factor concentration 
and stiffness to internal signaling and regulation of α-SMA and refine our initial 
estimates of lump parameters. Our first calibration experiment (Figure 3A-C) clarified 
the relationship between growth factor concentration, equilibrium p38 and ERK 
phosphorylation, and α-SMA expression in MEF+/+ cells. At 24 hours, there is no 
significant change in pp38 with treatment with 1 or 10 ng/mL FGF2, but there is a 
significant log-linear increase proportional to TGF-β1 concentration (Figure 3A). There 
is significant ERK phosphorylation after 24 hours treatment with TGF-β1 that is 
independent of TGF-β1 concentration. There is also a significant increase in ERK 
activation with FGF2 treatment, which is highly dependent on FGF2 concentration 
(Figure 3B). These data were used to refine estimates of kTpP, kFGFpE, and kα-SMAf 
(Table 3). The variability of the experimental measurements was considered in the 
optimization protocol; we selected the set of parameters which gave the minimum 𝜒2 
statistic for each candidate model. By this technique, we achieved good agreement with 
our calibration curves, with 𝜒2 values as low as 8.12 (p = 0.7) for the set of 15 growth 
factor measurements, indicating that the model is a good fit to the data.  
We measured α-SMA production over a range of substrate stiffness (Figure 3D) 
and found a statistically significant interaction between cell type and substrate stiffness 
(p = 0.009). α-SMA production was significantly reduced when cells were cultured on 
PDMS, with the lowest α-SMA expression corresponding to a PDMS stiffness of 900 
kPa. There was no significant difference between α-SMA expression on fibronectin 
coated TCP and uncoated TCP in either cell type. α-SMA in FAK-/- cells is significantly 
higher than in MEF+/+ (p < 0.001) on TCP (stiffness = 3E6 kPa) but is not statistically 
different at lower stiffness, indicating that FAK-/- are more sensitive to changes in 
stiffness than MEF+/+ cells. These data were also used to refine model fit and 
parameter estimation, especially in determining kIpP. 𝜒2 values as low as 2.9 (p = 0.96) 
were calculated for the set of 11 substrate measurements. After quantifying MAPK 
phosphorylation and α-SMA expression at 24 hours, we directed our focus to the details 
of dynamic signaling. 
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Figure A.1. Calibration curves for reaction to growth factors and stiffness. A-C. Concentration 
dependent changes to p38 and ERK activation and α-SMA expression in response to TGF-β1 and FGF2. 
D. Sensitivity to stiffness in production of α-SMA in MEF+/+ and FAK-/- cells. * indicates significant 
difference from the no treatment/TCP condition within each cell type. ^ indicates significant difference 
from MEF+/+ sample within substrate. Active p38 and pERK data from densitometry of western blots (A-
B) and α-SMA determined from indirect ELISA (C-D). Average results are presented (n=4-12). These data 
were used to refine model parameters. 
 
The dynamic ERK and p38 trends produced by model simulations share the 
same general shape as the experimental results, but the relative values are lower 
(Figure 4G-L). In this model, FGF2 does not directly activate p38, since the short 
duration and relatively low level of activation would not have a significant enough effect 
on α-SMA content to justify the addition of model complexity. The model does predict a 
slight rise in p38 activation in MEFs following FGF2 stimulation that is transduced 
through FAK enhanced Src activation (Figure 4G).  
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Figure A.2. Different dynamic activation profiles for activation of ERK and p38. Averaged results of 
western blot densitometry analysis for pp38 (A-C) and ERK (D-F) activation over a 3 hour time course in 
MEF+/+ (A,D) and FAK -/- (B,E) cells treated with 1ng/ml TGF-β1 or 10 ng/ml FGF. Average p38 and 
ERK activity after 24 hours of treatment (C,F). * indicates significant difference (p < 0.05) from average no 
treatment within cell type and time course. ^ indicates significant difference (p < 0.05) from the MEF+/+ 
sample within treatment and time point. G-L are the model output values for the same quantities at the 
same time points. 
 
Sensitivity Analysis 
Sensitivity analysis of the model with optimized parameters predicted that FAK-/- 
cells would be more sensitive to TGF-β1, FGF2, and stiffness relative to MEF+/+ cells. 
Sensitivity analysis indicates that the model’s response to TGF-β1 stimulation is most 
sensitive to changes in rate constants controlling the activation and deactivation of p38, 
Src, and TR2. Of the boundary constraints and initial conditions, the total amount of 1 
integrin has the largest effect on relative α-SMA in MEF+/+ and FAK-/- models, with 
sensitivity coefficients of -0.34 and -0.29, respectively. While the rank and sign of 
sensitivities is conserved between MEF+/+ and FAK-/- models, the magnitude of the 
parameters is often higher in FAK-/- models. One interesting exception is kTpP, which is 
slightly lower in FAK-/- models (0.152 vs. 0.176). In MEF+/+ simulations, the response 
to FGF2 is most sensitive to the rate of FGF2 activation of ERK, the deactivation rate of 
FAK, and the rate of FAK based activation by integrins. SYF-/- models have no reaction 
to TGF-β1, and their reaction to FGF2 is less sensitive to stiffness, FGF2, and the rate 
of ERK activation by FGF2 than the MEF+/+ model. Sensitivity to both TGF-β1 and 
FGF2 was predicted to increase on fibronectin coated PDMS (stiffness 900 kPa) relative 
to TCP. 
Model can predict results across substrate and cell type 
With optimized model parameters, we tested our model’s ability to predict the 
effect of growth factor treatment on cells lacking Src and FAK that we observed in vitro. 
Figure 5A shows the model results plotted over the experimental results (same as 
Figure 2). We also measured the combined effects of treatment and substrate stiffness 
by treating cells plated on fibronectin coated PDMS (Figure 5B) and found a statistically 
significant interaction between substrate and treatment (p = 0.004). Further, there is a 
significant difference (p < 0.05) between TCP and PDMS for NT and TGF-β1 treated 
cells, but not for FGF2 treated cells. Within each substrate, both FGF2 and TGF-β1 
treatment cause a significant (p < 0.05) change in α-SMA expression. The model 
predictions are plotted over the experimental results, and were within a standard 
deviation for all but the TGF-β1 treated sample on PDMS. 
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Figure A.3. Model fit to TGF-β1 and FGF2 treatment across cell types and substrates. Average 
values of α-SMA in MEF+/+ and FAK-/- cells (A) after 24 hour treatments and (B) in MEFs on TCP or 
fibronectin coated PDMS. Model predictions from model 04 with optimized parameters are plotted as 
triangles.  
 
Model comparisons 
Eight candidate models were developed and evaluated to find the most ideal fit to 
both steady state protein activation and dynamic protein phosphorylation events. The 
relative AIC (calculated as the difference between a given models AIC and the minimum 
AIC) provides a useful criterion for eliminating inferior models and improving model 
parsimony. After parameter optimization of kα-SMAf and kTpP for each model, 
simulated α-SMA outputs were compared against the validation data set (Figure A.3) 
and the MSE, 𝜒2 statistic, AIC, and DAIC were calculated (Table A4). The relative 
strength of evidence for any model (in comparison) can be estimated as e-DAIC/2. In other 
words, a model with DAIC > 10 is 148.4 times less likely than the best model [205, 206]. 
We found that the model with the lowest AIC also had a very low MSE and 𝜒2 while 
maintaining close agreement with the dynamic pp38 and pERK curves observed 
experimentally. Model 03 contained the modified α-SMA production equation (Equation 
2) which has a Src dependent term and negative feedback to Src but did not contain 
negative feedback to ERK. DAIC for the equivalent model (02) with the unmodified 
equation for α-SMA production (Equation 1) was 5.91, giving strong support that the Src 
dependent term is supported by the data. Model 15 does not have a negative feedback 
loop for ERK, which means that the observed change in relative ERK phosphorylation 
from 3 hours to 24 hours (Figure 4D-F) could not be replicated by this model. The 
equivalent model with negative feedback to ERK (model 04) had an DAIC of 1, so it is 
reasonably close to the optimal model. Furthermore, after optimization model 04 was 
able to achieve lower 𝜒2 values and better matching to the calibration data. Model 04 
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simulations are presented in Figures 4 and 5. Model 07 had the lowest MSE and best fit 
to the experimental data set via the addition of a calpain feedback loop which degrades 
3 integrin and FAK , but this addition of model complexity increased the AIC score 
above the simpler models 03 and 04. These data indicate that the features of the model 
presented above have reasonable support from the data. Our model comparison 
revealed that a direct dependency on active Src greatly enhanced the quality of model 
fit. It also indicated that including more complex network interactions like calpain based 
negative feedback can improve model accuracy, but not enough to justify additional 
model complexity. 
Table A11. Model comparison and statistical analysis 
Model Features MSE 𝜒2 DAIC 
01 
No Src dependency or Src 
feedback or ERK feedback 
0.768 541.96 6.66 
02 
No Src dependency term, but 
Src and ERK feedback 
0.499 278.9 6.03 
04* 
Src dependency, Src and ERK 
feedback 
0.090 24.79 0.93 
05 
Model 04 without stiffness 
dependence of IpP 
0.163 51.23 1.96 
06* 
Model 04 with 3 integrin 
positive feedback 
0.083 19.14 2.82 
07* 
Model 03 with Calpain 
negative feedback to ERK 
0.019 16.46 3.85 
08 
More direct αSMA 
dependence on ERK 
0.052 44.47 0.35 
03* 
Src dependency and Src 
feedback 
0.029 18.64 0 
* Indicates that the 𝜒2 value for the given model has a p < 0.05 for a 𝜒2 distribution with 
15 degrees of freedom, indicating that the model predictions are not significantly 
different from the experimental data set. 
 
A.3 - Discussion 
Using genetically modified MEFs, we have highlighted the importance of Src family 
kinases and FAK in the regulation of myofibroblast differentiation. Our results 
demonstrate a profound inhibitory effect of removing Src on αSMA production and 
stress fiber assembly. Densitometry revealed comparable levels of p38 and ERK 
phosphorylation in SYF-/- cells relative to MEF+/+ cells (data not shown), so the effect 
is likely operating through a different mechanism. This prompted the addition of a Src 
dependent term to the αSMA production equation to capture the significant αSMA 
reduction in SYF-/- cells (Equation A2). Without the addition of that term, SYF-/- cells in 
silico behave similarly to FAK-/-, since the absence of Src prevents the activation of 
FAK kinase ability. It is likely that signaling downstream of Cas and other Src substrates 
is necessary for proper αSMA synthesis. TGF-β1 signals to TGF-β activated kinase 1 
and subsequent αSMA production is significantly reduced with Src inhibition and the 
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removal of FAK [199]. This result is consistent with recent reports of Src’s prominent 
role in non-canonical TGF-β1 signaling in the context of myofibroblast differentiation 
[137].  
Our model uses an activation function proportional to the log of stiffness to 
simulate integrin activation of FAK, Src, and p38, which gives good agreement with 
experimental results (Figure 3D). We further showed the combinatorial effect of 
substrate changes and growth factor treatments and found a significant interaction, 
justifying the development of an integrated signaling model (Figure 5B). All the data in 
Figure 5 were well matched by a model whose parameters had been optimized to an 
independent data set (Figure 3), which strengthens our proposed model on the roles on 
p38 and pERK. The largest discrepancy between model prediction and experimental 
results, response to TGF-β1 in cells on PDMS, highlights an area needing more detailed 
investigation: the effect of stiffness and integrin signaling on TGF-β1 pathways. 
We developed a computational model of these overlapping signaling pathways and 
a set of tools for network analysis and hypothesis generation. Sensitivity analysis of the 
model predicted higher sensitivity to FGF2 and stiffness in FAK-/- cells relative to 
MEF+/+. Experimentally, FAK-/- cells demonstrated a larger relative change in response 
to FGF2 than in wild type cells (63% or 49% decrease, respectively), but a smaller 
relative response to TGF-β1 (55% or 73% increase, respectively) (Figure 4A). 
According to the constituitive equation for α-SMA activation, the sensitivity of equilibrium 
α-SMA to both p38 and pERK is inversely proportional to ERK activation, so lower basal 
ERK activation, as found in FAK-/- cells, should cause higher sensitivity to all 
parameters which affect ERK and p38 activation. Functionally, equations 1 and 2 mean 
that the presence of active ERK dampens the sensitivity of the system to changes in 
MAPK activation. Since the growth factors present in serum can cause a significant 
increase in ERK activation, we performed all of our ELISA and western blot experiments 
in serum free conditions. Sensitivity to both TGF-β1 and FGF2 was predicted to 
increase with decreasing stiffness according to the model prediction, and was observed 
in the case of FGF2 (54.5% vs. 49.5% decrease) though the reverse is true for TGF-β1 
(45% vs. 73% increase) (Figure 5B). Further investigation into altered signaling on 
softer substrates could help clarify this discrepancy. Future analysis of the model using 
larger calibration and validation data sets will give more insight into the dynamics of 
MyoFB regulation. Overall, this study demonstrates the feasibility of p38/ERK/Src based 
regulation of α-SMA production during fibroblast differentiation.  
In this study we have demonstrated that an ODE-based computational model of 
relative protein expression can capture a subset of the dynamic and steady-state events 
observed during fibroblast differentiation. We have further shown that the mechanism of 
Src/p38/ERK based regulation of α-SMA as described herein is a feasible model for 
regulation of MyoFB differentiation. Model simulations were able to replicate some of 
the dynamic features of TGF-β1 and FGF2 signaling to p38 and pERK and show that 
despite the fact that it increases with TGF-β1 treatment, ERK may still be acting 
primarily as a negative regulator of α-SMA. 
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APPENDIX B 
 
Additional Information About I-wire Model 
 
B1. Model details and derivation 
The geometry of the model is described in Figure B1, and our implementation of the Hill 
Model in Figure B2, both from Figure 1 of the main paper. All parameters are listed in 
Table B1. 
 
Figure B1: The geometry of an I-Wire measurement of the elastic and contractile 
properties of an engineered cardiac tissue construct. 
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Figure B2: The Hill model and key distances as adapted to an I-Wire measurement of 
the elastic and contractile properties of an engineered cardiac tissue construct. 
Table B1: Model variables 
Variable Description (units) 
𝐿 Half-length of unstretched I-Wire construct (m) 
𝛥𝑠 Distance I-Wire frame is moved (m) 
𝛥𝑠  Distance cantilever (probe) is moved (m) 
𝛥𝑠  𝛥𝑠 − 𝛥𝑠   (m) 
𝛥𝐿 Distance I-Wire construct is stretched (m) 
𝛥𝐿       Distance unstretched I-Wire construct is from resting (m) 
  Angle between hypotenuse and parallel leg of stretched I-Wire (rad) 
FP Force delivered by the cantilever (probe) (N) 
FC Force of the I-Wire construct in response to FP (N) 
prestress Estimated tension in unstretched construct (N) 
KM Steady-state stiffness of muscle construct (Nm
-1) 
KC Cantilever (probe) spring constant (Nm
-1) 
KPEam Spring constant of actin/myosin parallel element (Nm
-1) 
KSE Spring constant of series element (Nm
-1) 
KPEn Spring constant of non-actin/myosin parallel element (Nm
-1) 
b Dashpot stiffness (Nm-1s) (Note data reported in Nm-1milliseconds) 
FA Active force (N) 
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Derivation 
B1.1 Construct extension and the force on the probe, 
We begin with the Pythagorean Theorem 
𝐿 + Δ𝑠 
   (𝐿 + Δ𝐿)  ,  
which can be solved for Δ𝑠   
Δ𝑠   √(𝐿 + Δ𝐿) − 𝐿  √𝐿 + 2𝐿Δ𝐿 + Δ𝐿 − 𝐿   √Δ𝐿(2𝐿 + Δ𝐿)  
and Δ𝐿 
Δ𝐿   √𝐿 + Δ𝑠 
 − 𝐿  √𝐿 + (Δ𝑠 − Δ𝑠 ) − 𝐿 . 
Given the spring constant 𝐾  and displacement Δ𝑠  of the probe, the transverse force 
applied to the construct by the probe,   , is given by Hooke’s law,    𝐾 Δ𝑠 . This 
allows us to write  
Δ𝐿   √𝐿 + (Δ𝑠 −
  
𝐾 
)
 
− 𝐿 . 
The longitudinal force within each half of the construct is   . From the drawing, we see 
that    is balanced by the components    of each of the two forces    that are 
antiparallel to   , i.e.    2   (We ignore the minus sign). The geometry of the problem 
allows us to relate    and    directly 
    𝐾  Δ𝑠  𝐾 (Δ𝑠 − Δ𝑠 )  2      ( )   2   
Δ𝑠 
𝐿 + Δ𝐿
 .  
We can use our expression for Δ𝑠  to eliminate it from both sides of the equation 
    𝐾 (Δ𝑠 − √Δ𝐿(2𝐿 + Δ𝐿))  2   
√Δ𝐿(2𝐿 + Δ𝐿)
𝐿 + Δ𝐿
 . 
Solving this for   , we obtain 
     
 
2
 𝐾 
𝛥𝑠 − √𝛥𝐿(2𝐿 + 𝛥𝐿)
√𝛥𝐿(2𝐿 + 𝛥𝐿)
(𝐿 + Δ𝐿)  
 
2
 𝐾 (
𝛥𝑠
√𝛥𝐿(2𝐿 + 𝛥𝐿)
−  ) (𝐿 + 𝛥𝐿) . (  )  
We note for future use that    is simply a function of 𝛥𝐿, which we can write as 
   𝑓 (𝛥𝐿) .  
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We now need to compute the time derivative of    during a muscle contraction 
  ̇ ≝ 
d
d𝑡
    
 
2
𝐾 
d
d𝑡
 {(
𝛥𝑠
√𝛥𝐿(2𝐿 + 𝛥𝐿)
−  ) (𝐿 + 𝛥𝐿)} . 
We note that  
d𝛥𝐿
d𝑡
 𝑥 .̇  
By the chain rule, we find that 
  ̇
  
 
2
𝐾 {(𝐿 + Δ𝐿) (−
 
2
Δ𝑠(𝛥𝐿(2𝐿 + 𝛥𝐿))
    
(2𝐿?̇? + 2Δ𝐿?̇?))
+ (Δ𝑠(𝛥𝐿(2𝐿 + 𝛥𝐿))
    
−  ) ?̇?} , 
which simplifies to  
  ̇   
 
2
𝐾 {(𝐿 + Δ𝐿) (−Δ𝑠(𝛥𝐿(2𝐿 + 𝛥𝐿))
    
(𝐿 + Δ𝐿)) + (Δ𝑠(𝛥𝐿(2𝐿 + 𝛥𝐿))
    
−  )} ?̇? , 
  ̇   
 
2
𝐾 {−Δ𝑠(𝛥𝐿(2𝐿 + 𝛥𝐿))
    
(𝐿 + Δ𝐿) + Δ𝑠(𝛥𝐿(2𝐿 + 𝛥𝐿))
    
−  } ?̇? , 
  ̇
  
 
2
𝐾 {−Δ𝑠(𝛥𝐿(2𝐿 + 𝛥𝐿))
  
(𝛥𝐿(2𝐿 + 𝛥𝐿))
    
(𝐿 + Δ𝐿) 
+ Δ𝑠(𝛥𝐿(2𝐿 + 𝛥𝐿))(𝛥𝐿(2𝐿 + 𝛥𝐿))
  
(𝛥𝐿(2𝐿 + 𝛥𝐿))
    
−  } ?̇? , 
  ̇   
 
2
𝐾 {
Δ𝑠(−(𝐿 + Δ𝐿) + 𝛥𝐿(2𝐿 + 𝛥𝐿))
𝛥𝐿(2𝐿 + 𝛥𝐿)√𝛥𝐿(2𝐿 + 𝛥𝐿)
−  } ?̇? , 
  ̇   
 
2
𝐾 {
Δ𝑠(−𝐿 − 2𝐿𝛥𝐿 − 𝛥𝐿 + 2𝐿𝛥𝐿 + 𝛥𝐿 )
𝛥𝐿(2𝐿 + 𝛥𝐿)√𝛥𝐿(2𝐿 + 𝛥𝐿)
−  } ?̇? , 
  ̇   −
 
2
𝐾 {
Δ𝑠𝐿 
𝛥𝐿(2𝐿 + 𝛥𝐿)√𝛥𝐿(2𝐿 + 𝛥𝐿)
+  } ?̇? . 
This too is a function of 𝛥𝐿, which we can write as 
  ̇   𝑓 (𝛥𝐿) ?̇? . 
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B1.3 Hill model 
We now analyze the Hill model components in Figure B2 to interpret the response of the 
I-wire construct in terms of its elastic and contractile properties.  
 
The force in the I-wire construct is the sum of the forces in non-actin/myosin passive 
elements (  ), associated with the extracellular matrix, and in the myocytes themselves 
(  ) 
     +    . 
The non-actin/myosin contribution, the uppermost component in Figure S2, obeys 
Hooke’s law 
   𝐾    𝑥 . 
The lower components describe the contractile properties of the myocytes. The same 
force    is passed through the left (parallel) and right (serial) components of the 
myocyte contribution. We have for the series elastic component Hooke’s law 
   𝐾   𝑥  . 
For the parallel components, three terms, the active contractile element, the velocity-
dependent dashpot, and the parallel elastic element, contribute to    
      +  𝑥 ̇ + 𝐾    𝑥  .  
We can eliminate 𝑥  and its temporal derivative 𝑥 ̇to obtain 
      +  (?̇? − 𝑥 ̇) + 𝐾    (𝑥 − 𝑥 ) . 
We can use Hooke’s law for the series elastic element to eliminate 𝑥  and 𝑥 ̇ 
      +  (?̇? −
  ̇
𝐾  
) + 𝐾    (𝑥 −
  
𝐾  
) 
      +  (?̇? −
 ̇ −  ̇ 
𝐾  
) + 𝐾    𝑥 − 
𝐾      
𝐾  
 
(  +
𝐾    
𝐾  
)      +  (?̇? −
 ̇ −  ̇ 
𝐾  
) + 𝐾    𝑥 . 
We next replace    
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( +
𝐾    
𝐾  
)(  −   )     +  (?̇? −
 ̇ −  ̇ 
𝐾  
) + 𝐾    𝑥 
and then    and  ̇  to obtain 
( +
𝐾    
𝐾  
)(  − 𝐾    𝑥)     +  (?̇? −
 ̇ −  ̇ 
𝐾  
) + 𝐾    𝑥 . ( ) 
We collect terms such that all time-dependence is on the right side of the equation 
( +
𝐾     
𝐾  
)  − (𝐾     + 𝐾    +
𝐾    𝐾     
𝐾  
 ) 𝑥     +  (?̇? −
 ̇ − 𝐾    ?̇?
𝐾  
 ).  
At steady-state equilibrium, there is no active force and both temporal derivatives are 
zero 
( +
𝐾     
𝐾  
)  − (𝐾     + 𝐾    +
𝐾    𝐾     
𝐾  
)  𝑥  0 , 
which allows us to solve for    
   
(𝐾     + 𝐾    +
𝐾    𝐾     
𝐾  
) 
 +
𝐾     
𝐾  
𝑥  𝐾 𝑥 , 
where 
𝐾  
𝐾    + 𝐾   +
𝐾    𝐾     
𝐾  
 +
𝐾     
𝐾  
 . 
We can use this to simplify the preceding equation (1) when there is time dependence, 
i.e., during a contraction of the muscle 
( +
𝐾     
𝐾  
) (  − 𝐾  𝑥)     +  (?̇? −
 ̇ − 𝐾    ?̇?
𝐾  
 ) . (2) 
In order to explicitly identify and collect time- and length-dependent terms, we first 
replace    and   ̇ with their previously derived functions 
( +
𝐾     
𝐾  
)𝑓 (Δ𝐿) − 𝐾  𝑥     +  (?̇? −
𝑓 (Δ𝐿)Δ?̇? − 𝐾    ?̇?
𝐾  
 ) . (3) 
Recognizing the equivalence of ?̇? and Δ?̇?, this becomes 
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( +
𝐾     
𝐾  
)𝑓 (Δ𝐿) − 𝐾  𝑥     +  ( −
𝑓 (Δ𝐿) − 𝐾    
𝐾  
 ) Δ?̇?. (4) 
We can now solve this for Δ?̇? 
Δ?̇?  
( +
𝐾     
𝐾  
) 𝑓 (Δ𝐿) − 𝐾  𝑥 −    
 ( −
𝑓 (Δ𝐿) − 𝐾    
𝐾  
 )
 . (5) 
We introduce Δ𝐿      , the predicted distance from true resting length based on the 
prestress tension in the unstretched construct assuming a linear passive kM, 
Δ𝐿      + Δ𝐿  𝑥  𝑥 + 𝑥  
to obtain our final differential equation 
Δ?̇?  
( +
𝐾     
𝐾  
) 𝑓 (Δ𝐿) − 𝐾 (Δ𝐿 + Δ𝐿      ) −    
 ( −
𝑓 (Δ𝐿) − 𝐾    
𝐾  
 )
 . (6) 
This differential equation was used to predict the contraction traces and was solved in 
MATLAB using ode15s. Data were given as force applied on the probe, and the 
construct length change Δ𝐿 was calculated as described above (B1.1). This calculated 
Δ𝐿 was used to calculate the force in the construct during steady-state stretching and 
active contraction (B1.2-3).  
To accommodate the new starting length of the shortened construct, Equation 6 was 
modified to include a shortening factor (sf) which represented the relative change to the 
starting length of the construct: 
           
      ∗( (    )   )
    
  
      ∗( (    )   )
 √        ∗(    )
.  
 
S2. Parameter estimation details 
The first step of parameter estimation for each independent construct is a linear best fit 
through the passive force over relative length changes. Linear least squares fit the 
experimental trend to estimate stiffness (KM; slope) and prestress (intercept) in the 
construct (Figure B3 and Table B2), and this linear model projects down to the relative 
length where the construct would have no prestress (the offset of length change).  
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Figure B3: Passive model fits for all isoproterenol treated constructs. Experimental data is represented 
by blue asterisks, force applied by the probe (Eq. 7) is represented by the green lines, and the passive 
model fit (Eq. 5) is represented by red lines. 
 
Table B2: Individual passive model fits 
Construct 1 2 3 4 5 6 7 
KM (control) 6.37E-01 7.60E-01 5.87E-01 7.19E-01 5.24E-01 8.17E-01 8.90E-01 
KM (iso) 5.74E-01 5.68E-01 4.10E-01 7.92E-01 5.08E-01 7.29E-01 6.25E-01 
prestress 
(control) 
2.14E-04 1.88E-04 1.99E-04 2.36E-04 1.41E-04 2.59E-04 3.02E-04 
prestress 
(iso) 
1.17E-04 1.19E-04 1.18E-04 1.26E-04 5.68E-05 1.34E-04 1.86E-04 
         
(control) 
3.36E-04 2.47E-04 3.39E-04 3.30E-04 2.71E-04 3.17E-04 3.39E-04 
         
(iso) 
2.04E-04 2.09E-04 2.88E-04 1.59E-04 1.12E-04 1.84E-04 2.98E-04 
 
The passive parameters (Km, prestress, and Δ𝐿      ) were used as a starting point 
for parameter estimation for each construct. The lsqnonlin function in MATLAB was 
used to estimate the set of parameters that minimized the residual sum of squared 
errors (RSS) between the predicted and measured relative length over time for all 
applied tension conditions. The residuals and Jacobian matrix (i.e., the matrix of partial 
derivatives of the predicted lengths with respect to the model parameters, evaluated at 
the estimated model parameters) outputs from the lsqnonlin function were input into the 
nlparci function to calculate the confidence intervals for the estimated parameters. 
Active parameters (KSE, KPEam) were initially set at values which followed the equation 
𝐾      (𝐾 − 𝐾   )( −
 
     
) , where 𝑟𝑎𝑡𝑖𝑜  
   
     
, and has a value of 2 [244]. The 
viscosity parameter (b) was originally set to 0.315 for all samples. The initial simulations 
with these parameters fit the experimental data relatively poorly (Figure B4 and Table 
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B3.1). After the initial simulations, the parameters (KSE, KPE, b) were estimated with the 
lsqnonlin function. This optimization dramatically improved the quality of fit (Figure B4 
and Table B3.2). Comparing the estimated parameters before and after isoproterenol 
treatment with a paired t-test indicated a significant decrease (p = 0.037) in b (mean 
decreases from 0.66 to 0.33). We also performed an optimization using the traditional 
Hill model by setting KPEn to zero and found that the model was able to fit the data very 
similarly (Table B3.3), and that the stiffness previously associated with KPEn was 
represented among the remaining (stiffness) parameters. Two of the samples that ran 
into a lower bound (0.013) for optimization for the b parameter with KPEn = 0.67* KM were 
more stably fit when KPEn was set to 0. Taking KPEn = 0, both KSE and b were significantly 
reduced (p < 0.05) after isoproterenol. The parameters were also estimated by varying 
the initial ratio between KSE and KPEam and using an action potential trace as the active 
force model input. In both cases the quality of fit decreased (Table B3.4-5) and b was 
always significantly decreased after isoproterenol. 
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Figure B4: Original model predictions of position with ratio = 2. Experimental data plotted with 
thicker lines, and model prediction shown with thin lines.  
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Figure B5: Model predictions with estimated best fit parameter. Experimental data plotted with 
thicker lines, and model prediction shown with thin lines.  
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Table S3: Summary of parameter estimates (confidence intervals), and mean squared error 
(MSE) 
 Control Isoproterenol 
 KPEn KPE KSE b MSE KPEn KPE KSE b MSE 
Table S3.1: Original values with ratio = 2, KPEn = KM*0.67 
1 
4.26E-
01 
3.15E-01 6.31E-01 3.15E-01 1.55E-05 3.85E-01 2.22E-01 4.45E-01 3.15E-01 5.27E-05 
2 
5.08E-
01 
3.75E-01 7.51E-01 3.15E-01 1.21E-05 3.82E-01 8.80E-02 1.76E-01 3.15E-01 1.12E-04 
3 
3.94E-
01 
2.91E-01 5.80E-01 3.15E-01 2.90E-05 2.75E-01 2.51E-02 5.02E-02 3.15E-01 2.64E-04 
4 
4.83E-
01 
3.56E-01 7.10E-01 3.15E-01 2.03E-05 5.30E-01 4.64E-01 9.31E-01 3.15E-01 2.03E-05 
5 
3.50E-
01 
2.59E-01 5.17E-01 3.15E-01 9.40E-06 3.41E-01 2.35E-01 4.70E-01 3.15E-01 5.20E-05 
6 
5.49E-
01 
4.04E-01 8.08E-01 3.15E-01 3.89E-06 4.89E-01 2.72E-01 5.43E-01 3.15E-01 1.34E-05 
7 
5.96E-
01 
4.42E-01 8.80E-01 3.15E-01 8.44E-06 4.16E-01 4.16E-02 8.33E-02 3.15E-01 1.97E-04 
Table S3.2: Best parameter fit, KPEn = KM*0.67 
1 4.26E-01 
4.98E-01 
(4.86E-01, 
5.11E-01) 
8.30E-01 
(8.17E-01, 
8.42E-01) 
2.08E-01 
(2.05E-01, 
2.12E-01) 
2.31E-06 3.85E-01 
6.56E-01 
(6.25E-01, 
6.88E-01) 
6.28E-01 
(6.15E-01, 
6.40E-01) 
1.43E-01 
(1.38E-01, 
1.48E-01) 
9.72E-06 
2 5.08E-01 
6.94E-01 
(6.78E-01, 
7.10E-01) 
6.75E-01 
(6.66E-01, 
6.85E-01) 
1.68E-01 
(1.64E-01, 
1.72E-01) 
3.07E-06 3.82E-01 
4.48E-01 
(4.32E-01, 
4.64E-01) 
4.01E-01 
(3.91E-01, 
4.10E-01) 
1.00E-01 
(9.65E-02, 
1.04E-01) 
1.01E-05 
3 3.94E-01 
3.97E-01 
(3.94E-01, 
4.01E-01) 
1.21E+00 
(1.18E+00, 
1.23E+00) 
3.03E-01 
(2.98E-01, 
3.08E-01) 
1.57E-06 2.75E-01 
2.08E-01 
(1.97E-01, 
2.19E-01) 
1.60E-01 
(1.54E-01, 
1.66E-01) 
3.15E-02 
(3.00E-02, 
3.31E-02) 
9.38E-06 
4 4.83E-01 
5.36E-01 
(5.27E-01, 
5.49E-01) 
8.90E-01 
(8.74E-01, 
9.02E-01) 
1.61E-01 
(1.58E-01, 
1.64E-01) 
2.65E-06 5.30E-01 
1.02E+00 
(1.00E+00, 
1.05E+00) 
9.81E-01 
(9.65E-01, 
9.97E-01) 
1.83E-01 
(1.78E-01, 
1.87E-01) 
5.50E-06 
5 3.50E-01 
4.70E-01 
(4.64E-01, 
4.73E-01) 
4.95E-01 
(4.89E-01, 
4.98E-01) 
1.68E-01 
(1.67E-01, 
1.70E-01) 
1.24E-06 3.41E-01 
5.33E-01 
(5.24E-01, 
5.46E-01) 
3.79E-01 
(3.75E-01, 
3.85E-01) 
8.17E-02 
(7.89E-02, 
8.45E-02) 
4.70E-06 
6 5.49E-01 
4.89E-01 
(4.57E-01, 
5.21E-01) 
5.11E-01 
(5.02E-01, 
5.21E-01) 
2.01E-01 
(1.97E-01, 
2.05E-01) 
9.16E-07 4.89E-01 
8.93E-01 
(8.61E-01, 
9.21E-01) 
5.49E-01 
(5.43E-01, 
5.58E-01) 
1.61E-01 
(1.56E-01, 
1.64E-01) 
1.95E-06 
7 5.96E-01 
1.22E+00 
(1.21E+00, 
1.24E+00) 
1.01E+00 
(1.00E+00, 
1.02E+00) 
2.55E-01 
(2.52E-01, 
2.58E-01) 
1.50E-07 4.16E-01 
2.32E-01 
(2.19E-01, 
2.45E-01) 
1.97E-01 
(1.89E-01, 
2.05E-01) 
3.15E-02 
(3.00E-02, 
3.28E-02) 
2.40E-06 
Table S3.3: Best parameter fit, KPEn = 0 
1 0 
1.01E+00 
(1.01E+00, 
1.01E+00) 
2.27E+00 
(2.25E+00, 
2.29E+00) 
4.92E-01 
(4.86E-01, 
4.95E-01) 
2.58E-06 0 
1.46E+00 
(1.42E+00, 
1.51E+00) 
1.50E+00 
(1.47E+00, 
1.53E+00) 
3.08E-01 
(3.00E-01, 
3.15E-01) 
9.55E-06 
2 0 
1.21E+00 
(1.20E+00, 
1.21E+00) 
1.92E+00 
(1.91E+00, 
1.93E+00) 
4.13E-01 
(4.10E-01, 
4.16E-01) 
4.71E-06 0 
1.46E+00 
(1.43E+00, 
1.49E+00) 
1.38E+00 
(1.36E+00, 
1.41E+00) 
3.15E-01 
(3.09E-01, 
3.25E-01) 
9.96E-06 
3 0 
8.11E-01 
(8.04E-01, 
8.14E-01) 
3.31E+00 
(3.25E+00, 
3.41E+00) 
6.34E-01 
(6.28E-01, 
6.44E-01) 
1.85E-06 0 
8.04E-01 
(7.92E-01, 
8.17E-01) 
8.36E-01 
(8.23E-01, 
8.49E-01) 
1.34E-01 
(1.32E-01, 
1.37E-01) 
7.48E-06 
4 0 
1.06E+00 
(1.06E+00, 
1.06E+00) 
2.70E+00 
(2.67E+00, 
2.72E+00) 
4.04E-01 
(3.94E-01, 
4.10E-01) 
3.36E-06 0 
1.84E+00 
(1.80E+00, 
1.87E+00) 
1.94E+00 
(1.91E+00, 
1.97E+00) 
3.28E-01 
(3.22E-01, 
3.34E-01) 
5.99E-06 
5 0 
8.39E-01 
(8.36E-01, 
8.42E-01) 
1.29E+00 
(1.28E+00, 
1.30E+00) 
3.85E-01 
(3.82E-01, 
3.91E-01) 
1.62E-06 0 
1.19E+00 
(1.18E+00, 
1.19E+00) 
9.43E-01 
(9.43E-01, 
9.43E-01) 
1.98E-01 
(1.97E-01, 
1.99E-01) 
4.47E-06 
6 0 
1.56E+00 
(1.50E+00, 
1.61E+00) 
1.64E+00 
(1.62E+00, 
1.67E+00) 
5.62E-01 
(5.52E-01, 
5.74E-01) 
9.23E-07 0 
1.97E+00 
(1.95E+00, 
1.99E+00) 
1.44E+00 
(1.43E+00, 
1.46E+00) 
4.20E-01 
(4.10E-01, 
4.29E-01) 
2.21E-06 
7 0 
2.71E+00 
(2.68E+00, 
2.74E+00) 
2.08E+00 
(2.07E+00, 
2.09E+00) 
5.08E-01 
(5.02E-01, 
5.11E-01) 
1.47E-07 0 
1.21E+00 
(1.21E+00, 
1.22E+00) 
1.31E+00 
(1.30E+00, 
1.32E+00) 
1.85E-01 
(1.82E-01, 
1.87E-01) 
2.27E-06 
Table S3.4: Best ratio/b fit, KPEn = KM*0.67 
1 4.26E-01 2.71E-01 9.27E-01 
2.53E-01 
(2.45E-01, 
2.62E-01) 
3.62E-06 3.85E-01 2.94E-01 5.30E-01 
1.15E-01 
(1.11E-01, 
1.20E-01) 
1.77E-05 
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2 5.08E-01 4.35E-01 5.93E-01 
1.78E-01 
(1.75E-01, 
1.80E-01) 
4.69E-06 3.82E-01 3.11E-01 4.70E-01 
4.42E-02 
(4.26E-02, 
4.54E-02) 
1.61E-05 
3 3.94E-01 2.30E-01 1.22E+00 
3.34E-01 
(3.22E-01, 
3.47E-01) 
2.84E-06 2.75E-01 1.70E-01 6.62E-01 
3.15E-02 
(2.59E-02, 
3.72E-02) 
8.37E-05 
4 4.83E-01 3.34E-01 8.17E-01 
1.68E-01 
(1.63E-01, 
1.74E-01) 
4.71E-06 5.30E-01 4.16E-01 7.03E-01 
2.20E-01 
(2.13E-01, 
2.26E-01) 
1.41E-05 
5 3.50E-01 3.15E-01 3.79E-01 
1.47E-01 
(1.44E-01, 
1.50E-01) 
1.99E-06 3.41E-01 3.97E-01 2.88E-01 
7.00E-02 
(6.91E-02, 
7.10E-02) 
5.34E-06 
6 5.49E-01 5.30E-01 5.49E-01 
2.21E-01 
(2.16E-01, 
2.25E-01) 
9.74E-07 4.89E-01 5.27E-01 4.42E-01 
1.26E-01 
(1.24E-01, 
1.29E-01) 
4.24E-06 
7 5.96E-01 4.98E-01 7.13E-01 
1.50E-01 
(1.47E-01, 
1.53E-01) 
8.49E-07 4.16E-01 2.84E-01 7.44E-01 
3.15E-02 
(2.78E-02, 
3.50E-02) 
3.36E-05 
 Table S3.5: Best parameter fit, AP curve, KPEn = KM*0.67 
1 4.26E-01 
8.86E-01 
(8.86E-01, 
8.86E-01) 
2.25E+00 
(2.25E+00, 
2.25E+00) 
3.72E-01 
(3.72E-01, 
3.72E-01) 
9.54E-06 3.85E-01 
7.67E-01 
(7.67E-01, 
7.67E-01) 
2.30E+00 
(2.30E+00, 
2.30E+00) 
3.15E-01 
(3.15E-01, 
3.15E-01) 
2.08E-05 
2 5.08E-01 
1.06E+00 
(1.06E+00, 
1.06E+00) 
2.68E+00 
(2.68E+00, 
2.68E+00) 
3.72E-01 
(3.72E-01, 
3.72E-01) 
8.28E-06 3.82E-01 
7.57E-01 
(7.57E-01, 
7.57E-01) 
2.27E+00 
(2.27E+00, 
2.27E+00) 
3.15E-01 
(3.15E-01, 
3.15E-01) 
2.06E-05 
3 3.94E-01 
8.23E-01 
(8.20E-01, 
8.26E-01) 
2.00E+00 
(1.98E+00, 
2.02E+00) 
4.10E-01 
(4.07E-01, 
4.13E-01) 
1.14E-05 2.75E-01 
5.46E-01 
(5.46E-01, 
5.46E-01) 
1.64E+00 
(1.64E+00, 
1.64E+00) 
3.15E-01 
(3.15E-01, 
3.15E-01) 
4.96E-05 
4 4.83E-01 
1.01E+00 
(1.01E+00, 
1.01E+00) 
2.51E+00 
(2.51E+00, 
2.51E+00) 
3.79E-01 
(3.79E-01, 
3.79E-01) 
5.93E-06 5.30E-01 
1.05E+00 
(1.05E+00, 
1.06E+00) 
3.15E+00 
(3.15E+00, 
3.15E+00) 
3.15E-01 
(3.15E-01, 
3.15E-01) 
2.31E-05 
5 3.50E-01 
7.32E-01 
(7.32E-01, 
7.32E-01) 
1.83E+00 
(1.83E+00, 
1.83E+00) 
3.79E-01 
(3.79E-01, 
3.79E-01) 
4.81E-06 3.41E-01 
6.75E-01 
(6.75E-01, 
6.75E-01) 
2.03E+00 
(2.02E+00, 
2.03E+00) 
3.15E-01 
(3.15E-01, 
3.15E-01) 
2.73E-05 
6 5.49E-01 
1.15E+00 
(1.15E+00, 
1.15E+00) 
2.87E+00 
(2.87E+00, 
2.87E+00) 
3.75E-01 
(3.75E-01, 
3.75E-01) 
1.31E-05 4.89E-01 
9.72E-01 
(9.72E-01, 
9.72E-01) 
2.91E+00 
(2.91E+00, 
2.91E+00) 
3.15E-01 
(3.15E-01, 
3.15E-01) 
2.64E-05 
7 5.96E-01 
1.25E+00 
(1.25E+00, 
1.25E+00) 
3.14E+00 
(3.14E+00, 
3.14E+00) 
3.66E-01 
(3.66E-01, 
3.66E-01) 
4.49E-06 4.16E-01 
8.33E-01 
(8.33E-01, 
8.33E-01) 
2.49E+00 
(2.49E+00, 
2.49E+00) 
3.15E-01 
(3.15E-01, 
3.15E-01) 
3.65E-05 
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Figure B6: Panels A and C: Simulated experimental mechanical inputs (𝛥𝑦 is equivalent to 𝛥𝑠; cf. Figure 
B1). Panels B and D: Passive stretch in I-wire construct as predicted by modified Hill model (𝛥𝑥 is 
equivalent to 𝛥𝐿; cf. Figure 1).  
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